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ABSTRACT 
Diseases resulting from the dysregulation of adipocyte and osteoblast differentiation include 
diabetes type II and osteoporosis. Both adipocytes and osteoblasts are derived from the same 
progenitor cell type, known as mesenchymal stromal cells (MSCs), which may also 
differentiate into cells of several mesenchymal lineages. A more detailed understanding of 
the mechanisms involved in the differentiation of MSCs would provide valuable insight into 
the underlying causes of, as well as facilitate the development of improved treatments for, 
diseases related to MSC differentiation dysregulation. 
 
Tissue-nonspecific alkaline phosphatase (TNAP) is highly expressed in several tissues 
including bone tissue, where it has a well-established role in skeletal mineralisation. In recent 
years TNAP expression has been reported in adipocytes, and has been identified as identical 
to the stem cell marker, mesenchymal stem cell antigen-1 (MSCA-1). The above findings 
indicate that TNAP has diverse roles, and may be one of the factors involved in determining 
the differentiation pathway of MSCs.  
 
Previous studies have found that inhibition of TNAP in the mouse preadipocyte cell line, 
3T3-L1 resulted in a decrease in lipid accumulation during in vitro adipogenic differentiation, 
suggesting that TNAP is involved in adipogenesis. In the present study, rat-derived primary 
MSCs were isolated from bone marrow (bmMSCs) as well as subcutaneous (scADSCs) and 
peri-renal visceral adipose (pvADSCs) depots, and differentiated in vitro towards either an 
adipocytic or osteoblastic phenotype. The expression of TNAP was assessed in rat-derived 
MSCs undergoing both adipogenic and osteogenic differentiation.  
 
TNAP expression levels were highest in bmMSCs, followed by scADSCs and pvADSCs, 
with higher alkaline phosphatase (ALP) activity observed during adipogenesis compared to 
osteogenesis in all three MSC types. The addition of the reported TNAP inhibitor, levamisole 
during osteogenesis prevented mineralisation in all MSC types, but had no significant effect 
on lipid accumulation during adipogenesis. Other reported inhibitors were also examined; 
Histidine was not successful in reducing lipid accumulation or mineralisation, while L-
homoarginine was able to significantly reduce lipid accumulation in all MSC types. The 
inhibitor results were not conclusive due to possible off target effects within the cells. 
Attempts to inhibit adipogenic differentiation by knockdown of TNAP expression in 
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scADSCs using shRNA were not successful, as indicated by the presence of lipid droplets in 
cells where TNAP-specific shRNA was present.    
 
This study also revealed that ALP activity was localised to the membrane of intracellular 
lipid droplets characteristic of adipocytes, and that the same TNAP mRNA transcript type 
which is preferentially expressed in bone tissue is also preferably expressed during 
adipogenic differentiation of bmMSCs and scADSCs, while expression in pvADSCs was 
below detectable levels.  
 
TNAP isoforms differ from one another due to differences in posttranslational glycosylation 
pattern. Glycosylation differences were observed between bmMSCs differentiated from a 
naïve state towards an adipogenic, compared to an osteogenic, phenotype. Differences were 
also observed between scADSCs and bmMSCs when differentiated towards adipocytes. This 
may indicate that a distinct isoform of TNAP exists in adipocytes.  
 
In conclusion, this study confirms earlier findings on the presence of TNAP in adipocytes. 
Differences in TNAP expression from MSCs isolated from different tissue depots were also 
discovered. This study provides a characterisation of the role of TNAP in adipogenic 
differentiation; however, the exact mechanisms remain to be elucidated. 
 
 
Key words: Tissue-nonspecific alkaline phosphatase, mesenchymal stromal cell, bone-
marrow, adipocyte, osteoblast, rat, levamisole, L-homoarginine, histidine, glycosylation. 
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AFRIKAANSE OPSOMMING 
Die wanregulering van adiposiet en osteoblast differensiasie lei tot verskeie siektetoestande, 
insluitende tipe II diabetes en osteoporosis. Beide adiposiet en osteoblast seltipes is 
afstammelinge van dieselfde stamseltipe, naamlik mesenchiem stromale selle (MSSe). Meer 
breedvoerige kennis van die onderliggende faktore wat bydra tot hierdie wanregulering kan 
aanleiding gee tot verbeterde behandelingsmetodes vir siektes geassosieer met afwykende 
MSS differensiasie. 
 
Daar is ‘n hoë uitdrukking van weefsel nie-spesifieke alkaliese fosfatase (WNAF) in verskeie 
weefseltipes, insluitende been, waar dit ‘n welbekende rol speel in skelet mineralisering het. 
Daar is onlangs bevind dat WNAF in adiposiete uitgedruk word en dat dit identies is tot die 
stamsel merker, mesenchiem stamsel antigeen-1. Hierdie bevindinge dui daarop dat WNAF 
verskeie diverse funksies het en dat die ensiem een van die bepalende faktore mag wees wat 
bydra tot differensiasie van stamselle. 
 
Vorige navorsing het gewys dat inhibisie van WNAF in die muis pre-adiposiet sellyn, 3T3-
L1, lei tot ‘n afname in lipied akkumulasie tydens in vitro adipogeniese differensiasie. Dit 
impliseer dat WNAF betrokke is by adipogenese. In die huidige studie was daar gebruik 
gemaak van rot-afgeleide primêre MSSe geïsoleer uit beenmurg (bmMSSe), asook selle 
verkry uit subkutaan (skAASSe) en peri-renale visserale (pvAASSe) vet depots. Hierdie selle 
was gedifferensieer, in vitro, in ‘n adiposiet of osteoblast fenotipe. Die uitdrukking van 
WNAF was bepaal in rot-afgeleide MSSe wat gestimuleer was om of adipogeniese of 
osteogeniese differensiasie te ondergaan. 
 
Vlakke van WNAF uitdrukking was die hoogste in bmMSSe gevolg deur skAASSe en 
pvAASSe. Daar was meer alkaliese fosfatase aktiwiteit tydens adipogenese in al drie MSS 
tipes. Verder het die WNAF inhibitor, levamisool, mineralisering tydens osteogenese 
voorkom in al drie MSS tipes. Die inhibitor het egter geen beduidende effek gehad op lipied 
akkumulasie tydens adipogenese nie. 
 
Die effek van twee ander moontlike WNAF inhibitore, histidien en L-homoarginien, was ook 
ondersoek. Histidien het nie lipied akkumulasie of mineralisering onderdruk nie. 
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Inteenstelling hiermee het L-homoarginien lipied akkumulasie beduidend in al drie MSS tipes 
verminder. Resultate verkry met inhibitore was nie beslissend nie. Dit mag wees as gevolg 
van moontlike buite-teiken effekte van die inhibitore in hierdie selle. Dus was daar gepoog 
om adiposiet differensiasie te inhibeer deur die afklop van WNAF uitdrukking in skAASSe. 
Dit was bewerkstellig deur gebruik te maak van klein haarnaald RNAs (khRNAs). Selle het 
egter steeds lipied druppels vertoon in die teenwoordigheid van WNAF spesifieke khRNAs. 
 
Eksperimente in hierdie tesis het ook onthul dat WNAF aktiwiteit gelokaliseer is in die 
membraan van intrasellulêre lipied druppels. Verder is daar ook gedemonstreer dat dieselfde 
WNAF boodskapper RNA-transkripsie tipe wat met voorkeur in beenweefsel uitgedruk word, 
ook met voorkeur tydens adipogeniese differensiasie uitgedruk word in bmMMSe en 
skAASSe. Die uitdrukking van hierdie transkripsie tipe was nie in pvAASSe gevind nie.  
 
Verskille in post-translasie glikosilasie gee aanleiding to verkillende isoforme van WNAF. 
Glikosilasie-verskille was gesien in MSSe differensiasie in ‘n adipogeniese fenotipe in 
vergelyking met differensiasie in ‘n osteogeniese fenotipe. So ook was daar verkille gemerk 
tussen skAASSe en bmMSSe wat gedifferensieer was in ‘n adiposiet fenotipe. Dit mag 
aandui dat ‘n eiesoortige WNAF isoform in adiposiete voorkom. 
 
Bogenoemde saamgevat, die huidige studie bevestig vroeëre bevindinge dat WNAF 
teenwoordig is in adiposiete. Verskille is gewys in die uitdrukking van WNAF in MSSe 
geïsoleer uit versillende weefsel depots. Hierdie studie voorsien ‘n karakterisering van die rol 
wat WNAF speel in adipogeniese differensiasie, maar die presiese funksie van WNAF is 
egter nog ontwykend.  
 
Sleutel woorde: weefsel nie-spesifieke alkaliese fosfatase, mesenchiem stromale selle, 
beenmurg, vetsel, rot, levamisool, L-homoarginien, histidien, glikosilasie.  
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1.1 Introduction  
Glucocorticoid-induced osteoporosis (GIO) is the most common form of secondary 
osteoporosis. It is characterized by rapid initial increase in bone resorption, resulting from a 
transient increase in osteoclast activity, followed by a marked impairment in bone formation 
due to a chronic decrease in the numbers of osteoblasts, the cells responsible for bone 
mineralisation. GIO may therefore be viewed as primarily an osteoblast problem, with low 
numbers caused by decreased proliferation, increased apoptosis and elevated 
transdifferentiation of osteoblasts into an adipocytic phenotype. This increased switching of 
progenitor cells from an osteoblastic to an adipocytic phenotype produces “fatty bones”, 
which is indicative of the disease (Weinstein, 2001; Compston, 2010). A better understanding 
of the factors involved in the differentiation of precursor cells towards either an adipocytic or 
osteoblastic phenotype would provide a foundation for the development of better treatment of 
diseases resulting from adipocyte and osteoblast dysregulation, such as osteoporosis and type 
II diabetes. 
 
The enzyme tissue-nonspecific alkaline phosphatase (TNAP) is expressed in bone, liver, 
kidney and neural tissue, as well as in adipose and other tissues, and also has a role in stem 
cell differentiation.  The presence of TNAP in mesenchymal stromal cells (MSCs), which are 
the progenitor cells of osteoblasts and adipocytes, as well as in differentiated MSCs, indicates 
that TNAP may be playing an important role in MSC biology and differentiation (Sobiesiak 
et al., 2010; Kollmer et al., 2013).    
 
In humans, four alkaline phosphatase (ALP) isozymes of have been discovered, and are 
defined based on their gene sequence and tissue location (Harris, 1990). The basic types of 
ALP have been identified as three tissue-specific ALPs, including placental (PLAP), germ-
cell (GCAP) and intestinal (IAP) ALP, as well as one tissue-nonspecific ALP (TNAP) which 
is highly expressed in bone, liver and kidney and also at low levels in a variety of other 
tissues (Fishman, 1990; Harris, 1990; Millán et al., 2006). 
 
Due to its established function in bone mineralisation and high expression levels in 
osteoblasts, TNAP has been used as a classical marker for osteogenesis. Osteogenesis is the 
process where mesenchymal stromal cells (MSCs), the progenitor cells of several 
mesenchyme-derived tissue including bone, fat, muscle and cartilage, differentiate into 
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osteoblasts, the cells which form bone (Rebelatto et al., 2008). Recently, findings which seem 
to cast doubt on the role of TNAP as an exclusive marker of osteogenesis include the 
discovery that TNAP is expressed during, and may be involved in, the control of 
adipogenesis, which is the process whereby MSCs differentiate into adipocytes (Ali et al., 
2005; Kollmer et al., 2013).   
 
A study found that both TNAP mRNA and protein expression levels were inhibited after 
treatment of primary cultured rat bone marrow MSCs with the glucocorticoid (GC), 
dexamethasone (Dex) and levels of the adipogenic markers PPARγ and aP2 were up-
regulated in a dose-dependent fashion, resulting in the cells differentiating into adipocytes 
(Lin et al., 2010). A study using the murine preadipocyte cell line 3T3-L1 found that upon 
addition of either of the TNAP-specific inhibitors, histidine or levamisole, after initiation of 
adipogenesis using adipogenic differentiation medium containing Dex, insulin and 3-
isobutyl-1-methylxanthine (IBMX), a decrease in both alkaline phosphatase (ALP) activity 
and lipid accumulation was observed. Levamisole is known to be an uncompetitive inhibitor 
of TNAP, while the mechanism of inhibition by histidine is also thought to be uncompetitive 
(Cyboron et al., 1982; Ali et al., 2006). The tissue-specific ALP inhibitor Phe-Gly-Gly did 
not alter ALP or lipid accumulation in the same experiment, as it is known that Phe-Gly-Gly 
is a tissue-specific ALP isozyme inhibitor (Ali et al., 2005). A further study using 3T3-L1 
cells and primary cultured human preadipocytes showed ALP activity and lipid accumulation 
were blocked by histidine after the initiation of adipogenesis in these cells. Furthermore, only 
IBMX was found to be crucial for adipogenesis as removal of this from the growth medium 
prevented lipid accumulation and blocked ALP activity, indicating a role for cAMP/cGMP 
(Ali et al., 2006). 
 
These findings present strong evidence for the involvement of TNAP in lipid accumulation, 
as inhibition of ALP activity was found to directly affect adipogenesis (Ali et al., 2006). It is 
also believed that TNAP in 3T3-L1 and human preadipocytes is localised to the membrane 
surrounding the lipid droplets as ALP activity has been identified in this area, suggesting 
strongly that TNAP is involved in control of lipid accumulation within these cells (Ali et al., 
2005; Ali et al., 2006). This is in contrast with the location of TNAP in osteoblastic cells, 
which is on the cell surface as well as on the surface of matrix vesicles secreted by the 
osteoblastic cells (Orimo, 2010). 
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As outlined previously, it has been demonstrated that TNAP is present in a wide variety of 
tissues, and may be an essential enzyme for an array of different functions apart from its 
established role in bone mineralisation. Importantly for this study, is the observation that 
TNAP is involved in adipogenesis from murine preadipocyte cell line, 3T3-L1 cells (Ali et 
al., 2005; Ali et al., 2006). The following project aimed to elucidate the function of TNAP 
during adipogenesis, using a rat-derived MSC model, using both naïve and differentiating 
primary-cultured MSCs as opposed to immortalised cell lines, such as MBA15.4 and 3T3-L1 
cells. These cell lines, by nature, have a corrupted cell cycle and this may not only affect 
proliferation but also other cell fates such as differentiation. For this reason, results obtained 
using immortalised cell lines may be less significant than those from primary cells (Marko et 
al., 1995; Czekanska et al., 2014). The present study contrasted the expression of TNAP 
during differentiation of MSCs derived from rat bone marrow and adipose tissue, towards an 
adipocyte phenotype with the differentiation of the same cells towards an osteoblast 
phenotype. The main aim of this study was to further elucidate the function of this enzyme in 
cells derived from bone marrow and adipose tissue. 
 
This following literature review discusses the biochemistry and roles of alkaline phosphatases 
as well as biology and differentiation of mesenchymal stromal cells (MSCs), with specific 
focus on the role of tissue-nonspecific alkaline phosphatase within the context of 
osteoblastogenesis and adipogenesis of MSCs.  
 
1.2 Literature Review  
1.2.1 Alkaline phosphatase background 
Although it has been studied for over 80 years, much still remains to be discovered about 
alkaline phosphatase (ALP). Discovered in 1923 by Robert Robison, ALP was first 
hypothesized to function in bone mineralization; a hypothesis that was only proven to be 
correct more than 60 years later, in 1988 (Whyte, 2010). The name, “alkaline” phosphatase 
for this enzyme is a misnomer, resulting from in vitro studies of its pH optimum using 
artificial substrates, as alkaline phosphatase is known to function at physiological pH (pH 6.4 
- 7.6) (Sprokholt et al., 1982; Whyte, 2010).  ALP is found ubiquitously in a vast array of 
organisms, from bacteria to plants and animal species.   
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1.2.2 Biochemistry of ALPs  
Alkaline phosphatases are found widely in many species, ranging from bacteria to higher 
eukaryotes, including man (Millán et al., 2006). ALPs function to catalyse the hydrolysis of 
phosphomonoesters, which results in the release of inorganic phosphate molecules (Hoylaerts 
et al., 2006), and also have transphorylation activity when in the presence of high 
concentrations of phosphate acceptor molecules (Millán, 2006). Bacterial alkaline 
phosphatases are found in the bacterial cytosol, where they additionally function as part of a 
pathway to oxidise phosphite to phosphate (Yang and Metcalf, 2004). Substrates for ALPs 
include nucleic acids, which are dephosphorylated at the 5’ phosphate group. This has been 
exploited in molecular biology, where shrimp ALP is added to reactions in order to 
dephosphorylate the 5’ ends of the DNA after endonuclease digestion, which prevents self-
ligation of DNA (Nilsen et al., 2001; Twyman., 2006). Shrimp ALP is used here due to its 
thermolability, and may be irreversibly inactivated at 65° C, a temperature which does not 
harm the other reaction components (Nilsen et al., 2001). ALPs belong to the enzyme 
superfamily: nucleoside pyrophosphatase/phosphodiesterases (Gijsbers et al., 2001; Millán et 
al., 2006) and have homology with many different enzymes.  
 
1.2.3 Alkaline phosphatase structure and function   
The largest differences are found between ALPs of bacteria and that of mammals. These 
differences include the Km value, specific activity, glycosylation state, inhibitor susceptibility 
and heat stability  (Millán et al., 2006). Mammalian ALPs have a higher pH optimum (pH 8-
10) than their bacterial counterparts; however, TNAP functions in vivo at physiological pH, 
suggesting that the usage of the term “alkaline” is not entirely correct (Millán et al., 2006; 
Halling Linder et al., 2009; Whyte, 2010). The Km and specific activity is higher for 
mammalian ALPs compared to bacterial ALPs, while the heat stability is lower (Millán, 
2006). Additionally, mammalian ALPs are inhibited uncompetitively by L-amino acids and 
peptides (Millán, 2006). 
 
ALP enzymes have structural features which are highly conserved across all species, such as 
the catalytic site, as well as many major differences. The catalytic site of ALPs contains a 
catalytic serine, as well as three metal binding sites, namely M1 (also called Zn1) containing 
a Zn
2+ 
ion, M2 (or Zn2) also containing a Zn
2+ 
ion and M3, which contains a Mg
2+ 
ion 
(Millán, 2006). The Escherichia coli ALP is coded for by the phoA gene and is known as E. 
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coli ALP (ECAP) or PhoA, and was for many years the only available model for 
investigating the structural features of ALPs (Kozlenkov et al., 2002; Hoylaerts et al., 2006). 
ECAP exists as a soluble homodimer, as is located in the bacterial periplasm. ALPs exist 
nearly exclusively as homodimers in nature, with few exceptions, such as the silkworm 
(Bombyx mori) ALPs. Silkworm ALP isozymes exist as either a soluble or membrane bound 
form, encoded by two distinct genes, and are mainly present in a monomeric form (Eguchi, 
1995).  
 
The elucidation of the structure of human placental ALP (PLAP) has allowed for the structure 
of other mammalian ALPs to be modelled (Kozlenkov et al., 2002; Hoylaerts et al., 2006). 
All mammalian ALPs have a homodimeric structure with a catalytic site present on each 
monomer. The two Zn
2+ 
ions at sites M1 and M2 provide stability to the tertiary structure, 
while the Mg
2+
 ion at M3 acts as a cofactor for catalytic activity (Millán et al., 2006). From 
the PLAP model, it was found that the central core consisting of a β-sheet and several α-
helices was highly similar to that of ECAP (Kozlenkov et al., 2002). ECAP contains four 
cysteine residues, giving rise to two disulfide bonds (Sone et al., 1997), however all 
mammalian ALPs contain five cysteine residues, nonhomologous to the ECAP cysteines, of 
which four are involved in disulfide bonds. The fifth mammalian ALP cysteine residue 
appears to have a nonessential function, as mutations at this position have an insignificant 
effect on enzyme activity (Kozlenkov et al., 2002). Certain amino acid residues which are 
important for metal ion binding in the active site in PLAP, are conserved between 
mammalian ALPs, namely Asp-42, His-153, Ser-155, Glu-311, Asp-316, His-320, Asp-357, 
His-358, His-360, and His-432. Of these, His-153 is not conserved in PhoA, nor is His-317, 
both of which are located near the Mg
2+ 
site on PLAP (Kozlenkov et al., 2002; Millán, 2006). 
Figure 1.2.3.1 presents a structural model of TNAP which illustrates the main features of this 
enzyme in its naturally occurring homodimeric structure (Millan and Whyte, 2016). 
 
The mammalian ALPs are stabilized in their homodimeric structure by a “crown” or top loop 
domain, unique to mammalian ALPs and so named because of its position on the molecule, 
as well as by residues on the amino terminal sequence, which help to bind the monomers 
together (Le Du et al., 2001; Hoylaerts et al., 2006). The crown domain consists of a 60-
residue segment from each monomer containing two small β-sheets consisting of three 
parallel strands, and enclosed by six large flexible loops containing a short α-helix (Le Du et 
al., 2001). The crown domain is the least conserved feature amongst mammalian ALPs. 
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Variations in isozyme-specific properties of mammalian ALPs have been attributed to the 
crown domain, particularly to the residue at position 429 within the crown domain, including 
differences in heat-stability, uncompetitive inhibition and allosteric behaviour (Millán, 2006).  
Mammalian ALPs are noncooperative allosteric enzymes, meaning that the binding of 
substrate in the active site of one monomer will not affect the active site of the second  
monomer, when all the required metal ions are present on both subunits (Hoylaerts et al., 
1997; Le Du et al., 2001). The crown domain may facilitate interactions between mammalian 
ALPs and proteins in the extracellular matrix, and has been found to be involved in the 
collagen-binding ability of TNAP (Bossi et al., 1993; Hoylaerts et al., 2006; Millán et al., 
2006).  
 
The amino terminal sequence of mammalian ALPs contains an α-helix, which is not present 
in ECAP, and may be involved in stabilising the dimerization of the monomers, as the α-helix 
sequence of one monomer interacts with and embraces the second monomer (Hoylaerts et al., 
2006; Millán, 2006). The amino terminus is also required for catalytic activity of mammalian 
ALPs, as an example, it has been found previously that deletion of 5 residues of this sequence 
reduced the alkaline phosphatase activity of TNAP, whereas deletion of 9 residues totally 
eliminated catalysis (Hoylaerts et al., 2006). Despite the above similarities, several 
differences exist between alkaline phosphatases from different species, as well as between the 
various isozymes and isoforms within a species (Millán, 2006; Millán et al., 2006). 
 
In mammalian ALPs, a highly conserved tyrosine residue at position 367 is vital for catalytic 
ability. The Tyr-367 residue of one monomer protrudes into the active site of the second 
monomer in the vicinity of the M1 (Zn1) ion, where the hydrophobic phenyl ring of Tyr-367 
contributes to the formation of the hydrophobic pocket within PLAP.  Tyr-367 functions to 
stabilise the inhibitors of ALP, as removal of Tyr-367 destabilised the inhibitor binding at the 
active site of the enzyme (Kozlenkov et al., 2002).  
 
A fourth metal binding site, designated as M4, has been identified in mammalian ALPs, but 
not in ECAP, and contains a noncatalytic Ca
2+ 
 ion. The M4 site is found in the peripheral 
domain, and in PLAP consists of residues 250-297, a sequence which contains two α-helices. 
It is thought that the Ca
2+ 
ion at the M4 site is necessary to stabilise the conformation of the 
α-helices in the peripheral domain (Llinas et al., 2005). 
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Figure 1.2.3.1: Representation of the homodimeric structure of human tissue-nonspecific alkaline 
phosphatase (TNAP). A phosphate (PO43-) ion is shown in green at the active site of each monomer, 
surrounded by the three active site metal ions: two Zn
2+ 
(Zn1 and Zn2) and one Mg
+
 (Mg) ions, shown in white. 
The position of the structural Ca
2+ 
ion binding site is also shown in white. The positions of the crown domain 
and N-terminus are illustrated, as well as the position of the glycosylphosphatidylinositol (GPI) anchors at the 
carboxyl terminus for each monomer. Image taken from (Millan and Whyte, 2016). 
 
In vitro studies have shown that ALPs are able to hydrolyse a broad range of substrates, 
however only a small number have been confirmed as natural substrates of ALP; these 
include inorganic pyrophosphate (PPi), as well as phosphoethanolamine and pyridoxal-5ʹ-
phosphate (Whyte et al., 1995). PPi is an inhibitor of mineralisation, which is hydrolysed by 
TNAP to form inorganic phosphate (Pi), a necessary component for mineralisation of bone 
tissue (Orimo, 2010). Pyridoxal-5'-phosphate (PLP) was discovered to be a substrate of the 
TNAP present in leukocytes and the human osteosarcoma cell line SAOS-2. The TNAP in 
SAOS-2 cells is additionally able to hydrolyse phosphoethanolamine (PEA) (Wilson et al., 
1983; Fedde et al., 1988). Human PLAP and intestinal ALP (IAP) were found to hydrolyse 
all tested phosphatidates, while TNAP was not able to hydrolyse phosphatidates with long 
fatty acyl chains or another natural substrate for ALPs, inorganic polyphosphate (polyP) 
(Lorenz and Schroder, 2001). In contrast to mammalian ALPs, ECAP is not able to hydrolyse 
phosphatidate (Sumikawa et al., 1990).  TNAP is additionally able to hydrolyse nucleotides, 
such as ATP, ADP and AMP (Say et al., 1991), and has also been reported to have 
phosphodiesterase activity (Rezende et al., 1994). 
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Mammalian ALPs are ectoenzymes, and are anchored to the exterior of the cell membrane 
via a glycosylphosphatidyl inositol (GPI) anchor, which is attached post-translationally at the 
carboxyl terminus (Harris, 1990). GPI anchors are glycolipids found widely in eukaryotes, 
which function to anchor, as the name suggests, a large variety of proteins to cell membranes. 
GPI anchors only traverse the outer leaflet of the phospholipid bilayer, allowing the tethered 
protein to move readily across the surface of the membrane to different locations on the cell 
or vesicle. GPI-anchored proteins are often associated with lipid rafts, which are groupings of 
lipidated proteins, cholesterol and glycosphingolipids on the cell surface forming small areas 
on the cell where the close proximity of its constituents promotes and enhances specific 
processes such as cell signalling (Paulick and Bertozzi, 2008).   
 
1.2.4 Mammalian ALP isozymes  
In humans, four distinct isozymes of ALP are present, encoded at four separate gene loci: 
three tissue-specific isozymes, namely placental ALP (PLAP), germ cell ALP (GCAP) and 
intestinal ALP (IAP) and a single tissue-nonspecific ALP isozyme (TNAP). The tissue-
specific isozymes are found clustered on chromosome 2, and share a sequence homology of 
90 – 98%. TNAP is found on chromosome 1 and has approximately 50% homology to the 
tissue-specific ALPs (Hoylaerts et al., 2006). The E. coli ALP (ECAP), at 471 amino acids 
long, is only 25% homologous to human TNAP, and 29% homologous to human PLAP. A 
low degree of homology is, as expected, observed between human and E. coli ALPs, and 
differences in the primary amino acid sequence can be clearly visualised using a multiple 
sequence alignment of the amino acid sequences of human TNAP, PLAP as well as ECAP 
(Fig. 1.2.4.1) (Weiss et al., 1986).  
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Figure 1.2.4.1: Comparison of the amino acid sequences of E.coli (E), human placental (P), and human 
L/B/K (L) ALP precursor proteins. Gaps that have been introduced into the sequences to maximise pairing of 
homolougous amino acids are indicated by -. Amino acid +1 corresponds to the first residue in each of the 
mature proteins. Amino acids that are identical in all three proteins or in the two human proteins are boxed. 
Amino acids that comprise the active site region in the E. coli ALP, including the metal ligand sites (■) and the 
residues that interact with substrate phosphate (●), are indicated. Amino acids are shown in single letter code. 
Taken from (Weiss et al., 1986).   
 
 
It is currently presumed that an ancestral form of mammalian tissue nonspecific ALP 
appeared first, and at some point in time a gene duplication event occurred, resulting in the 
development of one gene into TNAP and the other into an ancestral IAP. It is believed that a 
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further duplication event of the IAP gene occurred, giving rise to GCAP, followed by another 
duplication from which PLAP arose (Fishman, 1990). The IAP is assumed to have been the 
original tissue-specific ALP form, as IAP is present in all mammalian species, while PLAP is 
only present in humans and apes (Doellgast and Benirschke, 1979; Fishman, 1990). The 
presumed relationship between the various human ALP isozymes is illustrated in figure 
1.2.4.2.  
 
Figure 1.2.4.2: Phylogenetic representation of the presumed relationship between mammalian alkaline 
phosphatase isozymes. Adapted from Fishman, 1990.   
 
It is worth noting that some ALP isozymes may be absent in some species and present in 
others. Similar to humans, mice possess four ALP isozymes, however PLAP and GCAP are 
absent in mice, and instead an intestinal-like ALP (IAP-like) and embryonic ALP (EAP) are 
present in addition to IAP and TNAP (Hahnel et al., 1990). Moreover, species-specific 
differences may exist in the tissue distribution pattern of the same ALP isozyme. For 
example, while rat and human serum contain the bone isoform of TNAP, the predominant 
ALP present in human serum is the liver isoform of TNAP, while the liver isoform of TNAP 
is absent in rat serum, and instead the intestinal ALP is the most predominant ALP 
(Dziedziejko et al., 2005).   
 
1.2.4.1 Tissue-specific ALP isozymes 
Human PLAP, as the name suggests, is synthesized in placental tissue, but may also be found 
in normal serum in trace amounts (Vergote et al., 1992). PLAP has 30% sequence identity 
with ECAP (Le Du et al., 2001), and 87% sequence identity with IAP (Henthorn et al., 1988).  
PLAP is heat-stable, and like other mammalian ALPs, is post-translationally modified and 
contains two N-glycosylation sites. Phosphatidates as well as inorganic polyphosphates 
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(polyP) have been confirmed as natural substrates for PLAP (Millán, 2006), with the enzyme 
being uncompetitively inhibited by L-amino acids including, L-Phe, and L-Trp and L-Leu (Le 
Du et al., 2001). 
 
PLAP is expressed most highly during the second and third trimesters, at which time it is also 
one of the major circulating ALP isozymes, but disappears rapidly from serum after birth 
(Valenzuela et al., 1987). A role for PLAP in the transferral of maternal IgG to the foetus has 
been suggested, as well as in cell division in both normal and cancerous cells (Stefaner et al., 
1997; She et al., 2000; Le Du et al., 2001). PLAP has been identified as a tumour marker, as 
it is ectopically expressed in cancer cells, where it is known as the Regan isozyme, named 
after a patient by the name of Mr. Regan, who had a PLAP-like isozyme of ALP in his cancer 
cells and serum. This led to the hypothesis that cancer cell progression may result from the 
deregulation of embryonic genes, or specifically by derepression of the genome in cancer 
cells, allowing enhanced expression of enzymes in cells or tissues where they are not 
normally expressed (Fishman et al., 1968; Fishman et al., 1968). PLAP may also be involved 
in the modulation of foetal growth, as the addition of highly purified PLAP to cultures of 
NIH 3T3 mouse embryo fibroblasts, as well as human foetal fibroblasts, was able to promote 
DNA synthesis and cell proliferation, in synergism with Zn
+
, Ca
2+
 and insulin. She et al. 
suggested that the mitogenic effect of PLAP may be due to the ability of PLAP to activate a 
variety of growth regulatory enzymes, including c-Raf-1, p42/p44 mitogen-activated protein 
kinases, p70 S6 kinase, Akt/PKB kinase and phosphatidylinositol 3P-kinase. The mechanism 
by which PLAP is able to stimulate DNA synthesis and cell proliferation is unknown, and the 
addition of either TNAP or IAP was not able to stimulate DNA synthesis in the same way as 
PLAP, indicating that the mechanism may be unrelated to the phosphatase activity of the 
enzyme (She et al., 2000).  
 
Germ cell ALP (GCAP), also known as placental-like ALP, and is found at low levels in 
germ cells, as well as in embryonal tissue, testis, thymus, cervix, lung and in trace amounts in 
placental tissue (Povinelli and Knoll, 1991; Tsai et al., 2000; Sharma et al., 2014). GCAP is 
heat-stable and has a 98% sequence homology to PLAP. Similarly to PLAP, GCAP, which is 
also called the Nagao isozyme, (Chang et al., 1980; Goldstein et al., 1982) and may have 
enhanced expression in cancer cells, such as germ-cell tumours of the testis, and particularly 
seminomas (Wahren et al., 1979). The Nagao isozyme, was named after the patient in which 
it was initially discovered, where it was found to have similar properties of heat stability, 
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immunological properties, electrophoretic mobility and urea sensitivity, but was more 
susceptible to inhibition by L-Leucine, and also displayed differences in enzyme kinetics 
compared to PLAP (Nakayama et al., 1970; Millan and Manes, 1988).  
 
IAP is highly expressed in intestinal tissue, both during foetal development and adulthood. 
Most species have only one IAP isoform, however two IAP isoforms have been identified in 
rat, and four IAP isoforms in cow (Ghosh et al., 2013; Estaki et al., 2014). IAP is expressed 
by all gut enterocytes in the duodenum in high levels, and in decreased concentrations in the 
jejunum, ileum and colon. IAP is secreted from gut enterocytes in luminal vesicles, from both 
the apical and basolateral surfaces, where it enters the intestinal lumen, as well as the 
circulation (Estaki et al., 2014).  
 
The cell walls of Gram-positive bacteria contain lipopolysaccharide (LPS), the presence of 
which in the blood as a consequence of bacterial infection, results in an inflammatory 
response by the host. IAP is able to dephosphorylate the lipid A moiety on the LPS molecule, 
which detoxifies the LPS, preventing inflammation and sepsis (Estaki et al., 2014). 
Nucleotides are known to inhibit the growth of gut bacteria. IAP promotes the growth of 
aerobic and anaerobic gut bacteria by dephosphorylating ATP as well as other nucleotide 
triphosphates, found in the lumen (Malo et al., 2014).  IAP has anti-inflammatory properties, 
as the addition of IAP is able to inhibit the release of the inflammatory cytokine IL-8 by cells 
induced by the presence of pro-inflammatory ligands, such as uridine diphosphate (UDP), 
LPS, flagellin, Pam3Cys and TNF-α (Moss et al., 2013). Several other functions for IAP have 
been identified, including modulation of long chain fatty acid (LCFA) absorption in the gut, 
detoxification of bacterial LPS, which reduces inflammation, as well as the regulation of 
bicarbonate secretion and gut pH (Lalles, 2010; Estaki et al., 2014; Lalles, 2014).  
 
1.2.4.2 Tissue-nonspecific ALP (TNAP)  
TNAP is found at low levels in a large variety of tissues, but predominantly in hepatic, renal 
and skeletal tissue, for which reason it is often referred to as liver/kidney/bone ALP (LBK 
ALP) (Sharma et al., 2014). TNAP, like the tissue-specific ALPs, exists either as a 
homodimer in circulation or a tetramer, where each unit is bound to the outer surface of the 
cell membrane by a GPI anchor. A high degree of heat stability is present in TNAP compared 
to tissue-specific ALPs, as a result of the conformation of the crown domain of the enzyme 
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(Bossi et al., 1993). TNAP occurs in several isoforms, as a result of a large variety of post-
translational modifications in the form of glycosylations. The various TNAP isoforms have 
an identical primary amino acid sequence, are often tissue-specific in expression pattern and 
vary in the characteristics, such as thermo-stability and sensitivity to various inhibitors 
(Nosjean et al., 1997; Martins et al., 2001) 
 
1.2.4.2.1 Posttranslational modifications of TNAP 
There are differences in glycosylation patterns between the TNAP expressed in bone and 
liver. O-linked glycosylations are found in bone and kidney TNAP isoforms, but are absent in 
the liver isoform. Differences concerning the presence or absence of O-glycosylations, as 
well as the number of O-glycosylations present, are thought to be the main factors 
contributing to the observed differences between TNAP isoforms, such as heat stability and 
inhibitor sensitivity (Nosjean et al., 1997). Removal of the O-glycosylations had different 
effects on the activities of liver and kidney TNAP (Martins et al., 2001). Differences in the 
activity levels of liver and kidney TNAP isoforms have also been found in the presence of 
certain drugs such as levamisole, indicating that the activity of these isoforms are not 
modulated in the same way, which is probably due to differences in glycosylation (Martins et 
al., 2001). N-linked glycosylation is required for catalytic activity of all three TNAP 
isoforms, but is not essential for the other tissue-specific ALP (TSAP) isozymes (Martins et 
al., 2001; Whyte, 2010). By examining the predicted translation of TNAP cDNA, five 
possible sites for N-linked glycosylation have been proposed in the protein sequence. It is not 
yet known how many of the possible N-linked glycosylation sites are actually glycosylated, 
but research has suggested that there is a difference in N-linked glycosylation between the 
two TNAP isoforms due to differences observed in their immunoreactivity (Nosjean et al., 
1997; Whyte, 2010). Heat stability differences between bone and liver TNAP isoforms have 
also been observed, with heat stability being lowered in both isoforms when the 
glycosylations are removed (Martins et al., 2001). 
 
The bone TNAP isoform is also found in circulation in the serum in soluble homodimeric 
form, due to cleavage of the GPI anchor by two endogenous phospholipases: GPI-specific 
phospholipase C and GPI-specific phospholipase D. Evidence exists that this soluble alkaline 
phosphatase is physiologically inactive, as infants suffering from hypophosphatasia: a 
condition resulting in impaired bone mineralisation arising from mutations in the TNAP 
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gene, who received either purified placental ALP or serum from patients with Paget’s bone 
disease, as these patients have elevated levels of soluble ALP in the serum, showed no sign of 
clinical improvement (Millán et al., 2006; Whyte, 2010). This however does not prove that 
that solubilised ALP is completely physiologically inactive. 
 
1.2.4.2.2 Tissue distribution and known functional roles of TNAP isoforms  
1.2.4.2.2.1 TNAP in skeletal tissue 
The well-established primary function of TNAP in bone tissue is the hydrolysis of inorganic 
pyrophosphate (PPi) to organic pyrophosphate (Pi). PPi is an inhibitor of mineralisation, 
while Pi is an essential component needed for mineralisation of collagen-rich osteoid to 
calcified bone. TNAP has the ability to bind collagen types I, II and X via the crown domain, 
and therefore the formation of a complex between TNAP and collagen may contribute the 
function of TNAP within its role in the mineralisation of osteoid to calcified bone (Vittur et 
al., 1984; Bossi et al., 1993). 
 
1.2.4.2.2.2 TNAP in liver and kidney tissue 
In the liver, TNAP is expressed on the apical surface of hepatocytes and cholangiocytes. The 
constituents of bile, produced in the liver, are highly controlled by the intrahepatic biliary 
epithelium through the secretion and/or re-adsorption of various components prior to its 
release into the duodenum. TNAP present on the surface of the intrahepatic biliary epithelial 
cells plays a role in this regulation by actively down-regulating secretion of bile components 
(Alvaro et al., 2000). In kidney, research suggests that TNAP may be involved in vascular 
calcification characteristic of renal failure. This may be due to increased activity of TNAP 
during conditions of renal impairment, resulting in an increase in hydrolysis of the 
mineralisation inhibitor PPi, which allows for calcification to occur (Lomashvili et al., 2008). 
 
1.2.4.2.2.3 TNAP in neural tissue  
Significant levels of TNAP expression have been discovered in neural tissue, including 
endothelial cells of the brain (Fonta et al., 2004; Negyessy et al., 2010). The function of 
TNAP in the brain has not yet been firmly established, however there is evidence that it plays 
an important role due to the phenomena of epileptic seizures and neurological dysfunction 
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associated with either hypo- or hyperphosphatasia (Negyessy et al., 2010). Studies in primate 
species have pointed to the possible role for TNAP in the blood/brain barrier and in 
neurotransmission (Fonta et al., 2004). Data from various primates, including humans, as 
well as rat neuronal and endothelial cells show expression of the bone-specific isoform of 
TNAP, while in mice the liver isoform of TNAP is additionally expressed in neuronal cells 
(Brun-Heath et al., 2011). TNAP has since been found in endothelial cells and at synaptic 
contacts within the brain, and the role in γ-aminobutyric acid (GABA) metabolism has been 
discovered. Pyridoxal-5′-phosphate (PLP) is an essential cofactor for the enzyme glutamate 
decarboxylase (GAD), the function of which is the synthesis of the inhibitory 
neurotransmitter, GABA. TNAP hydrolyses PLP to form pyridoxal (PL), and in mice where 
TNAP was knocked out, the deficiency in TNAP led to an increased level of PLP in the 
serum, while a decreased level of PLP was observed in neural tissue. The lack of PLP in 
neural tissue was proposed to lead to the impaired functioning of GAD and a subsequent 
reduction of GABA. Reduced levels of GABA are responsible for the seizures present in the 
mutant TNAP phenotype, and could be rescued by treatment of the animals with PL 
(Waymire et al., 1995; Kellett et al., 2011). In human adults, TNAP is expressed in the 
synaptic cleft of the nodes of Ranvier. Studies in mice have shown that in TNAP null mice, 
neurological symptoms including impaired myelination, synaptic dysfunction along with 
epilepsy are present, consistent with the symptoms which occur in severe hypophosphatasia 
in humans (Hanics et al., 2012). 
 
Evidence has been found that plasma TNAP is increased in patients with Alzheimer’s disease 
(AD), where lower cognitive function in patients is associated with higher levels of plasma 
TNAP (Kellett et al., 2011). The role of neuronal TNAP in AD is related to its ability to 
dephosphorylate hyperphosphorylated tau protein. AD is a neurodegenerative disease which 
is characterised by the presence of plaques of amyloid-β peptide and extracellular 
neurofibrillary tangles, consisting of the microtubule associated protein, tau. In AD, 
hyperphosphorylated tau protein disassociates from microtubules and forms aggregates inside 
neurons, causing degeneration and death of the neuron (Gomez-Ramos et al., 2006; Diaz-
Hernandez et al., 2010). TNAP dephosphorylates the hyperphosphorylated tau protein, which 
may be aggregated or soluble, which then binds to muscarinic receptors M1 and M3 on 
adjacent neuron, inducing an increase in intracellular calcium levels (Diaz-Hernandez et al., 
2010).The disruption in calcium homeostasis which results is toxic to the neuron, resulting in 
neuronal death and further release of tau protein. Results using the neuroblastoma cell line, 
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SH-SY5Y, showed that TNAP expression increased when muscarinic receptors were 
activated by dephosphorylated tau, which has been proposed to be induced by the increase 
calcium concentration (Diaz-Hernandez et al., 2010). A further function for neuronal TNAP 
has been postulated, wherein TNAP protagonistically affects the interaction of cellular prion 
protein (PrP
C
) with the cell adhesion molecule, laminin, by altering the phosphorylation state 
of laminin, as laminin is thought to be a substrate of TNAP. The interaction of PrP
C 
with 
laminin is thought to be dependent on the phosphorylation state of laminin. PrP
C 
is a 
membrane-bound protein thought to be involved in cell signalling, as well as having a 
function as a membrane receptor. The regulation of laminin-PrP
C 
binding by TNAP may 
therefore also contribute to neuronal homeostasis (Ermonval et al., 2009). 
 
1.2.4.2.2.4 TNAP as a stem cell marker 
The expression and regulation of alkaline phosphatases appears to be dependent on the 
cellular microenvironment, as well as the differentiation status of cells and tissues, both in 
vivo and in vitro. This makes ALP expression a good differentiation marker for certain cell 
types (Stefkova et al., 2015). A high level of ALP activity has long been a marker for 
pluripotent stem cells, both in humans and mice, including embryonal cancer (EC), 
embryonic germ (EG), embryonic stem (ES) and induced pluripotent stem (iPS) cells 
(Stefkova et al., 2015). The ALP isozymes expressed in stem cells include germ cell ALP 
(GCAP) in humans and embryonic ALP (EAP) in mice, as well as TNAP, while the 
remaining TSAPs are associated with more differentiated cells and tissues. TNAP is the main 
ALP of interest in the stem cell field, as in humans, TNAP is more widely and abundantly 
expressed than GCAP (Stefkova et al., 2015).  
 
In mice, EAP is mainly expressed in preimplantation embryos, however, from embryonic day 
7 to 14, EAP decreases rapidly, and TNAP becomes the predominantly expressed ALP in 
primordial germ cells (PGCs) as they migrate towards the developing gonad (Hahnel et al., 
1990). In humans, GCAP rather than TNAP remains in migrating PGCs (Stoop et al., 2005). 
TNAP expression is also high in mouse ES, EC, EG and PG cells (Ginsburg et al., 1990; 
Narisawa et al., 1997; Stefkova et al., 2015). Stefkova et al. suggest that the shift in 
expression between ALP isozymes during development may be due to the changing 
environment of the cells during development, where different isozymes of ALP are better 
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suited to changing environmental conditions of the cells as development proceeds (Stefkova 
et al., 2015). 
 
Although ALP expression is high in ES cells, it has not been proven to be a universal stem 
cell marker for other stem cells, including adult stem cells. TNAP expression has been 
observed in some neural cells from populations which are rich in neural stem cells and 
progenitors, where TNAP expression was more associated with the behaviour, such as 
proliferation and migration,  rather than phenotypic differences of the cells (Langer et al., 
2007). It was discovered by Sobiesiak et al. that TNAP is identical to mesenchymal stem cell 
antigen-1 (MSCA-1) (Sobiesiak et al., 2010) which has long been used to aide identification 
of MSC populations, along with other markers (Battula et al., 2009; Alexander et al., 2010; 
Sobiesiak et al., 2010). The presence of TNAP in naïve unexpanded human bone marrow-
derived MSCs (bmMSCs) was variable, meaning that some cells expressed TNAP and some 
cells did not. Naïve bmMSCs expressing TNAP had less multipotential capacity and greater 
expression of osteogenic-related genes, while naïve bmMSCs that did not express TNAP 
could be differentiated into either osteogenic, adipogenic and chondrogenic lineages (Kim et 
al., 2012). In 2013, Kollmer et al. detected TNAP expression in human MSCs derived from 
bone marrow while these cells were undergoing adipogenesis, in addition to the presence of 
the bone-specific markers osteopontin and osteocalcin (Kollmer et al., 2013). In the same 
study, the adipogenic markers, adiponectin and leptin were identified in the human MSCs 
when induced towards an osteoblast phenotype. These results further illustrate the known 
plasticity observed between the adipogenic and osteogenic lineages (Kollmer et al., 2013).  
 
Interestingly, a high level of TNAP expression characterises pluripotency in pluripotent stem 
cell phenotypes, however a high level of TNAP expression in adult stem cell populations 
corresponds to differentiation and a reduction in stemness (Stefkova et al., 2015). 
 
1.2.4.2.2.5 TNAP in adipogenic differentiation   
TNAP is well established as a marker for osteogenesis, however it has been found that it may 
also play a role in adipogenesis (Ali et al., 2005). Steroid hormones, and particularly the 
steroid hormones known as glucocorticoids (GCs), have been found to stimulate adipocyte 
differentiation as well as regulate fat metabolism (Grégoire et al., 1991). GCs have anti-
inflammatory and immunosuppressive properties and have been used successfully for the 
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treatment of asthma, inflammatory bowel disease as well as arthritis and spinal cord injuries, 
however long term use of GCs can result in loss of bone density (Lin et al., 2010). Studies 
have shown that both ALP mRNA and protein expression levels were inhibited after 
treatment of primary cultured rat bmMSCs with the GC, dexamethasone (Dex) and levels of 
the adipogenic markers PPARγ and aP2 were up-regulated in a dose-dependent fashion, 
resulting in the cells differentiating into adipocytes, implying that TNAP is not involved in 
adipogenic differentiation of these cells (Lin et al., 2010). In contrast, a study using the 
murine preadipocyte cell line 3T3-L1 found that upon addition of either of the ALP 
inhibitors, histidine or levamisole, after initiation of adipogenesis using adipogenic medium 
containing Dex, insulin and 3-isobutyl-1-methylxanthine (IBMX), a decrease in both ALP 
activity and lipid accumulation was observed (Ali et al., 2006). Levamisole is known to be an 
uncompetitive inhibitor of TNAP, while the mechanism of inhibition by histidine is uncertain 
(Cyboron et al., 1982; Ali et al., 2006). The ALP inhibitor Phe-Gly-Gly did not alter ALP or 
lipid accumulation in the same experiment, as it is known that Phe-Gly-Gly is a tissue-
specific ALP isozyme inhibitor (Ali et al., 2005), confirming a possible role played by TNAP 
in lipid accumulation. A further study using 3T3-L1 cells and primary cultured human 
preadipocytes showed ALP activity and lipid accumulation was blocked by histidine after the 
initiation of adipogenesis in these cells (Ali et al., 2006). Furthermore, only IBMX was found 
to be crucial for adipogenesis as removal of this from the growth medium prevented lipid 
accumulation and blocked ALP activity (Ali et al., 2006). These findings present strong 
evidence for the involvement of TNAP in lipid accumulation, as ALP activity was found to 
be directly affected when adipogenesis was inhibited (Ali et al., 2006). It is also believed that 
TNAP in 3T3-L1 and human preadipocytes is localised to the membrane surrounding the 
lipid droplets as ALP activity has been identified in this area and co-localises with perilipins. 
As these are a family of proteins that bind to the surface of lipid droplets, where perilipin 1 is 
known to play a role in mediating lipolysis as well as modifying the structure of the lipid 
droplet (Wang and Sztalryd, 2011), this co-localization suggests strongly that TNAP may be 
involved in control of lipid accumulation within these cells (Ali et al., 2005; Ali et al., 2006). 
 
1.2.5 Genetics of TNAP 
In humans, the TNAP gene (designated ALPL) is present as a single copy in the haploid 
genome, located on the distal arm of chromosome one, at bands p34-p36.1 and stretches over 
a region of approximately 50 kb (Smith et al., 1988; Weiss et al., 1988). The ALPL homolog 
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in mice is designated as Akp2 (Studer et al., 1991), and in rats as Alp1 (Toh et al., 1989b). 
The TNAP gene from humans, rats and mice has been shown to consist of 13 exons, where 
the first two exons are noncoding, designated as exons 1a and 1b, followed by 11 coding 
exons interspersed between large introns (Toh et al., 1989b; Matsuura et al., 1990; Studer et 
al., 1991). The first two exons (1a and 1b) are separated from one another by introns and also 
have separate promoter regions, which allows for either exon 1a or 1b to be incorporated into 
the mRNA in a mutually exclusive fashion. The second exon (exon II) is separated from 
exons 1a and 1b by a large introns, and contains a 5′-untranslated region as well as the 
translation start site ATG, while the final coding exon (exon XI) contains the translation stop 
site and a 3′-untranslated region (Weiss et al., 1988). The structure of the ALPL gene is 
illustrated in figure 1.5.1. The arrangement of the ALPL gene allows for the production of 
two different mRNA molecules, which encode the same primary amino acid sequence, but 
have different 5′-untranslated regions (Studer et al., 1991; Millán, 2006).   
 
 
Figure 1.2.5.1: Representation of the genomic structure of the human ALPL gene. Exons are shown in 
black while the 5′- and 3′-untranslated regions are shown in grey. Taken from (Millán, 2006). 
 
It has been found that in humans and rats, the upstream promoter (1a) is primarily used in 
osteoblasts, giving rise bone-type mRNA, while the downstream promoter (1b) is used 
mainly in kidney and liver tissues, where the mRNA transcript produced is referred to as 
liver-type mRNA (Zernik et al., 1991; Sato et al., 1994). The promoter activity of exon (1b) 
is five times weaker than that of the 1a promoter in neutrophilic granulocytes (Sato et al., 
1994). The TNAP present in human neutrophils cultured in vitro, is found on the plasma 
membrane and on the inner surface of secretory vesicles, however the expression of TNAP in 
the neutrophils of other species is variable, for example, TNAP is also found in the 
granulocytes of cows, horses and rabbits, but is absent from the granulocytes of cats, dogs 
and mice (Jain, 1968; Hulme-Moir and Clark, 2011). While the function of TNAP in 
neutrophils is unclear at present, it serves as a marker for different leukocyte populations and 
for tracking the location of secretory vesicles within the cell (Hulme-Moir and Clark, 2011). 
Bone-type mRNA is exclusively expressed in the neuronal and endothelial cells of brain 
tissue from humans, marmosets and rats, while mouse neurons additionally express liver-type 
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mRNA (Brun-Heath et al., 2011). The alternative designation of 1B (B for bone) and 1L (L 
for liver) for exon 1a and 1b indicate the tissue where each TNAP isoform is preferentially 
expressed (Sato et al., 1994; Millán et al., 2006; Orimo, 2010). In mice, the 1a promoter is 
used preferentially for all TNAP-expressing tissue types except heart tissue, where the liver-
type mRNA is expressed at high levels (Studer et al., 1991). The upstream promoter (1a) 
contains several regulatory elements which may influence the expression of TNAP, these 
include a TATA box, four Sp1 binding sites and a retinoic acid response element (Sato et al., 
1994).  
 
Several factors are known to increase TNAP expression in human cells, these include retinoic 
acid, cyclic AMP (cAMP) (Gianni et al., 1993), the transcription factor Sp3, which is part of 
the same family of transcription factors as Sp1, and binds to a consensus GC box on the 1a 
promoter region (Yusa et al., 2000), progestin, which induced TNAP expression in the 
human breast cancer cell line T47D (Di Lorenzo et al., 1991), as well as granulocyte colony-
stimulating factor (G-CSF), which was suggested to play a role in the regulation of TNAP 
expression in polymorphonuclear cells (PMNs) (Rambaldi et al., 1990). It has been reported 
that TNAP expression was induced in a human osteoblast-like cell line, SaOS-2, using β-
glycerophosphate and NaH2PO4, which may be due to an indirect signalling mechanism 
whereby the phosphate released from the hydrolysis of β-glycerophosphate induces a signal 
to increase TNAP expression, as neither of these compounds were found to directly increase 
TNAP at the transcriptional level (Orimo and Shimada, 2008). It has been reported that ALPL 
gene expression is regulated by DNA methylation of a CpG island on the proximal end of the 
ALPL gene. DNA methylation may occur where a cytosine precedes a guanine along the 
DNA sequence. It was reported in this study that the amount of TNAP activity in primary 
human osteoblasts, and the osteoblastic and mammary cell lines, MG-63 and MCF-1 
respectively, was inversely correlated to the amount of DNA methylation present at the CpG 
island, i.e. the greater the methylation, the lower the amount of TNAP transcription 
(Delgado-Calle et al., 2011). 
 
1.2.6 Genetic mutations of TNAP – hypophosphatasia  
Over 200 missense mutations in ALPL, the human gene for TNAP, have been reported to date 
and result in an inborn disorder known as hypophosphatasia (Orimo, 2010; Whyte, 2010). 
Hypophosphatasia is characterised by impaired mineralisation of bone throughout the body 
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with symptoms similar to rickets and osteomalacia (softening of bone) (Millán et al., 2006; 
Orimo, 2010). The degree of severity of hypophosphatasia varies widely depending on which 
mutation is present in the ALPL gene, and can range from stillbirth or death in early infancy 
to merely teeth problems in adulthood. Hypophosphatasia has been found to affect only hard 
tissues, while liver and other tissues expressing TNAP in significant quantities are seemingly 
unaffected (Whyte, 2010). Bone TNAP is found to be naturally present in circulation. 
However, evidence suggests that these proteins are not physiologically active when found 
soluble in the serum, as administration of serum containing soluble TNAP does not 
ameliorate the effects of hypophosphatasia to a satisfactory level (Orimo, 2010; Whyte, 
2010). No effective treatment for hypophosphatasia is available at present, although positive 
results have been obtained using allogenic mesenchymal stem cells for treatment of infantile 
hypophosphatasia (Tadokoro et al., 2009). Along with the development of TNAP-knockout 
mice (Orimo, 2010), studies of hypophosphatasia remain useful for gaining insight into the 
function of TNAP in humans.  
 
1.2.7 Mesenchymal stromal cells (MSCs) 
Both osteoblasts and adipocytes are derived from the same progenitor cells, namely 
mesenchymal stromal cells (MSCs). TNAP has been clearly defined as a highly necessary 
constituent for mineralisation (Whyte, 2010) and increased expression of TNAP  in MSCs 
has been conventionally used as a marker for osteogenesis (Rebelatto et al., 2008). More 
recently, it has been discovered that TNAP may also be involved in adipogenesis, prompting 
further investigation into the function of TNAP in MSC differentiation.  
 
MSCs are defined according to their spindle shape, plastic-adherent nature, and their ability 
to differentiate into cells of tissues such as osteoblasts found in bone, adipocytes in fat tissue, 
myocytes in muscle tissue and chondrocytes, from cartilage, as well as into cells which have 
other functional properties, including the tempering of immuno-inflammatory functions and 
stromagenesis (Pittenger et al., 1999; Covas et al., 2008; Casteilla et al., 2011). MSCs may 
also be able to differentiate towards neuronal and smooth muscle phenotypes (Fig. 1.2.7.1) 
(James, 2013). MSCs can be isolated from a variety of different tissues, including bone 
marrow, adipose tissue and umbilical cord blood, although these cells are most commonly 
derived from bone marrow or adipose tissue (Chen et al., 2007; Gazit et al., 2008). Interest in 
MSCs has been increasing greatly in recent years due to their possible uses in tissue 
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regenerative therapy, as well as for treatment of tumours (Horwitz et al., 2007; Rebelatto et 
al., 2008; Keating, 2012). The acronym MSC originally stood for mesenchymal stem cell, 
however it has been discovered that the plastic adherent cells isolated from various tissues 
mentioned earlier frequently exist as a heterogeneous population in vitro. Although the cells 
isolated and cultured in this way do exhibit multipotentiality, they may not meet the specific 
criteria to allow them to be designated as stem cells, such as the capacity for long-term self-
renewal, as well as the ability to differentiate into multiple cell types in vivo. The existence of 
true mesenchymal stem cells is not in dispute, and it is likely that they form a sub-population 
of plastic-adherent cells. The issue remains that unless the cells in question have been 
thoroughly evaluated for the aforementioned stem cell characteristics, they should be 
designated as stromal cells, and thus eliminate any confusion about their exact nature 
(Horwitz et al., 2005). These observations led investigators to propose that mesenchymal 
stem cells be renamed multipotent mesenchymal stromal cells, to allow for a more strict 
definition of stem cell characteristics (Horwitz et al., 2005; Horwitz et al., 2007).  Despite 
this proposal, many researchers continue to use the name “mesenchymal stem cell” in 
publications, resulting in a situation where both names are frequently used in the literature to 
describe the same cells. 
 
 
Figure 1.2.7.1: Representation of the multilineage differentiation potential of mesenchymal stromal cells 
(MSCs). MSCs are able to differentiate towards adipocytic, osteoblastic, chondrogenic, myogenic, neuronal as 
well as smooth muscle lineages. Adapted from (James, 2013). 
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Defining a set of characteristics that can be used to accurately and reliably identify MSCs has 
proven to be a challenging task for researchers, and as of yet there are no set criteria for 
identification of MSCs in vivo. However, basic in vitro purification allows MSC 
characteristics to be assessed (Chen et al., 2007). According to the International Society for 
Cellular Therapy (ISCT), the three criteria for a population of cells to be defined as MSCs are 
the ability of the cells to differentiate into bone, fat and cartilage in vitro, plastic adherence, 
expression of the markers CD105, CD73 and CD90, plus a lack of expression of the 
haematopoietic marker, CD45 as well as CD11b or CD14, CD19 or CD79α and HLA-DR, in 
over 95% of the cell culture population (Brinchmann, 2008; Liu et al., 2009; Gimble and 
Nuttall, 2012; Fernandez Vallone et al., 2013). MSCs isolated from different tissues exhibit 
similar, but not identical properties to bone marrow-derived MSCs, such as variation in 
aspects related to their differentiation potential (Rebelatto et al., 2008). Although much has 
been learnt about MSCs since their discovery in the 1960’s, there is still much about the 
nature of these cells that remains unknown. For example, a paper by Qian et al. highlighted 
that CD44, a surface marker thought to be characteristic of MSCs, is in fact not expressed on 
primary MSCs, with CD44 expression proposed to be a result of prolonged in vitro culture  
(Qian et al., 2012).  
 
To date, the routine therapeutic use of MSCs is limited, with only bone marrow cells and 
umbilical cord blood cells being used in bone marrow transplants and umbilical cord cells for 
transplantation. All other therapeutic uses of MSCs and other stem cells remain mainly 
experimental, with clinical trials ongoing (Casteilla et al., 2011; da Silva Meirelles and Nardi, 
2011). Genomic instability of in vitro cultured rat bone marrow-derived mesenchymal 
stromal cells (bmMSCs) has been reported, whereas the genome of human MSCs has been 
found to be relatively stable in culture, indicating that caution should be taken when 
extrapolating data obtained using an animal MSC model for human MSC therapy (Foudah et 
al., 2009). Research into the uses of MSCs in regenerative medicine is ongoing, with current 
investigations examining MSC therapy for regeneration of bone, fat and muscle and other 
somatic tissue (Horwitz, 2003; Derubeis and Cancedda, 2004; Rebelatto et al., 2008).  
 
The main source of MSCs for therapy has, up until recently, been limited to cells derived 
from bone marrow and stem cells from umbilical cord blood. The discovery of cells present 
in adipose tissue with similar properties to bmMSCs has had implications for therapy, as 
adipose tissue is more abundant and more easily- and less invasively obtained (Casteilla et 
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al., 2011). However, as stated earlier, differences in differentiation potential and other 
characteristics exist between MSCs derived from bone marrow and those derived from 
adipose tissue, and also between cells derived from different adipose tissue depots (Levi et 
al., 2010). Many researchers use the term “MSC” to describe cells isolated from both bone-
marrow and adipose tissue, however it has been put forward that the differences between the 
cells isolated from these tissues are so significantly large as to prompt some researchers to 
suggest that bone marrow-derived MSCs and adipose-derived MSCs be distinguished from 
one another in the literature, such that MSC refers specifically to bone marrow-derived cells 
and ADSC (adipose-derived stromal cell) refers to adipose-derived cells (Gimble et al., 2007; 
Casteilla et al., 2011). For this reason, it will be useful to discuss the characteristics of both 
bone marrow-derived mesenchymal stromal cells (bmMSCs) and adipose-derived stromal 
cells (ADSCs), including their similarities and differences.  
 
1.2.7.1 Bone marrow-derived mesenchymal stromal cells (bmMSCs) 
Bone marrow-derived MSCs reside in vivo in the bone marrow stroma, and are thought to be 
the precursor cells of osteoblasts. These bmMSCs are thought to occur in the vascular 
sinusoids of the bone marrow stroma, existing as CD146+ perivascular subendothelial cells.  
The CD146+ cells that reside in the bone marrow stroma are thought to be essential for the 
establishment of the haematopoietic microenvironment within the bone marrow, and 
interactions between bmMSCs and haematopoietic stem cells may play a role in the 
regulation of haematopoiesis (Sacchetti et al., 2007; Kassem et al., 2008). Bone-marrow 
derived MSCs from humans are often isolated from bone marrow samples aspirated from the 
periphery of large bones such as the femora or ilium. The aspirate is often processed by 
washing and density centrifugation to remove red blood cells where after the resulting bone 
marrow mononuclear cells (MNSCs) are seeded onto tissue culture plastic with the 
appropriate growth media. The bmMSCs are identified via plastic adherence and the ability 
of the cells to form colonies, and thus they are given the name colony forming unit-
fibroblasts (CFU-F) (Song and Tuan, 2004; Kassem et al., 2008; Rebelatto et al., 2008). Bone 
marrow isolations frequently contain haematopoietic stem cells which although are less 
plastic adherent than bmMSCs, still results in the contamination of bmMSC cultures. 
Furthermore, bmMSC cultures are largely heterogeneous, meaning that the cells cultured in 
this way differ in their differentiation potential, with only a percentage of cells being true 
mesenchymal stem cells. Up until recently, the available markers have not been able to 
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distinguish true mesenchymal stem cells from the heterogenous population of bmMSCs to a 
greater degree than selection by plastic adherence (Kassem et al., 2008). Additionally, 
prolonged in vitro culture of bmMSCs results in changes in the surface marker expression of 
these cells (Boiret et al., 2005), making it difficult to identify in vivo characteristics of 
bmMSCs from in vitro studies. Recent research has identified two markers in humans and 
mice, platelet-derived growth factor receptor-α (PDGFR-α) and stem cell antigen-1 (Sca-1) 
which when expressed together in MSCs derived from bone-marrow or collagenase digested 
bone of mice, identify cells that have an enhanced self-renewal and the capacity for 
differentiation into osteoblasts, adipocytes and chondrocytes. These markers may be useful in 
identifying MSCs in vivo and will allow for a better understanding of the true nature and 
function of these cells in vivo, which will hopefully lead to advances in their use for therapy 
(Sacchetti et al., 2007; Houlihan et al., 2012; Mabuchi et al., 2013) . 
 
1.2.7.2 Adipose-derived mesenchymal stromal cells (ADSCs)  
ADSCs have been found to reside in the vascular stroma of adipose tissue. In humans, 
ADSCs have been commonly isolated from the adipose tissue discarded from liposuction 
surgeries, known as lipoaspirates, as well as from surgical excision (Locke et al., 2011). The 
adipose tissue obtained by either method is usually washed to remove blood and then 
digested with collagenase in order to break down the connective tissue.  The cells that are 
released as a result of collagenase digestion are termed the stromal vascular fraction (SVF) 
and are able to be separated from the mature adipocytes via centrifugation on account of the 
buoyancy of the latter. The SVF is then seeded onto tissue culture grade plastic dishes with 
the appropriate growth medium (Casteilla et al., 2011; Locke et al., 2011). Researchers have 
over the years given various names to the cells derived from this method, including pre-
adipocytes, processed lipoaspirate cells, stromal cells, and adipose-derived stromal cells 
(ADSCs), the latter being the definition used in this review (Locke et al., 2011).  
 
Before multipotential ADSCs can become adipocytes, they must first become committed to 
the adipocyte lineage, and once this commitment occurs, the cells are termed pre-adipocytes. 
In vivo commitment of multipotential ADSCs to the adipocyte lineage occurs when there is 
an excess of energy intake and increased transport of glucose into fat cells (Shepherd et al., 
1993). The exact mechanisms involved in adipocyte lineage commitment have yet to be 
determined, however several molecular factors have been discovered which activate lineage 
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adipocyte lineage commitment, including bone morphogenic protein (BMP) -4 (Tang et al., 
2004; Bowers et al., 2006) as well as BMP-2 (Sottile and Seuwen, 2000; Huang et al., 2009). 
The pre-adipocytes will then differentiate into adipocytes when stimulated, after first 
undergoing several rounds of mitotic cell division (Bowers and Lane, 2007; Tang and Lane, 
2012). The full differentiation and clinical potential of ADSCs is unknown. Adipose tissue 
has a well established endocrine function, and is known to secrete hormones and adipokines 
(Wang et al., 2008; Casteilla et al., 2011). Thus far, the truly functional differentiation of 
ADSCs into a either the adipocytic, osteoblastic or chondrogenic lineage has not be 
conclusively demonstrated: It has been suggested that these cells are only expressing certain 
markers specific for the differentiated phenotype, while continuing to express other markers, 
indicating that the cells have not fully and functionally differentiated into the cell type which 
they may resemble phenotypically (Rose et al., 2008; Casteilla et al., 2011). Another 
possibility for the above observation may be that the marker expression pattern of each 
differentiated cell type as it appears in vivo is not yet fully understood,  and differentiated cell 
types may share markers. The known plasticity between adipocytic and osteoblastic lineages 
may indicate that certain markers are indeed naturally common to both cell types (Kollmer et 
al., 2013). A deeper, more thorough investigation into their biology is extremely important if 
these cells are going to be used clinically. More knowledge needs to be gained regarding the 
differentiation of ADSCs, as their potential for differentiation into lineages other than 
adipocytes is not fully understood. Furthermore, the differences in purity of cell populations 
and possibilities of contaminating cell types in ADSC cultures needs to be addressed (Locke 
et al., 2011). A further consideration is that there are differences in the differentiation 
potential between ADSCs derived from different adipose tissue depots in the body, as 
observed in both humans and rats (Levi et al., 2010; Sadie-Van Gijsen et al., 2010). 
 
1.2.8 MSC differentiation – osteoblastogenesis and adipogenesis  
As previously stated, MSCs are capable of differentiating into multiple lineages, including 
osteoblasts, adipocytes, chondrocytes and myocytes, however, crosstalk is known to occur 
between adipose and skeletal tissue via molecules secreted by the cells of these tissues, which 
contributes to homeostasis (Gomez-Ambrosi et al., 2008). The following section will discuss 
the mechanisms involved in MSC differentiation towards adipocytic and osteoblastic 
lineages.  
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1.2.8.1 Osteoblastogenesis  
Osteoblastogenesis is the process whereby undifferentiated MSCs or osteoprogenitor cells 
differentiate into osteoblasts. The established markers for osteoblastogenesis include Cbfa-
1/Runx2, Osterix, TNAP, bone sialoprotein and osteopontin (Post et al., 2008).  Runx2 is a 
key osteoblastic transcription factor that is expressed early during embryonic development, 
and activates progenitor cells to differentiate towards an osteoblastic lineage. In differentiated 
osteoblasts, Runx2 autoregulates it’s own expression, and is the first transcriptional activator 
of a cascade of genes related to extracellular matrix (ECM) deposition, including osteopontin, 
osteocalcin and type I collagen. (Ducy et al., 1999). Together with Runx2, other important 
transcription factors including transcription factor 7 (Sp7) and bone morphogeneic proteins 
(BMPs) function to direct naïve MSCs towards an osteoblastic lineage (Ding et al., 2009; 
Tokuzawa et al., 2010). Additional transcription factors supporting osteoblastogenesis 
include Msx2, tafazzin, Wnt5a and Wnt10b, CEPBβ and basic helix-loop-helix (bHLH) 
family member e40 (Bhlhe40). Recently, a transcription factor named Inhibitor of DNA 
binding 4 (Id4), belonging to the bHLH superfamily, has been identified in osteoblasts and 
functions to stabilise Runx2, thereby aiding its activity (Tokuzawa et al., 2010). Another 
recently identified transcription factor, known as Maf (or c-Maf), of the basic leucine-zipper 
type, has been identified as important for osteoblastogenesis. The expression of Maf has been 
found to decrease as oxidative stress increases, which is common with aging. The study of 
Maf may be useful in understanding the causes of age-related bone loss and senile 
osteoporosis (McCauley, 2010; Nishikawa et al., 2010).  
 
The cyokines, tumour necrosis factor (TNF)-α and interleukin (IL)-1β are known to decrease 
bone formation and increase bone resorption in inflammatory diseases such as rheumatoid 
arthritis, and in contrast, evidence exists that these cytokines may stimulate the formation of 
ectopic bone in diseases such as type II diabetes and atherosclerosis (Ding et al., 2009). 
TNFα and IL-1β together stimulated the expression of TNAP, resulting in increased 
mineralisation in human MSCs grown in osteoblastic differentiation medium, while the 
presence of the same cytokines caused a reduction Runx2 and COL1A2 (type I collagen) 
expression. The decrease in type I collagen synthesis caused by a reduction in Runx2 
expression has been suggested as the reason for the decreased bone formation seen in 
rheumatoid arthritis, as osteoblasts are not able produce ECM, which consists predominantly 
of type I collagen, which needs to be laid down before mineralisation and bone formation can 
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occur. The ectopic mineralisation present in atherosclerosis is possibly facilitated by the 
increased expression of TNAP, stimulated by the inflammatory cytokines. It is proposed that 
an increased hydrolysis of the mineralisation inhibitor, PPi, results in ectopic bone formation. 
This also indicates that RUNX2 is not essential for mineralisation to occur, but rather only 
collagen-rich tissue and TNAP expression are necessary (Ding et al., 2009). Additional 
protein markers of osteoblastogenesis include bone sialoprotein (BSP), as well as osteocalcin 
(OC) (Atmani et al., 2003). BSP is present in osteoblasts, hypertrophic chondrocytes as well 
as osteoclasts, and its functional role in osteoblasts appears to be the initiation of 
hydroxyapatite crystal formation during mineralisation (Malaval et al., 2008). OC is 
expressed exclusively by osteoblasts and is the most abundant protein in the ECM aside from 
collagen. Although OC is an osteoblast marker, it appears to inhibit osteoblast function, and 
in normal bone tissue acts as a negative regulator of bone formation (Ducy et al., 1996). 
 
An additional factor influencing osteogenesis is gravity, as it has been demonstrated that 
conditions of micro-gravity, as experienced by astronauts on prolonged space missions, leads 
to a loss in bone mineral density (Zayzafoon et al., 2004). Human bone marrow-derived 
MSCs cultured for 7 days under micro-gravity simulations on earth, using the Rotary Cell 
Culture System (RCCS) after the initiation of osteogenesis at normal gravity, did not 
differentiate into osteoblasts, even after the cultures were returned to normal gravity and 
cultured for a further 30 days under osteogenic conditions. The investigators of the above 
experiment reported the complete inhibition of expression of the osteogenic markers, TNAP, 
COL 1A1, a major part of collagen type 1 and osteonectin, as well as suppression of Runx2 
expression, after 7 days of micro-gravity culture (Zayzafoon et al., 2004).    
 
1.2.8.1.1 Basic biology of bone 
Bone tissue deposition is performed by cells known as osteoblasts, which develop from 
preosteoblast precursor cells. Osteoblasts are responsible for depositing osteoid, or 
proteinatious, non-mineralised bone matrix consisting mainly of closely packed and highly 
crosslinked type I collagen, and shed extracellular matrix vesicles (MVs) which participate in 
bone matrix mineralisation by depositing calcium phosphate (CaPO4) in the form of 
hydroxyapatite crystals into the matrix (Franz-Odendaal et al., 2006; Blair et al., 2007). 
During the progression of the osteoblasts life cycle, less active cells are buried in the bone 
matrix laid down by other more active osteoblasts. These buried osteoblasts then develop into 
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osteocytes, the predominant cell type found in bone, with long processes that travel 
throughout the bone matrix and connect the buried osteocytes to one another via gap 
junctions, forming an osteocyte network (Franz-Odendaal et al., 2006; Blair et al., 2007). 
Gap junctions also connect the buried osteocytes to a layer of osteoblasts on the bone surface, 
allowing for nutrients and minerals from the extracellular fluid to reach cells buried in the 
bone matrix. Gap junction-connected osteocytes and osteoblasts exist in groups separate from 
one another and each of these groups is referred to as an osteon (Blair et al., 2007).   
 
Osteoclasts are another cell type within bone, distinct from osteoblasts and osteocytes, and 
function in bone resorption in order to facilitate bone remodelling. Osteoclasts are members 
of the monocyte/macrophage family and are derived from haematopoietic precursors (Lacey 
et al., 1998). Osteoclasts are able to liberate calcium from the mineralised bone matrix by 
attaching themselves closely to the bone surface and creating a micro-compartment called a 
resorption lacuna. The osteoclast transports H
+ 
ions into the resorption lacuna, which creates 
an acidic environment causing the hydroxyapatite crystals to dissolve, where after the Ca
2+ 
is 
released into the extracellular fluid, where it may be used by cells throughout the body for 
calcium signalling and numerous other cellular regulation processes including attachment, 
motility and cell survival (Blair et al., 2007). Ca
2+ 
and PO4
3-
 may also be released from the 
skeleton in order to counteract a pH imbalance in the body (Blair et al., 2007). Interactions 
between osteoblasts, osteocytes and osteoclasts allow for a balance of bone deposition and 
resorption to be maintained at calcium homeostasis within the body (Franz-Odendaal et al., 
2006).  
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Figure 1.2.8.1.1: Organisation of osteoblasts and osteocytes in the osteon, depicting the process of 
mineralization. The osteocytes, which develop from osteoblasts, are buried in mineralized bone matrix, are 
connected to one another and to the osteoblasts on the bone surface by gap junctions containing connexin-43 
(CX43). Mineralisation occurs at the interface between the mineralised and unmineralised matrix. The 
transportation of Ca
2+ 
and PO
-
4 ions is towards the site of mineralization, while H
+ 
ions generated from the 
chemical formation of hydroxyapatite are transported away from the mineralization site. Taken from (Blair et 
al., 2007).  
 
1.2.8.1.2 Bone mineralisation 
Mineralisation of endochondral bone, which is bone formed by the mineralisation of 
cartilage, is initiated by the formation of hydroxyapatite crystals within the extracellular 
matrix consisting of non-mineralised cartilage or osteoid surrounding osteoblasts and 
chondrocytes (Simao et al., 2010). TNAP is highly expressed extracellularly on the plasma 
membrane of osteoblasts, hypertrophic chondrocytes and particularly highly on the surface of 
extracellular matrix vesicles, which are formed from the polarised budding of the cell 
membranes of osteoblasts, chondrocytes and odontoblasts, which are dentin-producing cells 
found in teeth (Millán et al., 2006; Orimo and Shimada, 2008; Orimo, 2010). TNAP is 
thought to have several physiological substrates, these include inorganic pyrophosphate (PPi), 
pyridoxal 5’-phosphate (PLP) and phosphoethanolamine (PEA), although other substrates 
may still be identified (Orimo, 2010). TNAP also has ATPase activity (Muruganandan et al., 
2009). The known function of TNAP in bone mineralisation is to hydrolyse inorganic 
pyrophosphate (PPi) to form inorganic phosphate (Pi), which together with Ca
2+
 is needed for 
hydroxyapatite formation (Millán et al., 2006; Orimo, 2010). PPi is generated in the 
extracellular space from adenosine triphosphate (ATP) by nucleotide pyrophosphatase 
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phosphodiesterase 1 (NPP1), a nucleotide triphosphate pyrophosphatase found on the surface 
of osteoblasts, chondrocytes and matrix vesicles (MVs) in close proximity to TNAP (Fig. 
1.2.8.1.1), NPP1 was previously known as plasma cell glycoprotein-1 (PC-1). It has been 
found that osteoblast TNAP and NPP1 antagonise one another and are essential to maintain 
PPi at the correct levels for mineralisation (Johnson et al., 2000; Hessle et al., 2002; Millan, 
2013). PPi generated from ATP by hydrolysis is also transported across the cell membrane to 
the extracellular space by the transmembrane PPi-channelling enzyme, ANK, the human 
homolog of the mouse progressive ankylosis (ank) gene product (Millán et al., 2006). The 
correct balance of PPi to Pi is crucial for mineralisation to occur, as PPi is an inhibitor of 
mineralisation.  
 
Figure 1.2.8.2.1 shows schematically the process of mineralisation accomplished by either an 
osteoblast, chondrocyte or odontoblast. The cell shown in figure 1.2.8.2.1 is in contact with 
the un-mineralised matrix, as depicted in figure 1.2.8.1.1, and from this cell a matrix vesicle 
buds off. The matrix vesicle is the main agent of mineralisation, and it is here that 
hydroxyapatite crystals are formed from CaPO4 and deposited into the osteoid. For CaPO4 to 
form within the matrix vesicle, a supply of Ca
2+ 
and H2PO
-
4 ions is needed.  
 
Ca
2+
 ions enter the matrix vesicle from the extracellular fluid via calcium channels formed by 
annexins. Ca
2+
 is also liberated from calcium-binding phospholipids, such as 
phosphatidylserine  and calcium-binding proteins, such as calbindin D9k and bone sialoprotein 
(Orimo, 2010). Pi for mineralisation is produced in two steps. Firstly, ATP is hydrolysed by 
the ectoenzyme, nucleoside pyrophosphohydrolase 1 (NPP1), to produce inorganic 
pyrophosphate (PPi). PPi is subsequently hydroylsed to Pi by TNAP on the outside of the 
matrix vesicle. Pi produced in this way is then transported into the matrix vesicle from the 
extracellular fluid by the type III Na/Pi cotransporter, located on the both the cell and matrix 
vesicle membrane (Orimo, 2010). Pi is also produced inside the matrix vesicle by hydrolysis 
of phosphocholine (PCho) and phosphoethanolamine (PEA) by phosphatase orphan 1 
(PHOSPHO1), a cytosolic phosphatase (Orimo, 2010). Once levels of Ca
2+
 and Pi exceed the 
solubility limit of CaPO4 inside the matrix vesicle, hydroxyapatite crystals are formed. If the 
concentration of Ca
2+
 and Pi in the extracellular matrix are suitable, the membrane of the MV 
breaks down and allows the formed hydroxyapatite crystals to be released and deposited 
between collagen fibrils within the extracellular matrix (Orimo, 2010). Mineralisation is also 
pH dependent, and will only occur under alkaline conditions. The chemical formation of 
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hydroxyapatite results in the release of 1.4 H
+ 
ions for every Ca
2+ 
ion that is deposited. H
+
 
ions released in this way must be removed from the site of mineralisation to prevent the pH 
from becoming acidic, which would halt the mineralisation process. 
 
Mineralisation is therefore thought to be carefully controlled by the functioning of TNAP, 
NPP1, ANKH, PHOSPHO1 and also the mineralisation inhibitor, osteopontin (OPN), a 
glycoprotein rich in negatively charged phosphate groups. OPN, the expression of which is 
induced by PPi, is thought to inhibit mineralisation by binding to hydroxyapatite, due to the 
high affinity of its negatively charged phosphate groups for mineral (Johnson et al., 2000; 
Hessle et al., 2002; Millán et al., 2006; Addison et al., 2007; Orimo, 2010). 
 
 
Figure 1.2.8.2.1: Schematic illustration of mineralisation. The cell depicted may be either an osteoblast, 
chondrocyte or ondontoblast. The matrix vesicle (MV) buds off from the cell membrane and is the main agent of 
mineralisation. Hydroxyapatite crystals form inside the MV from CaPO4, which in turn is made from Ca
2+ 
and Pi 
ions. Ca
2+
 is transported into the MV by annexins, whereas inorganic phosphate (Pi) ions are produced by 
hydrolysis of inorganic pyrophosphate (PPi) to Pi by TNAP and are transported into the MV via a Na/Pi 
transporter. PPi is produced by hydrolysis of ATP by nucleotide pyrophosphatase phosphodiesterase (NPP1). 
Additional Pi is produced by hydrolysis of phosphocholine (PCho) and phosphoethanolamine (PEA) by the 
cytosolic phosphatase, PHOSPHO1. When a suitable concentration of Ca
2+ 
and Pi is present, hydroxyapatite 
crystals are formed and will move through the MV membrane into the extracellular matrix, where they are 
elongated and deposited (Adapted from Orimo, 2010).  
 
Stellenbosch University  https://scholar.sun.ac.za
 34 
 
1.2.8.2 Adipogenesis  
Knowledge of the factors and mechanisms that play a role in adipogenic differentiation of 
MSCs are useful for gaining insights into the treatment possibilities for obesity as well as 
other diseases where adipose tissue is involved, such as osteoporosis and non-insulin 
dependent diabetes. The primary function of adipocytes is to store triglycerides for times 
when the body’s need for energy is greater than the amount of energy available from the diet 
(Gregoire et al., 1998). Adipocytes are derived from preadipocyte precursors which are 
themselves derived from a shared pool of MSC progenitors, capable of differentiation into 
multiple cell lineages (Covas et al., 2008). Adipogenesis is the process that results in the 
development of a mature functional adipocyte from an undifferentiated MSC, due to changes 
in gene expression, and is exquisitely regulated by transcription factors (Tang and Lane, 
2012). Cytidine-cytidine-adenosine-adenosine-thymidine (CCAAT)/enhancer binding 
proteins (C/EBPs) and peroxisome proliferator-activated receptor γ (PPARγ), are the major 
transcription factors which determine whether MSCs will become committed to the adipocyte 
lineage (MacDougald and Mandrup, 2002; Tang and Lane, 2012). The latter exists in the 
isoforms which are produced from one gene via alternative splicing and result in the proteins 
PPARγ1, PPARγ2 and PPARγ3. PPARγ is known as the master regulator of adipogenesis, 
with PPARγ2, the adipocyte specific isoform, also being more effective than PPARγ1 at 
causing cells to differentiate into adipocytes (Fujiki et al., 2009). Activation of the sequence 
of adipogenic transcription factors that are required for adipogenesis starts with C/EBPβ and 
C/EBPδ, which stimulate the next wave of transcription factors, namely C/EBPα and PPARγ. 
The major transcription factors, C/EBPα and PPARγ, are able to propagate their own 
expression as well as the expression of each other, and together, along with the ligands of 
PPARγ, are the main drivers of the expression of adipocyte-specific genes (MacDougald and 
Mandrup, 2002). In in vitro cell culture, exogenous inducers of adipogenesis added to the 
culture medium initiate the activation of these adipogenic transcription factors. These 
inducers include: a glucocorticoid receptor agonist, such as the commonly used 
dexamethasone, a stimulator of insulin-like growth factor-I receptor (IGF-IR) accomplished 
by the addition of insulin to at high concentration, a factor which elevates intracellular 
cAMP, such as 3-isobutyl-1-methylxanthine (IBMX), and a PPARγ ligand, the latter 
consisting of derivatives of long-chain polyunsaturated acids, as well as the synthetic ligands 
such as thiazolidinediones (TZDs) (MacDougald and Mandrup, 2002; Vater et al., 2011).  
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Recent data have suggested a role for the class B scavenger receptor and membrane 
glycoprotein known as CD36 in adipogenesis. CD36 expression has been detected in a 
variety of different cell types, including adipocytes, where it appears that CD36 has a number 
of different, cell type-specific functions (Christiaens et al., 2012). Evidence has been put 
forward that CD36 is a lipid sensor, and may be involved in metabolism, behaviour, 
immunity as well as in diseases such as Alzheimer’s disease, atherosclerosis and obesity 
(Martin et al., 2011; Christiaens et al., 2012). Experimental work by Christiaens et al. 
showed that CD36 has a functional role in adipogenesis, as silencing of CD36 in the murine 
preadipocyte cell line 3T3-F442A significantly reduced lipid accumulation after adipogenic 
induction in vitro, with a concurrent reduction in the expression of the adipocyte markers, 
aP2 and PPARγ (Christiaens et al., 2012).  
 
1.2.10 Bone morphogenetic proteins  
Bone morphogenetic proteins (BMPs) have been found to play an important role in both 
osteoblastogenesis and adipogenesis of MSCs. BMPs are members of the transforming 
growth factor-β (TGF-β) superfamily and are signalling molecules involved in pathways 
important for the regulation of differentiation and proliferation of cells both during 
development of an organism as well as in stem cells present in adulthood (Kang et al., 2009). 
In humans, 15 different BMPs have been identified. The osteogenic BMPs, such as BMP-2, -
6 and -9 have been shown to strongly promote osteoblastogenesis, while BMP-2, along with 
BMP-4 and -7 are more involved with adipogenesis, when certain adipogenic cofactors and 
supplements are present (Kang et al., 2009).  Additionally, it has been discovered that BMPs 
and Wnt signalling pathways interact during development and this interaction varies between 
tissues, as well as temporally (Itasaki and Hoppler, 2010). Much still remains to be learnt 
about the precise function and role of BMPs within differentiation and whole body 
homeostasis, as well as about their interactions with other molecules and signalling pathways 
(Kang et al., 2009; Itasaki and Hoppler, 2010).  
 
1.2.11 Other factors influencing MSC differentiation 
In addition to the various cellular signalling molecules involved in MSC differentiation 
already discussed, evidence exists for the involvement of several other factors in determining 
which differentiation pathway MSC take. Epigenetic regulation (Collas et al., 2008; Delgado-
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Calle et al., 2011), micro RNA (miRNA) control of gene expression (Laine et al., 2012), as 
well as reduction/oxidation (redox) potentials within the cell are all determinants of which 
differentiation pathway is taken (Imhoff and Hansen, 2010).  
 
Epigenetic modifications are regulatory mechanisms for gene expression, which include 
methylation of DNA as well as modifications of chromatin, in the form of post-translational 
histone modifications. These modifications function to either facilitate or repress 
transcription of genes, by either opening the DNA strand or causing condensation of the 
strand, respectively (Teven et al., 2011). Epigenetic modifications are heritable, and may be 
passed on to daughter cells produced via mitosis, as well as meiosis, where they may persist 
for several generations, even though they do not involve changes to the DNA sequence itself 
(Collas et al., 2008). Epigenetic regulation of DNA involves the methylation of cytosine 
residues at position 5, at cytosine-phosphate-guanodine (CpG) sites, which functions to 
silence the genes downstream from the methylation site (Collas et al., 2008). Histone 
modifications involve a variety of covalent modifications of the N-terminal tail of a translated 
histone protein, such as methylation or acetylation, which function to bring about gene 
regulation. Epigenetic regulation plays a major role in the life cycle of a cell, by either 
activating or repressing a variety of genes as the cell progresses from a progenitor to 
terminally differentiated phenotype (Teven et al., 2011). An important role for epigenetic 
regulation in MSC lineage differentiation has been discovered, as epigenetic modifications 
have been found to affect the expression of several adipogenic and osteogenic markers, 
including osteocalcin, osteopontin and PPARγ (Teven et al., 2011; Ozkul and Galderisi, 
2016). The extent of epigenetic regulation in MSCs is not yet fully understood, and much 
work is required to elucidate the contribution of epigenetic regulation on MSC lineage 
commitment, maintenance of a stem cell phenotype as well as cellular aging and senescence 
(Ozkul and Galderisi, 2016).  
 
MicroRNAs (miRNAs) are short, endogenous, non-coding RNA molecules, of around 19 to 
24 nucleotides in length, which are able to regulate gene expression by binding to a 
complementary region on 3` untranslated region (UTR) of a messenger RNA (mRNA) 
molecule. The result of miRNA binding to an mRNA molecule is either repression of the 
gene or degradation of the mRNA molecule itself (Ambros, 2004). MiRNAs have been found 
in all metazoans studied to date, and form a large regulatory network, with between 40 – 90% 
of expressed human proteins being targets for miRNA regulation (Hu et al., 2010). Studies 
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have shown that miRNAs may regulate stem cell pluripotency and differentiation (Singh et 
al., 2008). The pattern of miRNAs present in MSCs alters as the cells progress from a 
progenitor to terminally differentiated cell. The pattern of miRNAs present in terminally 
differentiated MSCs is different from the pattern present in progenitor MSCs (Guo et al., 
2011). Several miRNAs involved in gene expression of MSCs have been identified and 
function to either inhibit or activate various genes involved in either the osteogenic or 
adipogenic differentiation pathway (Laine et al., 2012). One gene may be targeted by several 
different miRNAs, and additionally, a single miRNA may target several different genes 
(Friedman et al., 2009; Guo et al., 2011). As an example, the endogenous miRNA-204 (miR-
204) negatively regulates the expression of Runx2 in bmMSCs and mesenchymal progenitor 
cell lines ST2, C2C12 and C3H10T1/2. Overexpression of miR-204 was found to decrease 
the expression of Runx2, which resulted in the inhibition of osteogenesis and an increase in 
adipogenesis. When miR-204 was inhibited, osteogenesis was increased and adipogenesis 
was impaired (Huang et al., 2010). 
 
Oxidative stress in the form of oxidising extracellular reduction/oxidation (redox) potential 
results in a deregulation in the production of reactive oxygen species (ROS) within the cell. 
Low levels of ROS are necessary for cell function and survival, however high levels of ROS 
resulting from oxidative stress leads to cellular damage and dysfunction (Denu and Hematti, 
2016). In MSCs, increased levels of ROS have been found to impair cellular proliferation, 
differentiation and self-renewal capacity (Alves et al., 2010; Ko et al., 2012; Alves et al., 
2013). MSCs are thought to be more sensitive to ROS than more differentiated cell types 
(Denu and Hematti, 2016). In general, increased oxidative stress and ROS production has 
been found to inhibit osteogenic differentiation of MSCs (Chen et al., 2008), however, 
increased ROS and oxidative stress have been found to enhance adipogenesis in MSCs 
(Imhoff and Hansen, 2010). Tormos et al. discovered that ROS generated by mitochondrial 
metabolism during adipogenic differentiation of primary human MSCs were necessary for 
adipocyte differentiation to occur, rather than a by-product thereof (Tormos et al., 2011). 
ROS levels were also found to increase during chondrogenesis, and stimulated chondrogenic 
hypertrophy (Denu and Hematti, 2016).  
 
The overall aim of the current project was to provide a better understanding of the role of 
tissue-nonspecific alkaline phosphatase (TNAP) during the differentiation of primary 
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mesenchymal stromal cells (MSCs) towards an adipogenic phenotype, contrasted with the 
better known role of TNAP during osteogenesis. To this end, the first aim of the project was 
to establish the suitability of the model used for investigation, which consisted of primary rat  
MSCs derived from subcutaneous and perirenal visceral adipose, and bone marrow depots. 
This was achieved by assessing the surface marker expression, as well as adipogenic and 
osteogenic differentiation potential of MSCs derived from each depot, in order to verify that 
the cells used were MSC in nature. The second aim of the study was to investigate the effect 
of known TNAP inhibitor compounds, levamisole, L-homoarginine and histidine, on MSCs 
undergoing adipogenesis and osteogenesis, in order to determine if inhibiting TNAP activity 
would have an effect on the outcome of the differentiation process. The third aim of the 
project was to further characterise the TNAP present in rat-derived MSCs, by investigating 
the subcellular location of TNAP in MSCs undergoing adipogenesis, the TNAP mRNA 
transcript type present, as well as the glycosylation pattern differences of TNAP isoforms 
present in adipocyte and osteoblast phenotypes. Finally, the project aimed to investigate 
whether knocking down TNAP mRNA expression during adipogenic induction would inhibit 
lipid accumulation in scADSCs.  
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CHAPTER 2 
Materials and Methods 
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2.1 Materials  
Euthanasia was performed using sodium pentobarbitone (Eutha-naze) obtained from Bayer 
(Pty) Ltd. (Ref83/91, #22079248DJ, Isando, RSA). Dulbecco’s modified Eagle’s medium 
(DMEM) was purchased from BioWhittaker, (#BE12-604F, Lonza, Basel, Switzerland) and 
foetal bovine serum (FBS) was purchased from Biochrom (S0615, 0459B, Berlin, Germany). 
Collagenase type I was purchase from Worthington Biochemical Corporation (CLS1, 
#XOM12195J, Lakewood, New Jersey, USA). Trypsin (200 mg/l Versene EDTA, #BE171616, 
Lonza), penicillin/streptomycin solution (BioWhittaker, #DE17-6026, Lonza) and Hank’s 
balanced salt solution (HBSS) (BioWhittaker, #10-508F, Lonza) were purchased from Lonza, 
BioWhittaker ® (Walkersville, MD, USA). Plastics for cell culture were purchased from 
either Greiner Bio-One (Cellstar ®, Frickenhausen, Germany) or Corning Incorporated 
(Corning ®, NY, USA) or Nest Biotech Co. Ltd. (China). Bovine serum albumin (BSA) was 
bought from Sigma-Aldrich BSA (#A4503-100G, Sigma–Aldrich). Levamisole (L 
tetramisole) (L9756-5G), histidine (H6034) and L-homoarginine (H1007-5G) were purchased 
from Sigma-Aldrich (St. Louis, MO, USA). The GoTaq® G2 Flexi DNA Polymerase kit 
(M7801) and ImProm-II™ reverse transcriptase (#M314A) were procured from Promega 
(Madison, WI, USA). The RNAeasy Mini kit for total RNA isolation was procured from 
Qiagen (#74106) (CA, USA). Primers were purchased from Integrated DNA Technologies 
Incorporated (IDT). All other chemicals were purchased from Sigma-Aldrich (St. Louis, MO, 
USA) and liquid solvents were procured from Merck Chemicals (Pty) Ltd (South Africa). 
 
2.2 Methods  
2.2.1 Isolation of rat mesenchymal stromal cells from subcutaneous and 
visceral adipose tissue depots.  
Adipose-derived mesenchymal stromal cells (ADSCs) were isolated from the inguinal 
subcutaneous fat pad and peri-renal visceral depots of male Wistar rats, approximately 8 
weeks of age, weighing 150 g. All the rats used for this study were housed in a facility at the 
University of Stellenbosch which is accredited by the AAALAC (Association for Assessment 
and Accreditation of Laboratory Animal Care), and animals were handled according to 
ethical guidelines of the University of Stellenbosch. Ethical clearance for the study was 
granted by the University of Stellenbosch with the clearance number given as (#SU-
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ACUD15-00012). The rats were sacrificed by intraperitoneal injection with sodium 
pentobarbitone (Eutha-naze Ref83/91, #22079248DJ, Bayer) at 100 mg/kg body weight. As 
there are two inguinal subcutaneous and peri-renal visceral depots present in each animal, on 
each side of the groin or either kidney, adipose tissue from both sides were pooled together 
and used for the ADSC isolation. The tissue was excised using surgical scissors immediately 
after the animal was sacrificed, and rinsed after excision in 70% (v/v) ethanol to ensure 
sterility and briefly stored in high-glucose (4.5 g/l glucose: L-glutamine) Dulbecco’s 
Modified Eagle’s Medium (DMEM) (BioWhittaker, #BE12-604F, Lonza, Basel, 
Switzerland). All further processing was performed in a laminar flow biosafety cabinet 
(Laboratory and air purification systems cc., model LA1200BII, Midrand, RSA) under sterile 
conditions. The adipose tissue was placed in a sterile cell culture Petri dish, and finely 
macerated and teased apart with a sterile razor blade to loosen the connective tissue and 
increase the surface area. The tissue sample was placed in a sterile 50 ml Falcon™ tube 
(352070, BD, USA) containing 10 ml digestion mixture of Hank’s balanced saline solution 
(HBSS) (BioWhittaker, #10-508F, Lonza) containing 0.075% (w/v) collagenase type 1 
(CLS1, #XOM12195J, Worthington, Lakewood NJ, USA) and 1.5% (v/v) bovine serum 
albumin (BSA) (#A4503-100G, Sigma-Aldrich) followed by immersion of the tube 
containing the digestion mixture in a 37 °C water bath for 30 min with occasional agitation in 
order to aid the digestion of the connective tissue surrounding the MSCs. The digested tissue 
was subjected to centrifugation (250 x g, 10 min) to pellet cells freed from the tissue. Pelleted 
cells were transferred to a clean tube using a sterile Pasteur pipette and washed twice with 
phosphate buffered saline (PBS) pH 7.4. Cells were then pelleted by centrifugation (250 x g, 
5 min) and resuspended in 2 ml DMEM with 1% penicillin/streptomycin (BioWhittaker, 
#DE17-6026, Lonza) containing 20% foetal bovine serum (FBS) (Biochrom, S0615, 0459B). 
The cell suspension, which constitutes the stromal vascular fraction (SVF) (Gimble et al., 
2007) was seeded at 1 ml into two 6 mm x 15 mm cell culture dishes (#430166, Corning, NY, 
USA) and the volume increased to 4 ml with DMEM containing 20% FBS with 1% 
penicillin/streptomycin. The cell cultures were maintained in a Forma Series II water jacketed 
CO2 incubator (model 3111, Thermo Scientific) with 80-90% humidification at 37 °C with 
5% CO2 for 24 hr to allow the cells of the SVF, which contain ADSCs, to adhere to the 
surface of the dish. Cell cultures were visually evaluated after 24 hr using an Olympus light 
microscope (CKX41, CachN 10X/0.25 PhP objective, EOS600D Canon digital camera) to 
determine whether healthy cells were present, indicating that the isolation was successful. 
Cell cultures were then washed 2x with sterile PBS (pH 7.4, 37 °C) in order to remove debris 
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and any unattached cells and the medium was then replaced with standard growth medium 
(SGM) (DMEM with 1% penicillin/streptomycin, containing 10% FBS) and the cultures 
maintained at 37° C with 5 % CO2 and constant humidity for further expansion.  
 
2.2.2 Isolation of rat mesenchymal stromal cells from bone marrow.  
Both femurs were excised from a 150 g male, Wistar rat directly after the animal was 
sacrificed by intraperitoneal injection of sodium pentobarbitone at 100 mg/kg body weight 
(Section 2.2.1). The femurs were rinsed briefly in 70 % (v/v) ethanol and placed in DMEM. 
In a sterile biosafety cabinet, the bones were manually denuded of adherent muscle tissue and 
ligaments by rubbing them with sterile gauze strips, after which the femurs were briefly 
rinsed in 70% (v/v) ethanol, and the ends of the bones severed using a surgical side cutter. 
Each bone shaft was flushed with 3 ml of DMEM containing 20% FBS and 1% 
penicillin/streptomycin by inserting a sterile syringe with an 18 G needle into the end of the 
bone shaft and flushing the bone marrow out with moderate force into a 6 mm x 15 mm cell 
culture dish. The bone marrow from each femur was flushed into a separate cell culture dish. 
The flushed marrow was then subjected to vigorous pipetting with a P1000 pipette to break 
up the large marrow cores, after which the volume of medium in the dish was adjusted to 4 
ml and incubated at 37 °C and 5% CO2 in a humidified incubator. After 24 hr of incubation, 
the plates were each washed 4 to 5 x with sterile PBS (pH 7.4) warmed to 37 °C in order to 
wash off non-adherent cells and debris, such as red blood cells and bone fragments, and the 
medium then replaced with 4 ml of SGM and incubation continued at 37 °C with 5 % CO2. 
The cell culture at this time is at passage 0 (P0) and once the cell culture reached 80% 
confluence, typically after 5 to 7 days in culture, the cells were passaged (Section 2.2.3) to 
allow for further expansion of the cell number and to improve the homogeneity of the culture. 
Cells were passaged from P0 to P1 (passage 1) at roughly a 1:2 ratio, where cells from each 6 
cm dish are pooled and split into two 10 cm Petri dishes, with a volume of 8 ml of SGM per 
dish. Further expansion was carried out in 10 cm Petri dishes and cells are passaged at a 1:2 
ratio from P1 to P2 and at a 1:4 ratio for P2 to P3, at which passage cells are used for 
experimentation.   
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2.2.3 Cell culture maintenance and Passage  
Naïve scADSCs, pvADSCs and bmMSCs from passages 0 to 3 (P0 – P3) were maintained in 
standard growth medium (SGM). Cells were incubated at 37° C in 5 % CO2 under constant 
humidification, which allows for expansion of the cell number in culture as well as the 
maintenance of an undifferentiated phenotype.  
 
Normal maintenance of cell cultures at less than 70% confluence in SGM was carried out by 
aspiration of spent medium after 2 to 3 days in culture, followed by replacement with fresh 
expansion medium and immediately placing cultures back into previous incubation 
conditions. Passaging was performed once cells had reached a confluence of 70-80%, by 
aspiration of SGM from culture dishes, followed by briefly washing the cells 2x with sterile 
PBS (37 °C, pH 7.2) in order to remove traces of SGM. Trypsin at 0.5 % (200 mg/l Versene 
EDTA, #BE171616, Lonza) was added to cells in a ratio of 1:10 trypsin solution: original 
medium volume, and incubated at 37 °C for 1 to 2 min to dislodge cells. Gentle tapping of 
the dish was done after incubation to encourage detachment of cells, and cells were briefly 
viewed under a light microscopy (CKX41, CachN 10X/0.25 PhP objective, EOS600D Canon 
digital camera) to confirm that detachment was complete and no cells remained adhered to 
the culture surface. SGM was added to the dish in order to neutralize the trypsin enzyme at a 
ratio of 2:1 SGM: trypsin solution.  Volume of the SGM containing the detached cells was 
adjusted to the desired amount to allow cells to be split at the ratio of either 1:4 for scADSCs 
and pvADSCs or 1:2 for bmMSCs. Once the volume of SGM in the freshly passaged cultures 
was adjusted to the required level for the culture vessel, the vessels were swirled gently in 
order to ensure even distribution of the cell suspension and after which were immediately 
placed in the incubator to allow for the cells to settle and reattach to the culture dish surface.  
 
2.2.4 Alkaline phosphatase (ALP) extraction and activity assay 
Total alkaline phosphatase (ALP) activity in crude cell lysates (Section 2.2.4.1),  as well as in 
semi-purified enzyme extracts (Section 2.4.2) was quantified using a colourimetric assay 
based on the hydrolysis of the substrate para-nitrophenylphosphate (pNPP) to yield a 
coloured product, para-nitrophenol (pNP), as outlined below. 
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2.2.4.1 Cell lysates preparation for alkaline phosphatase (ALP) activity 
assay  
Cells from which ALP activity was to be measured were cultured in 24-well Cellstar® cell 
culture plates (#662160, Greiner bio-one, Germany) until required for assay. Medium was 
aspirated from the wells which were immediately washed 2x with Tris-buffered saline (TBS) 
(pH 7.2, RT) and plates immediately placed on ice.  To each well, 250 μl of Lysis buffer (100 
mM Tris-Cl, 0.001% Triton X-100, pH 7.4) was added and wells were scrapped using a 
standard 1000 µl pipette tip to dislodge cells from the well surface.  Once the cells were 
detached, the lysates were transferred to a chilled 1.5 ml microcentrifuge tube (#509-GRD-Q, 
Quality Scientific Products). At this point cell lysates were either frozen at -20 °C and stored 
for later analysis or processed immediately.  
 
Frozen lysate samples were thawed on ice before further processing. Thawed lysates were 
sonicated (at an amplitude of 20 microns peak to peak) for 3 x 5 sec bursts, while cooling the 
lysate on ice. The sonicated lysates were subjected to centrifugation (15 min, 15 000 x g, 4 
°C) to pellet insoluble material. After centrifugation, the samples were placed on ice and the 
supernatant was transferred to a clean, chilled 1.5 ml microfuge tube. Samples were then 
frozen at -20 °C until needed or were used immediately for the ALP activity assay.  
 
2.2.4.2 Alkaline phosphatase extraction  
Alkaline phosphatase (ALP) extraction from cell lysates was necessary for scADSCs and 
pvADSCs to be used for glycosylation analysis, as these cell types do not possess sufficiently 
high ALP activity in crude cell lysates for glycosylation studies. The ALP extraction method 
was adapted from Merchant-Larios et al. (Merchant-Larios et al., 1985). Cells were cultured 
in 10 cm Petri dishes until ready for ALP extraction. The medium was removed by aspiration 
and the cells washed 2 x with TBS (pH 7.2, RT) and immediately placed on ice.  A 500 μl 
volume of ice-cold extraction buffer (100 mM Tris-Cl, 1% Triton X-100, pH 7.4) was added 
to the plate and the lysed cells dislodged from the plate by scraping using a cell scraper. The 
lysate was transferred to a chilled 1.5 ml microfuge tube and sonicated 3x 10 sec (at an 
amplitude of 20 microns peak to peak) while cooling the lysates on ice during sonication 
intervals. Lysates were subjected to centrifugation (15 000 x g, 15 min, 4° C) to pellet cell 
debris, and the supernatant transferred to a clean 1.5 ml microfuge tube and kept on ice. Ice-
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cold butanol was added to the supernatant at a 1:5 ratio and the solution mixed by vortexing 
until it turned from clear to opaque/milky in appearance. The solution was then mixed using a 
tube rotator (G207378, Labnet Inc., USA) for 45 min at 4 °C, followed by centrifugation at 
15000 x g, 1 hr, 4 °C. The lower aqueous phase was carefully removed and placed in a clean 
1.5 ml microfuge tube, and a 0.6 volume ice-cold acetone added. The solution was vortexed 
for 5 sec followed by centrifugation (15 000 x g, 30 min, 4 °C). The resulting pellet was 
carefully resuspended in 20 μl of lysis buffer (100 mM Tris-Cl, 0.001 % Triton X-100, pH 
7.2).  To obtain a sufficient volume for glycosylation analysis, 6 to 10 ALP extraction 
samples were pooled together. Alkaline phosphatase activity was measured using 5 μl of 
sample. Semi-purified samples of ALP were stored at -20 °C. 
 
2.2.4.3 Alkaline phosphatase activity assay  
The alkaline phosphatase activity assay was adapted from the method of Sabokar et al.  
(Sabokbar et al., 1994). Cell lysates or samples of semi-purified ALP were thawed on ice and 
either 5 µl for bmMSCs or 80 µl for scADSCs and pvADSCs, due to the higher ALP activity 
present in bmMSCs compared to ADSCs, of each internal replicate was added to wells of a 
96-well plate and the total volume brought to 80 μl using lysis buffer (100 mM Tris, 0.001% 
Triton X-100, pH 7.4). Substrate solution was prepared immediately before use by adding  2 
x 5 mg para-nitrophenylphosphate (pNPP) phosphatase substrate tablets (50942-50TAB, 
Sigma-Aldrich) into 5.4 ml of ice-cold DEA buffer (1 M diethanolamine, 0.5 mM MgCl2, pH 
9.8) protected from light and mixed by gentle shaking until the pNPP had dissolved. The 
substrate solution was added at a volume of 50 μl to each well, and the plate immediately 
incubated in a heating MultiskanGo plate reader (Thermo Scientific) with SkanIt Software 
version 3.2 (Thermo Scientific) at 37° C while absorbance at 405 nm was read at 2 min 
intervals for a total period of 20 to 40 min. Multiple readings were taken as the reaction 
progressed, as this allowed for a time point to be determined for which alkaline phosphatase 
activity in all samples was increasing in the linear phase of the reaction, as using a single 
endpoint reaction with one selected time would have resulted in some samples reaching a 
plateau in the reaction before others and the resultant incorrect ALP activity being calculated. 
A standard curve was constructed using known concentrations of para-nitrophenol (pNP) 
(1048-5G, Sigma Aldrich), which is the coloured product formed from the hydrolysis of 
pNPP. A stock solution of 25 mM pNP was made in ultrapure water and serial dilutions were 
made to give a concentration range of 0, 12.5, 25, 50, 100 and 200 μM, with 150 μl placed in 
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each well in triplicate.  The amount of pNP in μmol for each concentration of the standards 
was calculated and used for a standard curve. From this curve the amount of product formed 
in the test samples was determined, an example of which is shown in figure 2.2.4.3.1. The 
amount of pNP calculated from the standard curve enabled the activity of the test samples to 
be measured using the following equation:  
 
Activity (units/ml) = A/V/T 
 
Where A is the amount of pNP (μmol) in the sample as determined from the standard curve. 
V is the volume of lysate in ml. 
T is the time of the reaction in minutes. 
 
The specific activity of the samples was determined by the following equation:  
 
Activity (units/mg prot) = units/ml 
          mg/ml prot  (determined separately by Bradford protein assay)  
 
 
Figure 2.2.4.3.1: Standard curve example for para-nitrophenol with absorbance at 405 nm and standard 
concentrations of para-nitrophenol of 0, 12.5, 25, 50, 100 and 200 µM.  
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2.2.4.4 Protein concentration determination  
Protein content in mg/ml was determined using the Bradford protein assay (Bradford, 1976). 
Bovine serum albumin (BSA) (#A4503-100G, Sigma-Aldrich, Germany) standards for use in 
the Bradford assay were made up in lysis buffer at concentrations of 1.4, 1.2, 1.0, 0.5, 0.25, 
0.125 and 0 mg/ml.  The Bradford assay was performed in a 96-well plate, where 5 μl of test 
sample or BSA standard were added to the well followed by 250 μl of Bradford reagent (10% 
(w/v) Coomassie Brilliant Blue G-250 10% (v/v), 85% Phosphoric acid, 5% (v/v) 95% 
EtOH). For the blank, lysis buffer with no Bradford reagent was used. Once the Bradford 
reagent was added, the plate was incubated for 5 min at RT to allow the colour to develop, 
after which the absorbance was read at 595 nm no longer than an hour after addition of the 
Bradford reagent, and the concentration of each sample calculated from the standard curve. 
Figure 2.2.4.4.1 shows an example of a standard curve for BSA. A BSA standard curve was 
included each time test samples were measured.  
 
 
Figure 2.2.4.4.1: Example of standard curve for BSA with absorbance at 595 nm and standard 
concentrations of BSA from 0, 0.125, 0.25, 0.50, 1.0, 1.2 and 1.4 mg/ml.  
 
2.2.5 Adipogenic differentiation  
Adipogenic differentiation was adapted from the method of Ogawa et al.  (Ogawa et al., 
2004). Adipogenesis was induced in scADSCs and pvADSCs while cells were in P2, whereas 
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bmMSCs were grown to P3 before induction. Cells that were 2 days post confluence were 
incubated in a cocktail consisting of standard growth medium (SGM) plus 0.5 mM 3-
isobutyl-1-methylxanthine (IBMX) (STBC7632V, Sigma Life Sciences), 1 µM 
dexamethasone (Dex) (D4902-100MG, BCBK1265V, Sigma Life Sciences), 10 µM insulin 
(19278-5ML, SLBD5980, Sigma Life Sciences) and 56 µM indomethacin (17378-5G, 
064K1207, Sigma Life Sciences), as well as 50 µM ascorbic acid (A4544-25G, SLBB4446V, 
Sigma Life Sciences). The concentrations of the components of this adipogenic 
differentiation media (AM) are given in Table A1, Addendum A. AM was prepared 
immediately before use and warmed to 37 °C, before being applied to cell cultures directly 
after the aspiration of expansion medium. Cell cultures undergoing adipogenic induction 
were incubated at 37 °C in 5 % CO2 and constant humidity. AM was exchanged on cell 
cultures every 2 to 3 days for up to 14 days, by aspirating off spent medium and the 
immediate addition of fresh AM.  
 
2.2.6 Oil Red-O staining   
Oil Red-O (ORO) (O0625-100G, Sigma Aldrich) is a dye which binds lipids and is used to 
determine the quantity of intracellular lipid droplets present in a cell culture at specific time-
points during adipogenic differentiation. ORO staining was performed according to the 
method of Laughton (Laughton, 1986). ORO stock solution (1% ORO dissolved in 
isopropanol (K44414134 315, Merck) was diluted to 70% ORO using ultrapure H2O to make 
the working solution, which was filtered immediately before use using a Whatmann no. 1 
filter paper. Culture medium was removed from cells cultured in a 24-well plate followed by 
direct addition of ~1 mL of ORO working solution and the cells incubated for 30 min at RT. 
A separate fixation step was not necessary as isopropanol in the ORO working solution fixes 
and stains the cells simultaneously. Wells were washed 3x with ultrapure H2O followed by 
addition of phosphate buffered saline (PBS) at pH 7.4. The wells were then photographed for 
image analysis and lipid quantification (Section 2.2.9)  
 
2.2.7 Osteogenic differentiation  
Osteogenesis was induced in scADSCs and pvADSCs grown to P2 and bmMSCs while in P3 
at 2 days post confluence using a cocktail consisting of standard expansion medium 
(DMEM+ 10% FBS) containing β-glycerophosphate (G5422-100G, 029K54241V, Sigma 
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Life Sciences), ascorbic acid and dexamethasone (Dex), and termed Osteogenic 
differentiation medium (OM), according to the method of Jaiswal et al. (Jaiswal et al., 1997). 
OM was made immediately prior to use and warmed to 37 °C. OM used to induce osteogenic 
differentiation in scADSCs and pvADSCs contained 100 nM Dex, compared to 10 nM Dex 
in the OM cocktail used for bmMSCs, as the ADSCs were found to require a higher 
concentration of Dex in order to differentiate. Osteogenic differentiation was induced in cell 
cultures by aspirating off expansion medium, followed by immediate addition of OM, and 
incubation of the cells at 37 °C in 5% CO2 and constant humidity. OM was changed every 3 
to 4 days by aspiration of spent medium and the immediate addition of fresh OM followed by 
incubation for up to 21 days for scADSCs and pvADSCs and 14 days for bmMSCs (See 
Addendum A, Section A2 for OM components).  
 
2.2.8 Alizarin red staining for mineralisation  
Mineralisation on the cell culture plate surface after cells were cultured in OM was visualised 
by staining with Alizarin red S (#9436, Amresco, Solon, OH, USA) (Reinholz et al., 2000). 
Alizarin red dye solution was made up in ultrapure water to a concentration of 100 mM and 
adjusted to pH 4.0 using 10 mM ammonium phosphate solution, and stored at RT protected 
from light. Medium from cell cultures to be stained with Alizarin red S, was aspirated off and 
plates were gently washed 2 x with PBS (pH 7.4) to avoid dislodging any formed mineral 
deposits, followed by fixing of the cells by addition of 70% (v/v) ethanol for 5 min at RT. 
The plates were then washed 2 x with ultrapure H2O and incubated with Alizarin red dye 
solution (pH 4.0) for 16 hr at RT in the dark.  Following staining, plates were washed 3 x 
with ultrapure H2O to remove unbound Alizarin red S. PBS (pH 7.4) was then added to the 
stained wells, which were immediately photographed for image analysis and quantification of 
mineralisation (Section 2.2.9).   
 
2.2.9 Quantification of lipid accumulation and mineralisation by image 
analysis 
Images acquired for image analysis and quantification were taken with an Olympus light 
microscope (CKX41, CachN 10X/0.25 PhP objective, EOS600D Canon digital camera). 
Three replicates for each experimental condition were performed and four images (one in 
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each quarter) were taken per replicate well. The images were analysed using ImageJ software 
(version 1.46, nih.gov) and area of positively stained lipid accumulation or mineralisation 
present was expressed as a percentage area of each well.    
 
2.2.10 Surface marker expression of MSCs by FACS analysis  
Subcutaneous ADSCs and pvADSCs in passage 2 (P2) and bmMSCs in P3 were expanded in 
SGM until 80% confluence was reached in 10 cm cell culture dishes. The cells were 
harvested through trypsinisation (Section 2.2.2) and after neutralisation with 2 ml DMEM + 
10% FBS per dish, cells were subjected to centrifugation (250 x g, 5 min, RT) and 
resuspended in 10 ml PBS containing 1% BSA. A 30 μl aliquot of the cell suspension was 
then taken for cell counting, and the remainder of cell suspension was again subjected to 
centrifugation (250 x g, 5 min, RT) and resuspended in PBS containing 1% BSA (#A4503-
100G, Sigma-Aldrich, Germany) at a concentration of 1 x 10
6 
cells/ml. A 100 μl aliquot of 
cell suspension (containing 100 000 cells) was transferred to a FACS tube (BD Biosciences, 
CA USA) at RT. Cell suspensions at a concentration of 1 × 10
5
 cells per 100 µL were co-
labelled with mouse anti-rat fluorescent antibodies against progenitor cell- (CD90 (Thy-1) 
FITC, #554897, BD Biosciences; CD106 Alexa Fluor 647, # MCA4633A647T, AbD 
Serotech), fibroblast- (CD26 PE, #559641, BD Biosciences) and leukocyte- (CD45 V450, 
#561587, BD Biosciences) associated surface markers. Refer to table 3.2.2.1 for antibody 
information. After addition of the antibody cocktail specific for each cell type analysed, cell 
suspensions were gently vortexed and incubated in the dark at RT for 30 min. After 
incubation, 200 μl of 0.5 % paraformaldehyde in PBS containing 1% BSA was added to each 
sample tube and the tube vortexed briefly to resuspend the cells. The cells were immediately 
analysed by flow cytometry. Flow cytometric analysis was performed using a FACS Canto II 
(BD) and FACSDiva software (BD). Since a multicolour cytometric analysis was carried out, 
fluorescent compensation settings were established through a compensation experiment and 
regions of positive and negative staining were determined through a fluorochrome minus one 
(FMO) experiment. An unstained sample was used as a negative control for gating purposes. 
A total of 30 000 events were recorded for each sample and data was analysed using Flow Jo 
Vx (Treestar) software. (See figure A in Addendum A for compensation controls).   
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Table 2.2.10.1 Flow cytometry antibodies to determine expression marker pattern of isolated MSCs. 
Specificity 
(Mouse anti-
rat) 
Conjugate Concentration  
per 106 cells  
Isotype Manufacturer  
CD106  Alexa Fluor 647 5µL  IgG1 AbD Serotech, Cat # MCA4633A647T  
CD26  PE 5µL Mouse (BALB/c) IgG2a,ĸ BD Pharmingen, Cat # 559641, Lot #10178 
CD90  FITC 5µL Mouse (BALB/c) IgG1,ĸ BD Pharmingen, Cat # 554897, Lot # 2195904 
CD45  V450 2.5µL Mouse (BALB/c) IgG1,ĸ BD Horizon, Cat # 561587, Lot # 2223891 
 
2.2.11 5-bromo-2’-deoxyuridine (BrdU) assay for cellular proliferation  
The BrdU assay for cellular proliferation is based on the incorporation of BrdU into newly 
synthesized DNA in cells undergoing  proliferation, and is measured colourimetrically where 
absorbance values obtained are proportional to the amount of cellular proliferation occurring. 
The Cell Proliferation ELISA, BrdU (colourimetric) kit (#11647229001, Roche Diagnostics 
Corporation, IN, USA) was used and the assay was performed according to manufacturer’s 
instructions. scADSCs and pvADSCs at P2 or bmMSCs at P3 were seeded at 10
4 
cells per 
well in 96-well plates and incubated in standard expansion medium at 100 μl/well overnight 
at 37 °C in 5% CO2 and constant humidity. The following day the cell cultures were serum 
starved in order to synchronize the cell cycle, this was done by exchanging the expansion 
medium with starvation medium (DMEM + 1% FBS), at 100 μl/well and incubated for a 
further 16 hours. After synchronization of the cell cycle was complete, starvation medium 
was aspirated and replaced with expansion medium. Treatments which may affect cellular 
proliferation were given to the cells at this time. Cells, in expansion medium, with or without 
treatment, were incubated at 37 °C in 5 % CO2 and constant humidity for a further 22 hr, 
followed by addition of 10 μl of BrdU labeling solution (1:100 dilution of BrdU labeling 
stock in DMEM) to each well containing cells, and the plate was incubated for a further 2 hr 
to allow for the BrdU to be incorporated. Medium containing BrdU labeling solution was 
then removed by aspiration and the plate either allowed to air-dry followed by storage at 4 °C 
for up to 7 days before further processing, or the assay was carried out immediately.  
 
To perform the BrdU assay, the wells were incubated with 200 µl/well FixDenat solution for 
30 min at RT. After removal of FixDenat, the cells were incubated with 100 µl/well anti-
BrdU-POD [monoclonal antibody from mouse-mouse hybrid cells (clone BMG 6H8, Fab 
fragments) conjugated with peroxidase] working solution (1:10 anti-BrdU-POD: Antibody 
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dilution solution) for 90 min at RT. After 90 min, the anti-BrdU-POD was removed and wells 
washed with Washing solution (PBS) at 200 µl/well x 3. Substrate solution (tetramethyl-
benzidine) was then added at 100 µ/well and colour allowed to develop for 5 min before 
reading the absorbance at 370 nm (reference wavelength 492 nm). For the blank, the assay 
was performed in wells containing no cells. Background was controlled for by performing the 
BrdU assay on wells which contained cells that were not labeled with BrdU labeling solution.   
 
2.2.12 Nucleic acid methods  
Confirmation of the expression of genes associated with adipogenesis and osteogenesis are 
necessary to ensure that a true adipogenic or osteogenic phenotype has been achieved with 
adipogenic or osteogenic induction. Adipogenic marker genes that were quantified were 
PPARγ2, aP2 and adipsin, while the osteogenic marker genes that were quantified were 
alkaline phosphatase, RunX2 and bone sialoprotein (BSP) (Sadie-Van Gijsen et al., 2012).  
This section details the procedures used to isolate total RNA from naïve cells or cells 
differentiated with AM or OM, followed by synthesis of cDNA from the isolated total RNA, 
and finally semi-quantitative real time PCR to quantify relative gene expression levels using 
the synthesized cDNA. 
 
2.2.12.1 Total RNA isolation 
Subcutaneous ADSCs and pvADSCs at P2 and bmMSCs at P3, to be used for RNA isolation, 
were cultured in 6-well plates (Nest Biotech Co., Ltd, China) under various conditions until 
RNA was harvested at the required time point. RNA was isolated from cells using the 
RNeasy® RNA isolation kit (Qiagen, #74106) as recommended by the manufacturer. At the 
required time point, medium was aspirated from the wells followed by immediate addition of 
350 µl of RLT (rapid lysis treatment) buffer supplied in the kit. Gentle pipetting was used to 
dislodge the cells from the well surface and the lysate was transferred to an RNAse-free 1.5 
ml microfuge tube. RNA lysates were stored at -80 °C before RNA isolation was carried out.    
 
The RNA isolation procedure was carried out on thawed previously prepared RNA lysates. A 
volume of 350 µl of 70% EtOH was added to each tube containing RNA lysate and gently 
mixed by pippeting. A 700 µl volume of the EtOH/lysate mixture was transferred to an 
RNeasy mini column, inserted into a 2 ml collection tube, followed by centrifugation (8 000 
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x g, 15 sec, RT). The flow through was discarded, and a volume of 700 µl of wash buffer 
RW1 was applied to the column, the column and collection tube were centrifuged (8000 x g, 
15 sec, RT), and the flow through was again discarded. 500 µl of buffer RPE was applied to 
the column, which was centrifuged (8000 x g, 15 sec, RT) and the flow through discarded. A 
final 500 µl volume of buffer RPE was applied to the column and this was again centrifuged 
(8000 x g, 2 min, RT) for a longer period of time in order to dry the column. The column was 
carefully removed from the collection tube, so as not to make contact with any flow through, 
and placed in a clean 1.5 ml microfuge tube. A volume of 30 µl of RNAse-free water was 
applied directly to the membrane of the column, and the column and collection tube were 
centrifuged (8000 x g, 1 min, RT) in order to elute the RNA from the column. Isolated RNA 
was stored at -80 °C before cDNA synthesis was carried out.  
 
2.2.12.2 cDNA synthesis  
Samples of total RNA isolated using the RNeasy® RNA isolation kit (Section 2.2.12.1) were 
thawed on ice and heated at 65 °C for 10 min and immediately placed on ice. The optical 
density (OD) of the RNA was measured using a NanoDrop 2000 spectrophotometer (Thermo 
Scientific, DE, USA) to determine the concentration of RNA in µg/ml. The absorbance ratio 
of 260/280 nm which was also measured to determine the purity of the RNA, with a value of 
~ 2.0 indicating pure RNA and a value of ~1.8 indicating pure DNA. Values for 260/230 nm 
provide a secondary measure of RNA purity, and a ratio of 2.0 is considered to be indicative 
of pure RNA (Wilfinger et al., 1997).   
 
Once the concentration of the RNA and purity of the RNA as shown by the A260/280 and 
A260/230 ratios had been determined, 1.1 µg of RNA was transferred to an RNAse-free 0.6 
ml PCR tube (QSP) and the volume of each sample made up to 8 µl with RNAse-free H2O.  
 
A 1:1 mixture of 10 x DNase reaction buffer (Promega, Madison, WI, USA) and RQ1 DNase 
(Promega, Madison, WI, USA) was made and 2 µl of this mixture was added to each sample, 
which were then incubated at 37 °C for 30 min in a PCR Express thermocycler (22962, 
Hybaid, UK) in order to digest any DNA present in the sample. The DNase reaction was 
stopped by the addition of DNase stop solution (Promega, Madison, WI, USA) and the 
DNase enzyme inactivated by incubation of the samples at 65 °C for 10 min in the 
thermocycler. 
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A volume of 10 µl of the DNase-treated RNA, containing approximately 1 µg of RNA, was 
transferred to a clean RNAse-free 0.6 ml PCR tube, and a volume of 1.7 µl of 100 µM 
oligo(dT) primer (IDT) was added to each sample. Samples were incubated in a thermocycler 
at 70 °C for 5 min for RNA denaturation, and placed on ice immediately after to prevent the 
primers from annealing to one another. To each sample, 7.8 µl of the following cocktail was 
added:  
 
 4 µl of RT buffer consisting of 80% ImProm-II™ reaction buffer (Promega, Madison, 
WI, USA) and 20% M-MLV™ reaction buffer (Promega, Madison, WI, USA)  
 0.5 µl of 10 mM dNTPs (Sigma-Aldrich) 
 1.8 µl RNAse-free H2O  
 0.5 µl RNAsin (Promega, Madison, WI, USA) 
 1 µl ImProm-II™ reverse transcriptase (RT) (Promega, Madison, WI, USA) 
 
After the addition of the above cocktail, samples were incubated at 25° C for 5 min, followed 
by 42 °C for 1 hr, in a 2-step RT reaction. Finally, the RT was inactivated by incubation of 
the samples at 70 °C for 15 min. Samples containing synthesized cDNA were stored at -20 
°C.  
 
2.2.12.3 Conventional PCR  
Brun-Heath et al. designed and published primers that were able to distinguish between bone-
type and liver-type TNAP mRNA transcripts in rat, as each forward primer was specific for a 
region on the 5′-untranslated region which varies between bone or liver transcripts, and a 
single common reverse primer, complimentary to a protein-coding region of the mRNA 
(Brun-Heath et al., 2011). The sequence of the bone-type forward primer is 5′ 
GCCGGGACAGACCCTCCCCAC 3′, the liver-type forward primer is 5′ 
GCTGAAGGTTGAGCATTCTAGTGCAGG 3′ and the reverse primer is 5′ 
GGCGTATGCCTCCTGCATTGG 3′. The expected PCR products from the use of the bone 
or liver primer sets are 1595 and 1607 bp respectively. PCR template samples included 
cDNA synthesized from RNA isolated from AM- or OM-treated bmMSCs, scADSCs and 
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pvADSCs, as well as from RNA isolated from rat liver for use as a positive control (Section 
3.2.12.2).  PCR was performed using the GoTaq® G2 Flexi DNA polymerase kit (Promega, 
Madison, WI, USA) according to manufacturer instructions, with a PCR reaction volume of 
50 µl [10 µl of GoTaq® Flexi Buffer, 2 µl MgCl2 (25 mM), 1 µl dNTP mixture (10 mM), 
0.25 µl GoTaq® Flexi DNA Polymerase (5 U/µl), 1 µl of forward primer (10 µM) and 1 µl of 
reverse primer (10 µM), 2 µl template cDNA, volume made up to 50µl with nuclease-free 
water]. PCR reactions were carried out using a PCR Express thermocycler (Hybaid, UK). 
Amplification conditions for the bone-type primer set were as follows: Denaturation at 94 °C 
for 5 min, followed by 40 cycles at 94 °C for 1 min, 60 °C for 1 min and 72 °C for 2 min, 
followed by a final extension of 72 °C for 15 min. Amplification conditions for the liver-type 
primer set were as follows: Denaturation at 94 °C for 5 min, followed by 40 cycles at 94 °C 
for 1 min, 57 °C for 1 min and 72 °C for 2 min, followed by a final extension of 72 °C for 15 
min.  For analysis, amplicons were subjected to electrophoresis on a 1% agarose gel 
containing 0.5 µg/ml ethidium bromide (EtBr), run at 80 V for 45 min.  The DNA bands were 
visualised by the fluorescence of the EtBr dye under UV light, using a ChemiDoc imaging 
system (Bio-Rad Laboratories, CA, USA).  
 
2.2.12.4 Quantitative real-time PCR (RT-qPCR) 
RT-qPCR was performed using a Rotor-Gene Q 2-Plex (Qiagen) and data was analysed using 
Rotor-Gene Q series software version 2.2.3 (Build 11) to quantify relative gene expression. 
Synthesized cDNA samples (Section 2.2.12.2) were diluted 1:125 with nuclease-free water in 
order to assess levels of the reference gene (RG), acidic ribosomal phosphoprotein (Arbp) 
(Rplp0)  (van Wijngaarden et al., 2007). For evaluation of the various genes of interest 
(GOIs), cDNA samples were diluted 1:5 with nuclease-free water. Quantification of the 
expression of the various GOIs was achieved by normalization of the relative expression of 
each GOI to the relative expression of the RG. Three biological repeats were employed for 
each experiment, where the individual repeats were assayed in duplicate.   
 
RT-qPCR reaction components for a single PCR sample (total volume of 10 µl) included: 
 0.1 µl forward primer (10 µM)  
 0.1 µl reverse primer (10 µM)  
 5.0 µl 2x Sensimix SYBR No Rox (Bioline, London, UK) 
 3.8 µl nuclease-free H2O  
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 1 µl cDNA template diluted 1:5 with nuclease-free water 
 
Primer sets used for detection of the various GOIs are given in Table 2.2.12.4.1. 
Table 2.2.12.4.1: Primer sequences used for semi-quantitative real-time PCR (RT-qPCR). 
Transcripts 
(reference) 
 
Primer sequences (5’ -3’) 
Product 
size (bp) 
Pparγ2 (Pparg2) (Tanabe et al., 2004b) F: ACT GCC TAT GAG CAC TTC AC 
R: CAA TCG GAT GGT TCT TCG GA 
448 
Ap2 (Fabp4) (Fukuen et al., 2005) F: TGA AAT CAC CCC AGA TGA CAG 
R: CTC ATG CCC TTT CAT AAA CT 
194 
Adipsin (Adps)  (van de Vyver et al., 
2014) 
F: CAC GTG TGC GGT GGC ACC CTG 
R: CCC CTG CAA GTG TCC CTG CGG T 
476 
Alkaline phosphatase (Alp) (Kuroda et 
al., 2005) 
F: GAG CAG GAA CAG AAG TTT GC 
R: GTT GCA GGG TCT GGA GAG TA 
202 
RunX2  (Liu et al., 2004) F: GAT GAC ACT GCC ACC TCT GA 
R: ATG AAA TGC TTG GGA ACT GC 
118 
Bone Sialoprotein (BSP) (Tanabe et al., 
2004a) 
F: GAT AGT TCG GAG GAG GAG GG 
R: CTA ACT CCA ACT TTC CAG CG 
172 
Arbp (Rplp0) (van Wijngaarden et al., 
2007) 
F: AAA GGG TCC TGG CTT TGT CT 
R: GCA AAT GCA GAT GGA TCG 
91 
 
Thermal cycling conditions varied slightly according the primer set used, with the steps 
commonly used including an initial denaturation of 95 °C for 10 min, followed by a sequence 
cycle starting with a short denaturation step of 95 °C for 3 sec, a variable annealing step, and 
a variable extension step, repeated 35 x, and lastly, a final extension step of 72 °C for 5 min. 
Table 2.2.12.4.2 gives the thermal cycling conditions for the primer sets used to amplify the 
various GOs.   
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
 57 
 
Table 2.2.12.4.2: Thermal cycling conditions for the primer sets used to amplify the various genes of 
interest (GOIs). 
Transcripts  Annealing 
temperature (°C) 
Annealing 
time (sec)  
Extension 
temperature (°C) 
Extension 
time (sec) 
PPARγ2 (Pparg2) 53 10 72 20 
Ap2 (Fabp4) 50 5 72 6 
Adipsin (Adps) 60 3 72 15 
Adiponectin  54 7 72 5 
Alkaline phosphatase (Alp) 52 5 72 8 
Bone sialoprotein  52 10 72 8 
RunX2  52 8 72 6 
Arbp (Rplp0) 52 10 72 8 
 
2.2.13 Fluorescence microscopy – optimization of perilipin A staining in 
subcutaneous and visceral adipose derived stromal cells. 
ScADSCs and pvADSCs at passage 2 (P2) and bmMSCs at passage 3 (P3) were seeded at 
30 000 cells/well into a sterile Lab-Tek Chambered #1.0 Borosilicate coverglass system 8-
well chamber dish (120177LE 1007, Nunc, NY,USA) and incubated with SGM at 37° C in 
5% CO2 until two days post confluence. Thereafter, cells were induced with adipogenic 
differentiation media (AM) as previously described (Section 2.2.5), and cultured for a further 
5 days for ADSCs and for 14 days for bmMSCs in AM with media changes every third day.  
 
2.2.13.1 Immuno-fluorescent Perilipin A staining  
Once cells were ready for staining, at either day 5 or 14, as described above, the medium was 
aspirated off and cells were fixed with 4% paraformaldehyde in PBS (pH 7.4, 100 µl/well, 10 
min, 4 °C). The wells were then washed 1 x for 30 sec with 200 µl/well PBS (pH 7.4), 
followed by the addition of 100 µl/well Triton X-100 (10 min at 4 °C). Wells were again 
washed 1 x with 200 µl/well PBS for 30 sec and 100 µl/well of blocking serum (FBS) was 
added and the plate incubated for 20 min at RT. Blocking serum was drained and not washed, 
followed by addition of 100 µl/well of primary antibody [Rabbit polyclonal Perilipin A (1.00 
mg/ml) (#ab3526, Abcam, UK) at a 1:50 dilution with PBS] and the dish was incubated 
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overnight at 4 °C in the dark. The wells were then washed with 200 µl/well PBS (pH 7.4) for 
30 sec and 100 µl/well of the secondary antibody [goat polyclonal secondary antibody to 
rabbit IgG – H&L (Alexa Fluor® 594) (2.00 mg/ml) (#ab150080, Abcam, UK) at 1:250 
dilution in PBS] was added and the dish incubated for 1hr at RT in the dark. The wells were 
washed 2x with 200 µl/well PBS (pH 7.4) and either a single drop of Dako fluorescent 
mounting medium (S3023, North America Inc., CA, USA) was applied to the wells to 
preserve integrity of the cells, or the wells were co-stained for endogenous alkaline 
phosphatase activity using the ELF® 97 endogenous phosphatase detection kit (Roche 
Diagnostics Corporation, IN, USA).  
 
2.2.13.2 Alkaline phosphatase activity detection using a fluorescent probe. 
The ELF® 97 endogenous phosphatase detection kit (#E6601, Molecular Probes™, 
Invitrogen, Leiden, The Netherlands) was used to detect alkaline phosphatase activity, and 
was performed according to manufacturer instructions. The ELF 97 phosphatase substrate 
was diluted 20 x in detection buffer and filtered with a 0.2 µm pore size filter immediately 
before use. The diluted substrate was applied to the wells at 50 µl/well for a period of 5 min 
in the dark at RT. The reaction was stopped by washing the wells 3 x with 200 µl/well wash 
buffer (PBS containing 25 mM EDTA, 5 mM levamisole, pH 8.0) for 5 min each wash. The 
wash buffer was removed by aspiration with a pipette, as much as possible without drying the 
sample, and a drop of ELF 97 mounting medium was applied to the well. The dish was then 
covered in foil to protect it from light and stored at -20 °C until ready to view. Images were 
acquired using a A Zeiss LSM780 Elyra S1 confocal microscope with ZEN 2011 software 
(Carl Zeiss, Jena, Germany)  using a standard Hoeschst/DAPI longpass filter set, as the 
maximum emission of the ELF alcohol product is 530 nm. 
 
2.2.14 Knockdown of tissue-nonspecific alkaline phosphatase (TNAP) gene 
(Alp1) using the MISSION® viral transduction system (Sigma) 
Knockdown of the alkaline phosphatase (Alp1) gene was performed in scADSCs undergoing 
adipogenic differentiation using the MISSION® viral transduction system (Sigma) according 
to the manufacturer recommendations, in order to determine the contribution of TNAP on 
lipid accumulation and adipogenesis. Confirmation of knockdown was performed by RT-
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qPCR (Section 2.2.12). The MISSION viral transduction system is based on RNA 
interference (RNAi), where the short hairpin RNA (shRNA) specific for a particular gene is 
inserted into a viral vector (amphotropic lentiviral particles), which is transfected into the 
cells of interest. Once integrated into the cellular genome, the shRNA are expressed and 
processed intracellularly into siRNA. Selection of transfected cells is based on resistance to 
the antibiotic puromycin, as the puromycin resistance gene is expressed from the viral vector. 
Figure 2.2.14.1 presents the vector diagram of the lentiviral plasmid pLKO.1-puro used in 
this study.   
 
Subcutaneous ADSCs in P1 were transfected with MISSION pLKO.1-puro Non-Target 
shRNA Control Transduction Particles (SHC016V) or MISSION® Lentiviral Transduction 
particles (SHCLNV) targeting TNAP at a ratio of 2:1 particles to cells. Roughly 40 000 
cells/well were grown in a 6-well plate before transfection commenced with polybrene being 
also added at a final concentration of 8 µg/ml to the standard expansion medium. The cells 
were incubated at 37 °C in 5 % CO2 and constant humidity for 24 hr to allow for viral 
transfection to occur. After 24 hours, the medium containing viral particles and polybrene 
was aspirated off and the medium was replaced with SGM. The cells were incubated for a 
further 24 hr before the addition of puromycin (#P8833, Sigma-Aldrich) at 2 µg/ml. 
Puromycin was also added to untransfected cells as a control, in order to confirm the efficacy 
of antibiotic selection. The antibiotic-containing medium on the wells containing the 
transfected cells was replaced with SGM without antibiotic and cells were incubated for a 
further 24 hr at 37 °C, 5% CO2 with constant humidity. After 24 hr, the transfected cells were 
passaged (into P2) for experimentation and incubated for a further 24 hr at 37 C, 5% CO2 
with constant humidity (Section 2.2.3). After this step, the SGM on the cells was replaced 
with SGM containing 2 µg/ml puromycin, and cells were maintained in this medium until the 
time that adipogenic induction was initiated (Section 2.2.5). During adipogenic 
differentiation of the transfected cells, no puromycin was added to the AM. At day 5 of 
adipogenic differentiation, cells were harvested for RNA isolation and RT-qPCR to assess 
knockdown of the Alp1 gene (Section 2.2.12.3). 
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Figure 2.2.14.1: Vector diagram of the TRC1 and TRC1.5 Lentiviral Plasmid Vector pLKO.1-puro 
features (Taken from, MISSION® shRNA control transduction particles, Technical bulletin, Sigma-
Aldrich,http://www.sigmaaldrich.com/content/dam/sigma-aldrich/docs/Sigma/Bulletin/1/shc016vbul.pdf, 
Accessed: 6 July 2016). 
  
2.2.15 Glycosylation analysis of TNAP 
Samples for glycosylation analysis were cell lysates (bmMSCs) (Section 2.2.4.1) and alkaline 
phosphatase extraction samples (scADSCs and pvADSCs) (Section 2.2.4.2).  ALP isozymes 
present in the samples were separated by wheat germ lectin (WGL) affinity electrophoresis 
on a 1% agarose gel buffered to an alkaline pH of 9.4 (HYRAGEL 7, ISO-PAL kit), using a 
Hydrasys semi-automated electrophoresis system (Sebia, France) according to manufacturer 
instructions. Samples were run in duplicate in adjacent wells, with 10 µl of sample applied 
per well, and with the addition of 10 µl of lectin solution in one well of each duplicate pair. 
Each sample was run at an ALP concentration of 200U/L, as determined by ALP activity 
assay (Section 2.2.4.3). The migration was carried out for approximately 30 minutes, at 10 W 
constant power at 30 °C. Following migration, 2.5 ml of ISO-PAL substrate solution [2 ml 
BCIP (5-Bromo-4-Chloro-3-Indolyl Phosphate) in Aminomethyl Propanol buffer (AMP) pH 
10.1 ± 0.5 + 0.5 ml chromogen (Nitro Blue Tetrazolium) in water] is applied to the gel and 
incubated at 37 °C for 45 min. Following substrate incubation, the remaining substrate 
solution is removed and the gel is blotted with filter paper at 45 °C for 3 min. The filter paper 
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was discarded after blotting and the gel remained in the Hydrasys instrument for drying at 60 
°C for 2 min. The final washing and processing of the gel was performed by the Hydrasys 
instrument, and the final dried, processed gel was visually evaluated.   
 
2.2.16 Statistical analysis  
Variables were subjected to unpaired t-tests (for comparing two groups) or analysis of 
variance (ANOVA) (for comparing 3 or more groups) followed with Tukey’s post hoc test to 
compare all groups where appropriate. Biological repeats of a minimum of n=3 were 
performed per experiment, with three technical repeats performed per n=1, unless otherwise 
stated. Values are expressed as mean ± SEM. Statistical significance was denoted using 
asterisks (*). Results were considered statistically significant where P < 0.05. GraphPad 
Prism 5 software (GraphPad Software, Inc.) as well as Statistica software (StatSoft, version 
10) were used to perform statistical analysis.  
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CHAPTER 3 
Characterisation of mesenchymal stromal cells 
(MSCs) from adipose and bone marrow 
depots. 
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3.1 Introduction 
Mesenchymal stromal cells (MSCs) were first isolated from bone marrow tissue by 
Friendenstein et al. in the 1960s, when it was discovered that these cells were plastic-
adherent and capable of spontaneous bone formation (Friedenstein et al., 1970). These bone 
marrow-derived MSCs were also found to have stem cell-like characteristics, in that they 
were able to undergo several rounds of expansion in culture and could be differentiated 
towards various mesenchymal cell types, including osteoblasts, adipocytes and chondrocytes  
(Chen et al., 2007; Galderisi and Giordano, 2014). MSC-like cells were later found in various 
other tissues, including adipose and umbilical cord tissue, and were characterised based on 
their ability to differentiate into the various mesenchymal lineages (Dominici et al., 2006; 
Peng et al., 2008). 
 
Interest in MSCs has grown in recent years due to the potential clinical use of these cells for 
regeneration of damaged tissue, such as bone, cartilage and adipose tissue, damaged either as 
a result of injury, cancer or a congenital defect (Arrigoni et al., 2009; Shah et al., 2014). A 
greater understanding of the biology and mechanisms underlying the differentiation of MSCs 
into the various lineage phenotypes is necessary in order that the full therapeutic potential of 
these cells is realised, as well as for understanding the development of certain metabolic 
diseases, such as those brought about by osteoblast and adipocyte dysfunction, including 
osteoporosis and obesity (Nuttall and Gimble, 2004; Yu et al., 2010; Czekanska et al., 2012). 
 
Immortalized cell lines are often derived from cancers or other malignancies, and have been 
extensively utilized as models to study cellular differentiation due to their ease of use. 
Immortalized cell lines can be expanded extensively in culture and are more phenotypically 
stable than primary-derived cells. There are however, drawbacks to using various 
immortalized cell lines, including a limited differentiation profile, an aberrant cell cycle, 
chromosome abnormalities, lack of growth inhibition, as well as findings that suggest a lack 
of homogeneity between cells from earlier and later passages (Czekanska et al., 2014). For 
the above reasons, the present study selected to use primary-derived MSCs as a model for 
studying adipogenesis and osteoblastogenesis, as the characteristics of primary cells are 
known to be closer to those of cells in vivo than immortalized cell lines (Marko et al., 1995).  
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Rats provide a well-established immunocompetent small animal model for studying MSC 
biology. MSCs have been successfully harvested from a variety of rat tissues, including bone 
marrow, as well as inguinal subcutaneous and peri-renal visceral adipose depots. While rat 
MSCs provide a suitable model for investigation into the mechanisms of mesenchymal 
differentiation, a limitation exists in the form of a paucity of reagents for surface marker 
characterisation, a situation which may improve as more of these products become available 
(Arrigoni et al., 2009; Lopez and Spencer, 2011).  
 
Despite the ability of MSCs isolated from various tissues to differentiate into osteoblastic, 
adipocytic and chondrocytic lineages, as well as having similar surface marker expression, 
several differences exist between MSCs isolated from various sources, including variations in 
proliferation and differentiation capability, and gene expression profiles (Noel et al., 2008; 
Casteilla et al., 2011). For the above reason, it is necessary to characterise MSCs from 
various depots with regards to phenotype, proliferation rate, as well as differentiation 
capability, in order to establish the suitability of those particular MSCs as a model for the 
cellular differentiation pathway of interest.  
 
The present study utilised rat MSCs derived from bone marrow (bmMSCs) as well as the 
inguinal subcutaneous and peri-renal visceral adipose-derived MSCs (scADSCs and 
pvADSCs, respectively) as models for both adipogenesis and osteoblastogenesis. Previous 
studies have shown differences in the response of rat scADSCs and pvADSCs when induced 
towards adipogenic and osteogenic differentiation, particularly that scADSCs have a greater 
osteogenic potential than pvADSCs, while pvADSCs had a greater potential for lipid 
accumulation during adipogenic induction than scADSCs (Arrigoni et al., 2009; Sadie-Van 
Gijsen et al., 2012). Additionally, rat-derived bmMSCs have been reported to have a greater 
osteogenic differentiation potential in comparison to scADSCs, while the adipogenic 
differentiation potential of scADSCs is superior to bmMSCs (Yoshimura et al., 2007; 
Hayashi et al., 2008).  
 
The in situ identification of MSCs has proven to be difficult, as no single marker is available 
which is able to identify undifferentiated naive MSCs within intact tissue (Baer and Geiger, 
2012). Immunohistochemistry and cell sorting techniques have identified populations of 
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perivascular cells in various human organs, which share many characteristics with cultured 
MSCs, suggesting that MSCs may originate from a perivascular niche (Corselli et al., 2010). 
MSC characterisation is still most often retrospective rather than prospective, where MSCs 
isolated from various tissues and cultured in vitro are characterised by plastic adherence, 
surface marker expression and the ability to differentiate into osteoblasts, adipocytes and 
chondrocytes. There is at present a lack of standardization in cell culture techniques, media 
composition and other reagents used for cell culture between different investigators, and this 
has led to difficulties in making direct comparisons between the results obtained from 
different studies (Baer and Geiger, 2012). It is therefore necessary to characterise the MSCs 
isolated for this study in terms of surface marker expression, proliferation and differentiation 
potential, in order to verify that the isolated cells are indeed MSCs.  
 
One of the drawbacks of using primary-derived MSCs is that primary cell cultures are known 
to be heterogeneous, and may contain several different progenitor sub-populations.  MSCs 
also have a limited lifespan in culture, and as such for each experiment cells must be isolated 
from fresh tissue, so that experiments can be performed consistently with cells at a specified 
passage (Bianco et al., 2001; Sethe et al., 2006; Brinchmann, 2008; Baer and Geiger, 2012).  
 
In order to compare MSCs from different anatomical locations, the MSCs isolated from bone-
marrow and adipose depots were characterised in terms of their morphology, which is based 
on qualitative visual evaluation, as MSCs typically have a fibroblastic or spindle-shaped 
appearance in culture, but may also appear as random polygonal. Differences in 
morphological appearances of MSCs may be a consequence of the inherent heterogeneity 
observed in primary-derived MSC cultures (Bianco et al., 2001; Kollmer et al., 2013). We 
have also performed flow cytometry on the MSCs isolated from different depots, which 
provided a more rigorous measure of cellular morphology and allowed for individual cells 
within a sample population to be characterised based on the size and internal complexity, 
termed granularity, of the cells. Flow cytometry analysis also allows for the presence of 
different populations of cells with a sample population to be identified.  
 
We have evaluated the MSC populations isolated from bone-marrow and adipose tissue for 
expansion rate in culture, which was assessed by cellular proliferation rate, as this allowed us 
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to gain a better understanding of the behaviour of the cells in culture, and to identify which 
culture conditions would be suitable for cells from each MSC depot, such as cell density prior 
to passage. The MSCs isolated were further characterised using cell surface markers and flow 
cytometry, to allow positive confirmation of the MSC phenotype and exclude the possibly 
that the cell types isolated were of the hematopoietic or fibroblastic lineage. Adipogenic and 
osteogenic differentiation capabilities were also assessed, by treating cells from adipose- and 
bone-marrow depots with either adipogenic or osteogenic differentiation media followed by 
staining and quantification of lipid and mineral content, respectively. Differentiation of 
MSCs into either adipogenic or osteoblastic lineages was confirmed using reverse-
transcription semi-quantitative PCR (RT-qPCR) to detect the presence of adipogenic or 
osteoblastic gene marker (mRNA) expression levels, and differences in the relative 
expression of the various markers between MSC depots were compared to the housekeeping 
gene, Arbp.  
 
3.2 Results 
3.2.1 Mesenchymal stem cell (MSC) morphology 
MSCs from subcutaneous (scADSCs) and visceral (pvADSCs) adipose depots, as well as 
bone-marrow (bmMSCs), were cultured with DMEM and 10% foetal bovine serum at 37° C 
with 5% CO2 in a humidified environment (Section 2.2.3). The morphology of the cells was 
fibroblastic, i.e. elongated and spindle-shaped, for all three cell types at passage 0 (P0).  The 
adipose-derived MSCs (ADSCs) appeared to be evenly spaced from one another at 24 to 48 
hr after seeding at P0 (Fig. 3.2.1.1, A and D) and proliferated to form clusters of cells with 
sparsely populated gaps between the clusters after 4-6 days and then a confluent lawn. In 
contrast, bone-marrow derived MSCs (bmMSCs) were observed as loose clusters one to two 
days after initial seeding at P0, and subsequently spread out from these regions to form a 
confluent lawn after 4-6 days in culture (Fig. 3.2.1.2, A).  
 
After the first passage (P1), the ADSCs became slightly broader and less elongated in 
appearance while still retaining a fibroblastic morphology, and were generally homogenous 
in appearance (Fig. 3.2.1.1, B and E). Cells proliferated rapidly in P1 and typically reached 
confluence within three to four days after seeding. Morphology of ADSCs after passage 2 
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(P2) was highly similar to cells in P1, where cells formed a confluent lawn after seeding after 
3-5 days. ADSCs were used for experimentation at P2. Cells at P2 which had reached 
confluence appeared as a lawn, where individual cells were not easily distinguishable (Fig. 
3.2.1.1, C and D).  
 
Bone marrow-derived MSCs were more heterogeneous in appearance at P0 than ADSCs, and 
were used at passage 3 (P3) for experimentation. Bone marrow-derived MSCs were observed 
to become more homogenous in appearance with increased passaging (Fig. 3.2.1.2, B, C and 
D), while cells maintained a polygonal/fibroblastic morphology throughout all passages.  
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Figure 3.2.1.1: Morphology of adipose tissue-derived MSCs. Images of scADSC (A, B and C) and pvADSC 
(D, E and F) at P0 (A, D), P1 (B, E) and P2 (C, F). Cells at P2 are shown at confluence on the first  day of 
treatment. Images were taken using an Olympus (CKX41) microscope at x20 magnification. 
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Figure 3.2.1.2: Morphology of bone marrow-derived MSCs (bmMSCs). Images of bmMSCs at P0 (A), P1 
(B), P2 (C) and P3 (D). P3 cells are shown at confluence on the first day of treatment. Images were taken using 
an Olympus (CKX41) microscope at x 20 magnification. 
 
3.2.2 Mesenchymal stem cell (MSC) surface marker expression 
In order to determine the purity of the isolated MSC populations, flow cytometry was 
performed to assess surface marker expression. ADSCs at P2 and bmMSCs at P3 were 
harvested by trypsinisation and re-suspended in PBS containing 1% BSA. Cell suspensions at 
a concentration of 1 × 10
5
 cells per 100 µL were co-labelled with mouse anti-rat fluorescent 
antibodies against progenitor cell (CD90 (Thy-1)) (Dominici et al., 2006), fibroblast- (CD26) 
(Sgodda et al., 2007) and leukocyte- (CD45) (Dominici et al., 2006) associated surface 
markers as well as vascular cell adhesion molecule 1 (VCAM1) (CD106)  (Cappellesso-
Fleury et al., 2010) (Refer to Section 2.2.10 for antibody information).  
 
The scADSC and pvADSC populations were expected to be positive for CD90, as this is an 
established marker for mesenchymal stromal progenitor populations (Dominici et al., 2006). 
The International Society for Cellular Therapy (ISCT) also defines MSCs as negative for the 
surface marker CD45, which is a haematopoietic cell marker (Dominici et al., 2006). The 
Stellenbosch University  https://scholar.sun.ac.za
 70 
 
surface marker, CD26 is a fibroblast marker, and therefore was not expected to be present on 
the surface of MSCs (Sgodda et al., 2007). The bmMSC populations were expected to be 
CD90 positive, as well as CD106 positive, as CD106 has been identified as a marker 
expressed in bmMSCs (Cappellesso-Fleury et al., 2010) and negative for CD45 and CD26. 
Results see Table 3.2.2.1 and Figure 3.2.2.1. 
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Figure 3.2.2.1: Surface marker expression profile of scADSCs, pvADSCs and bmMSCs. Flow cytometry on scADSCs (A), pvADSCs (B) and bmMSCs (C) was 
performed on a FACS Canto II instrument using FACSDiva software with a total of 30 000 gated events recorded prior to data analysis. Q1 – CD90-CD45+ (Leukocytes); 
Q2- CD90
+
CD45
+
 (haematopoietic progenitors); Q3 – CD90-CD45- ; Q4 – CD90+CD45- (MSCs). The x axis describes the size of the cell, while granularity on the y-axis 
describes the internal complexity of the cell.  
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Flow cytometry revealed that cells from all scADSC, pvADSC and bmMSC samples 
analysed contained a single population (Fig. 3.2.2.1) which were all positive for CD90, and 
negative for CD26 and CD45 (Table 3.2.2.1). The scADSCs samples had a greater 
percentage of cells positive for CD90, as compared to the pvADSCs, with CD90 percentage 
mean values of 85.7% and 57.32%, respectively (Table 3.2.2.1). In the bmMSC samples, 
81.7% of cells were positive for CD90. Subcutaneous ADSCs and bmMSCs had a similarly 
low percentage of cells positive for CD26, with a mean value of 6.4% and 6.3%, respectively, 
while pvADSCs had a CD26 positive population of 22.1% (Table 3.2.2.1). ADSC samples 
were virtually devoid of CD45 positive cells, with similar percentages of CD45 cells at 0.2% 
for scADSCs and 0.3% for pvADSCs, while bmMSC samples had a low level of CD45 
expression, as 6.4% of the sample population were positive. bmMSC samples analysed were 
54.1% positive for CD106 (Table 3.2.2.1).  
 
Table 3.2.2.1: Percentage of positive staining for cell surface markers CD90, CD26, CD45 and CD106 in 
scADSCs, pvADSCs and bmMSCs.  
Cell type CD90
+
 CD26
+
 CD45
+
 CD106
+
 
scADSCs (n=4) 85.7 ± 3.8 6.4 ±3.3 0.2 ± 0.1 n.a 
pvADSCs (n=4) 57.32 ±4.0 22.1 ±5.9 0.3 ± 0.1 n.a 
bmMSCs (n=5) 81.7 ± 3.79 6.3 ±2.2 6.4 ±2.6 54.1 ±17.3 
Footnote: Values are presented as the percentage (%) of analysed cells which were positively stained (mean ± 
SE).   
 
3.2.3 Proliferation 
Cellular proliferation was measured in MSCs from adipose and bone marrow depots as part 
of the characterisation of the various cell types. Cellular proliferation was quantified by a 
colourimetric immunoassay, measuring the amount of 5-bromo-2’-deoxyuridine (BrdU) 
incorporated into the cells during DNA synthesis, using the BrdU Cell Proliferation ELISA 
kit (Roche) (Section 2.2.11). Briefly, proliferation is measured by the incorporation of BrdU, 
an analogue of thymidine, into the DNA strands during DNA replication prior to cell 
division. After fixing and denaturing the DNA, an anti-BrdU monoclonal antibody 
conjugated to peroxidase is used to bind to the incorporated BrdU in the newly synthesized 
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DNA strands. Cleavage of a substrate by the peroxidase produces a coloured product, which 
is quantified by absorbance using an ELISA plate reader. 
 
Subcutaneous ADSCs and pvADSCs at P2 and bmMSCs at P3 were seeded at 10
4
 cells per 
well in a 96-well plate and serum-starved overnight to synchronise the cell cycle, where after 
standard growth medium conditions were restored, and proliferation then quantified at 24 and 
48 hours. The absorbance reading was higher at both 0 and 24hr time points for the scADSCs 
and pvADSCs, when compared to bmMSCs; however by 48hr the absorbance measurement 
for the scADSCs and pvADSCs had dropped below initial starting levels, while the bmMSCs 
continued to increase from levels seen at 24hr. The drop in absorbance measurement 
observed in scADSCs and pvADSCs is likely due to a contact inhibition, where by 48hrs 
after initiation, the cells had reached confluence and as a result experienced a drop in 
proliferation (Leontieva et al., 2014). The bmMSCs exhibit a lower absorbance measurement 
at 0 and 24hrs compared to the ADSCs, and as these cells had not reached confluence by 
48hr, cellular proliferation continued. This may be due to the ADSCs having a higher initial 
rate of proliferation and reaching the exponential phase of proliferation between 24 and 48 
hrs, while the bmMSCs experience a slower initial rate and therefore reach exponential 
proliferation at a later time point than the ADSC samples.  
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Figure 3.2.3.1:  Quantification of BrdU incorporation to provide a comparison of the increase in cell 
number of MSCs derived from each of the different depots over a 48hr period. Statistical analysis: 
Factorial ANOVA with Tukey post hoc test. A significant effect of time within each cell type is indicated with 
*. Significant difference between cell types at the same time point is indicated with a (scADSC vs bmMSC) or b 
(pvADSC vs bmMSC). Level of significance was accepted at p < 0.05. 
 
3.2.4 Differentiation 
The adipogenic and osteogenic differentiation potential of the ADSCs and bmMSCs was 
assessed by culturing each cell type in the presence of adipogenic (AM) or osteogenic (OM) 
differentiation medium for specific amounts of time (Section 2.2.5 and 2.2.7 for detailed 
methodology on culturing conditions). Differentiation was assessed in order to confirm that 
the cells isolated from adipose and bone marrow depots were mesenchymal progenitor cells 
and able to undergo differentiation into both adipogenic and osteogenic lineages. This also 
allowed the differences in differentiation potential between cell types to be qualitatively and 
quantitatively compared.   
 
3.2.4.1 Adipogenic differentiation 
ADSCs and bmMSCs were cultured for up to 14 days in the presence of AM in order to 
induce adipogenesis. The presence of lipid droplets within the cells provided a visual 
indication that adipogenesis had occurred. Cell cultures were stained with the dye, Oil Red O 
which stains lipid red, in order to visualise and quantify the amount of lipid accumulation 
during adipogenesis.  Differentiated cells from scADSC, pvADSC and bmMSC cultures in 
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AM contained lipid droplets stained red with Oil Red O after 14 days of culture (Fig. 
3.2.4.1.1, D, E and F), in contrast to control cells cultured in standard growth medium 
(DMEM + 10% FBS + vehicle) which do not contain any visible lipid droplets (Fig. 
3.2.4.1.1, A, B and C). bmMSC control cultures were observed to form dense clusters of cells 
during long term culture, which when stained with Oil Red O were observed to trap dye and 
give rise to aberrant staining (Fig. 3.2.4.1.1, C. indicated by arrows). The aberrant staining 
present in the bmMSC day 14 controls is indicated in the increase in positive staining during 
quantification, at 1.5 ±0.5%, compared to the controls for scADSCs of 0.4 ±0.04% and 
pvADSCs of 0.3 ±0.05% at the same time point (Fig. 3.2.4.1.1, A,B and C).  
 
 
Figure 3.2.4.1.1: Adipogenic differentiation of scADSCs, pvADSCs and bmMSCs. Subcutaneous ADSCs 
(A and D), pvADSCs (B and E) and bmMSCs (C and F) were cultured for 14 days in standard growth medium 
(SGM) as control (A, B and C) or adipogenic differentiation medium (AM) (D, E and F) and stained with Oil 
Red O to visualise lipid droplets. Arrows indicate areas of aberrant staining in control bmMSCs due to 
formation of cell clusters during culture. Images were taken using an Olympus CKX41 inverted microscope at 
x10 magnification. 
 
Lipid accumulation in ADSCs and bmMSCs was quantified by image analysis, and the 
results expressed as the percentage area containing lipid droplets stained with Oil Red O. 
Analysis commenced at day 5 after induction of adipogenesis, as this was the time point 
when the first lipid droplets became visible. In addition to analysis at day 5, lipid 
accumulation was quantified on days 7, 10 and 14 for all cell types.  Oil Red O staining 
increased for all cell types over the 14 day differentiation period, with the highest percentage 
of staining achieved in the pvADSCs, followed by the scADSCs, with the lowest percentage 
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of staining in the bmMSC cultures (Fig. 3.2.4.1.2). Data showed that lipid accumulation 
increased significantly between day 5 and days 7, 10 and 14 for pvADSCs, and days 10 and 
14 for scADSC and bmMSCs (Fig. 3.2.4.1.2). Staining showed that lipid accumulation 
increased most rapidly between days 7 and 10 for scADSCs and pvADSCs, with only a slight 
increase observed between days 10 and 14 for pvADSCs, while lipid accumulation in 
scADSCs appeared to plateau between these time points. bmMSCs showed the greatest 
amount of lipid accumulation between the day 10 and 14 time points, which was however 
significantly lower than either the scADSCs or pvADSCs at both day 10 and 14 (Fig. 
3.2.4.1.2.).  
 
 
Figure 3.2.4.1.2: Quantification of Oil Red O staining of differentiated MSCs derived from bone-marrow, 
subcutaneous adipose and peri-renal visceral adipose depots. Values are presented as percentage of 
positively stained surface area (mean ± SE). Statistical analysis: Factorial ANOVA with Tukey post hoc test. A 
significant effect of time within each cell type is indicated with *. Significant difference between cell types at 
the same time point is indicated with a (scADSC vs bmMSCs) or b (pvADSC vs bmMSCs). Level of 
significance was accepted at p < 0.05. 
 
ADSCs and bmMSCs were treated with AM, and RNA isolated at days 3, 5, 7, 10 and 14 for 
RT-qPCR analysis of mRNA expression of the adipogenic markers, PPARγ, aP2 and adipsin 
(Fig. 3.2.4.1.3). RT-qPCR was performed as per Chapter 2, Section 2.2.12.4. Levels of 
mRNA expression were presented as relative to the house-keeping gene, Arbp (van 
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Wijngaarden et al., 2007). PPARγ, and specifically the PPARγ2 isoform in adipocytes, is the 
master regulator of adipogenesis, and is expressed early in adipocyte lineage commitment 
(MacDougald and Mandrup, 2002; Fujiki et al., 2009). Adipsin, a serine protease, is the 
mouse homolog of complement factor D, and is expressed at an increasing rate during 
adipogenic differentiation (Wilkison et al., 1990). Another adipose-specific product is a fatty 
acid binding protein named aP2, also known as 422, which was first identified in murine 
3T3-L1 cells and is activated by PPARγ during adipogenesis (Bernlohr et al., 1984; Gregoire 
et al., 1998). 
 
 Relative expression of PPARγ, aP2 and adipsin were found to increase significantly in 
scADSCs, over the course of the differentiation period (day 3 to day 10), as compared to 
time-matched controls under standard growth media conditions (Fig 3.2.4.1.3, A – F), 
whereas the increase was not statistically significant for either pvADSCs or bmMSCs. 
Subcutaneous ADSCs showed significantly higher expression of all adipogenic markers at 
day 10, compared to pvADSCs or bmMSCs (Fig. 3.2.4.1.3, A, C, and E). No significant 
increase in the relative expression of any of the adipogenic marker genes was found when 
comparing scADSCs with either pvADSCs or bmMSCs by day 10 of adipogenic 
differentiation (Fig. 3.4.2.4.1.3, A – F).   
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Figure 3.2.4.1.3: RT-qPCR comparing the expression of adipogenic genes in MSCs derived bone-marrow, 
subcutaneous adipose and peri-renal visceral adipose depots under standard growth media conditions 
and during adipogenic differentiation.  The relative expression of PPARγ (A and B), aP2 (C and D) and 
Adipsin (E and F) is shown in scADSCs, pvADSCs and bmMSCs. Values (mean ± SE) are presented as relative 
expression compared to the expression of the housekeeping gene (ARBP). Statistical analysis: Factorial 
ANOVA with Tukey post hoc test. A significant effect of time within each cell type is indicated with *. 
Significant difference between cell types at the same time point is indicated with a (scADSC vs bmMSCs). 
Level of significance was accepted at p<0.05. 
 
3.2.4.2 Osteogenic differentiation 
Cells were cultured in the presence of osteogenic differentiation medium for a period of 21 
days for ADSCs and 14 days for bmMSCs in order to induce osteogenesis. At the desired 
time points, cell cultures were stained with Alizarin Red dye which stains calcium mineral 
deposits red. The presence of calcium mineral deposits indicates that osteogenic 
differentiation has taken place. Mineral deposits were observed as early as day 5 for 
bmMSCs, with mineralisation being complete by day 14, however mineral deposits were only 
observed at day 21 for scADSCs and pvADSCs (Fig. 3.2.4.2.1, D, E and F). ADSCs cultured 
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in standard growth medium (DMEM+10% FBS+ vehicle) as a control did not stain positively 
by day 21, with scADSCs and pvADSCs exhibiting only 0.8 ± 0.1%  and 1.25 ±0.1% area 
positively stained, respectively (Fig. 3.2.4.2.1, A and B, and Fig. 3.2.4.2.2). The bmMSC 
controls had a low percentage of the well area stained positively with Alizarin Red at day 14 
of 2.1 ±0.2%, a value slightly higher than that of ADSC controls. The slight positive stain in 
the bmMSC controls is a result of aberrant staining due to the clustering phenomenon 
observed in these cells after prolonged periods in culture, which has previously been 
observed in controls during experiments where bmMSCs were differentiated into adipocytes 
(Fig. 3.2.4.2.1, C and Fig. 3.2.4.2.2).   
 
 
Figure 3.2.4.2.1: Osteogenic differentiation of scADSCs, pvADSCs and bmMSCs. Subcutaneous ADSCs (A 
and D), pvADSCs (B and  E) and bmMSCs (C and F) were cultured for 21 Days for scADSC and pvADSC and 
14 days for bmMSC in either standard growth medium (SGM) as control (A, B and C) or osteogenic 
differentiation medium (OM) (D, E and F) and stained with Alizarin Red to visualise calcified mineral deposits 
(red colour). Images were taken using an Olympus CKX41 inverted microscope at x10 magnification. 
 
Mineralised surface area, as visualised by Alizarin Red staining and quantified by image 
analysis with values expressed as percentage positively stained area, was over 10% on day 7 
for bmMSC cultures and increased significantly at both day 10 and 14 time points. Positive 
staining for both scADSC and pvADSC cultures was only significantly greater from day 7 to 
day 21, with no significant difference observed between either ADSC types. Mineralisation in 
bmMSCs was significantly greater than either scADSCs or pvADSCs on days 7 10 and 14, 
and showed a steady increase in percentage of mineralised surface area throughout all time 
points measured (Fig. 3.2.4.2.2).   
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Figure 3.2.4.2.2: Quantification of Alizarin Red S staining comparing the osteogenic differentiation of 
MSCs derived from bone marrow (bmMSC), as well as subcutaneous adipose (scADSC) and peri-renal 
visceral adipose (pvADSC) depots. Values are presented as percentage of positively stained surface area (mean 
± SE). Statistical analysis: Factorial ANOVA with Tukey post hoc test. A significant effect of time within each 
cell type is indicated with *. Significant difference between cell types at the same time point is indicated with a 
(scADSC vs bmMSCs) or b (pvADSC vs bmMSCs). Level of significance was accepted at p<0.05. 
 
ADSCs and bmMSCs were treated with OM and RNA from ADSCs was collected at days 0, 
3, 5, 7, 10 and 21 for gene expression analysis, and at days 0, 3 and 5 for bmMSCs (Fig. 
3.2.4.2.3). RNA concentration in bmMSCs undergoing osteogenesis was too low to be 
measured from day 7 onwards, possibly due to excessive mineralisation. The expression of 
the osteogenic marker genes Runx2, bone sialoprotein (BSP) and alkaline phosphatase (ALP) 
were measured and presented as relative expression compared to the housekeeping gene 
Arbp. The transcription factor Runx2, also known as Cbfa1, is the key regulator of osteoblast 
differentiation and in mature osteoblasts also functions to regulate mineral deposition in bone 
matrix (Ducy, 2000). BSP is, apart from collagen, one of the major proteins found in 
mineralised bone matrix, and is almost exclusively found in this tissue where it is involved 
with cell adhesion (Tanabe et al., 2004a). ALP is a common marker for identification of an 
osteoblastic phenotype, and has been used extensively to for this purpose (Kuroda et al., 
2005; Sadie-Van Gijsen et al., 2012). 
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A significant effect of time in ALP expression compared to control was observed by day 5 in 
bmMSCs, when compared to day 0. ALP expression was significantly higher at day 5 for 
bmMSCs as compared to scADSCs or pvADSCs. No significant increase in ALP over time 
was observed for scADSCs and pvADSCs (Fig. 3.2.4.2.3, A, B and C). Runx2 expression 
peaked at day 3 in scADSCs undergoing osteogenesis, whereas no significant differences in 
Runx2 expression were observed in other cell types or controls (Fig. 3.2.4.2.3, D, E and F). 
Expression of BSP was significantly higher at day 3 and 5 compared to day 0 for bmMSCs 
with no effect of time observed for scADSCs or pvADSCs. BSP expression was also 
significantly higher in bmMSCs compared to scADSCs and pvADSCs at day 3 and 5 of 
osteogenic differentiation (Fig. 3.2.4.2.3, G, H and I).  
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Figure 3.2.4.2.3: RT-qPCR comparing the expression of osteogenic genes in MSCs derived from each of the different depots under standard growth media 
conditions and during ostegenic differentiation. The relative mRNA expression of ALP, (A, B and C), Runx2 (D, E and F) and BSP (G, H and I) in bmMSCs, scADSCs, 
and pvADSCs. Values (mean ± SE) are presented as relative expression compared to the expression of the housekeeping gene, Arbp. Statistical analysis: Factorial ANOVA 
with Tukey post hoc test. A significant effect of time within each cell type is indicated with *. Significant difference between cell types at the same time point is indicated 
with a (scADSC vs bmMSCs) or b (pvADSC vs bmMSCs). Level of significance was accepted at p<0.05. 
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3.3 Discussion 
In this chapter, MSCs were isolated from bone-marrow (bmMSCs), subcutaneous adipose 
(scADSCs) and peri-renal visceral adipose (pvADSCs) depots and were compared to one 
another by examining morphology, proliferation rate, surface marker expression, and 
osteogenic and adipogenic differentiation. Adherence to plastic was the main selection 
criteria used for isolation of bmMSCs, scADSCs and pvADSCs, and this proved to be 
sufficient to obtain morphologically homogenous populations of cells with MSC 
characteristics. Cells derived from all three MSC depots appeared morphologically similar, 
with cell shapes commonly observed to vary between elongated and spindle-shaped cells as 
well as random polygonal-shaped cells and cells with a broad flattened appearance (Fig. 
3.2.1.1 and Fig. 3.2.1.2), consistent with observations of MSC morphology found in the 
literature (Bianco et al., 2001; Kollmer et al., 2013). 
 
The isolation of the ADSCs and bmMSCs used in this study was by the use of a common 
technique, with selection by plastic adherence (Bunnell et al., 2008; Peng et al., 2008; Lopez 
and Spencer, 2011; Mendez-Ferrer et al., 2015). ADSCs are isolated by collagenase digestion 
of adipose tissue to break down the fibrous collagen network, followed by a centrifugation 
step which allows for the ADSCs and other released cells to be collected as a pellet, 
consisting of a heterogeneous mixture known as the stromal vascular fraction (SVF) (Bunnell 
et al., 2008; Baer and Geiger, 2012; Bassi et al., 2012). A limitation with this technique is 
that the SVF may contain a combination of different cell types, including ADSCs with true 
multipotential characteristics, as well as fibroblasts, immune regulatory 
monocytes/macrophages and vascular endothelial cells (Bunnell et al., 2008; Baer and 
Geiger, 2012; Bassi et al., 2012). The heterogeneous appearance that was observed in 
bmMSC cultures selected by plastic adherence is also consistent with the literature, as these 
cultures typically may contain a small population of primitive stem cells, and cells which are 
already partially or fully lineage committed, such as fibroblasts (Mendez-Ferrer et al., 2015).  
 
The proliferation rate of bmMSCs was observed to be lower than that of both scADSCs and 
pvADSCs, which agrees with the finding by Yoshimura et al. using cells from Sprague-
Dawley rats, and Hayashi et al. using Fischer 344 rats (Yoshimura et al., 2007; Hayashi et 
al., 2008). An earlier study using bmMSCs isolated from Lewis rats found that rat bmMSCs 
had almost twice the maximal expansion rate of human bmMSCs, when plated at low density 
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of approximately 2 cell/cm
2
 (Javazon et al., 2001), while Yoshimura et al. reported that in 
their own experiments, the expansion rate of rat bmMSCs was lower than that of human 
bmMSCs (Yoshimura et al., 2007). The present study made use of Wistar rats, and did not 
subject the bone marrow to density gradient centrifugation during the isolation procedure, but 
rather plated the bone marrow directly onto the culture surface. Culture medium also differed 
between the present study and that used by others; in this study cells were cultured in DMEM 
with 10% FBS, while Yoshimura et al. and Javazon et al. made use of αMEM with 20% FBS, 
and Hayashi et al. used MEM with 15% FBS (Javazon et al., 2001; Yoshimura et al., 2007; 
Hayashi et al., 2008). Batch-to-batch variation of FBS and the resulting variation in the 
suitability for cell culture is a well-known phenomenon, and this may also have played a role 
in observed cellular expansion rates observed. Yoshimura et al. noted that FBS selected for 
rapid growth of human bmMSCs may not necessarily provide the most favourable growth 
conditions for rat bmMSCs (Yoshimura et al., 2007). A further difference between the 
present study and previous work is that bmMSCs proliferation was measured at P3, while 
previous work measured expansion capability by colony forming unit-fibroblast (CFU-F) 
assay in cells from P0 or P1 (Javazon et al., 2001; Yoshimura et al., 2007; Hayashi et al., 
2008). The data, however, indicates that the lower expansion rate of bmMSCs compared to 
scADSCs was not a strain-specific effect, and was also independent of the use of density 
gradient centrifugation, or culture medium composition, between cells from Sprague-Dawley, 
Fischer 344 and Wistar rats. The differences noted above between the present study and 
previous studies underlines the well-known lack of standardisation of methods for isolation 
and culture conditions for MSCs, which greatly complicates any attempts to compare results 
from different laboratories. Subtle difference in cell culture conditions have been known to 
support the expansion of different subsets of the culture population, which may result in 
greater differences in the results obtained (Ho et al., 2008).  
 
Subcutaneous ADSCs at P2 had a higher rate of proliferation than pvADSCs, which is in 
agreement with the results obtained by Arrigoni et al., who reported a shorter doubling time 
for rat-derived scADSCs compared to pvADSCs with increasing passage number. The 
doubling times reported by Arrigoni et al. for scADSCs and pvADSCs appeared to be similar 
at P2 and P3, while the present study found a small difference in proliferation rate between 
scADSCs and pvADSCs at P2 (Fig. 3.2.3.1), a discrepancy which may be due to differences 
in the methods used for evaluating the expansion rate of the cells (Arrigoni et al., 2009).  
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The proliferation rate of both scADSCs and pvADSCs dropped rapidly after 48 hours in 
culture, while the rate of bmMSCs increased at 48 hours compared to earlier time points. The 
decrease in proliferation of scADSCs and pvADSCs is likely to be due to growth arrest, 
observed in cell cultures upon reaching high density, as a result of the phenomenon of contact 
inhibition (CI) (Leontieva et al., 2014). Due to the slower rate of proliferation observed in 
bmMSCs at earlier time points compared to the ADSCs, cell numbers had not yet reached a 
high enough density by the 48 hour time point for CI to substantially retard proliferation.  
 
Subcutaneous ADSCs, pvADSCs and bmMSCs were positive for CD90 (Thy1.1), which was 
expected based on previous reports in the literature, as CD90 is a well-established MSC 
surface marker (Javazon et al., 2001; Dezawa et al., 2005; Yoshimura et al., 2007; van de 
Vyver et al., 2014). Subcutaneous ADSCs and pvADSCs were negative for CD45 (leukocyte 
common antigen), however, a small population of CD45 positive cells were present in 
bmMSC samples. The presence of CD45 positive cells in bmMSCs has been previously 
reported, along with the markers CD34 and c-Kit, while the majority of the population 
remains negative for these markers (Dezawa et al., 2005). A small percentage of all MSC 
types expressed the ectopeptidase dipeptidylpeptidase type IV (CD26), known to be a 
hepatocyte (Sgodda et al., 2007) and fibroblast (Cappellesso-Fleury et al., 2010) marker, with 
the highest expression in pvADSCs at 22% positive. The expression of CD26 in human 
bmMSCs is known to be variable (40-78%), while Sgodda et al. found expression of CD26 in 
rat adipose-derived MSCs after 7 days of hepatocyte induction, indicating that CD26 is 
absent in naïve rat adipose-derived MSCs (Sgodda et al., 2007; Cappellesso-Fleury et al., 
2010). The increased percentage of CD26 postive cells in the pvADSC population compared 
to the other cell types suggests that pvADSCs may contain a small population of fibroblasts 
(22%). However, the presence of CD26 postive cells may not be indicative of the presence of 
fibroblasts, as fibroblasts are reported to not able to differentiate towards an adipocyte or 
osteoblast phenotype (Cappellesso-Fleury et al., 2010), while pvADSCs were observed to 
have higher lipid accumulation than scADSCs, which had a lower fraction of CD26 positive 
cells (Fig. 3.2.2.1). Since expression of CD26 in bmMSCs has been reported to be variable, it 
may be possible that variable expression of CD26 also occurs in pvADSCs, and possibly 
scADSCs. In order to confirm the identity of the CD26 positive population of pvADSCs as 
either MSC or fibroblast in nature, the CD26 population may be sorted via fluorescence 
activated cell sorting (FACS) analysis and induced to differentiate towards either an 
osteogenic or adipogenic phenotype. Human bmMSCs are known to be positive for CD106 
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(vascular cell adhesion molecule 1, VCAM1) (Pittenger et al., 1999; Cappellesso-Fleury et 
al., 2010), however one study reported that two stem cell clones derived from rat bmMSCs 
were negative for CD106 (Schwarz et al., 2014). The results from the present study, 77% of 
the population of rat bmMSCs sampled were positive for CD106, indicating that some 
CD106 negative cells may be present in the rat bmMSC population. This is consistent with 
the literature findings in that bmMSCs are largely positive for CD106, and also indicates that 
rat derived bmMSCs may contain a mixed population of CD106 positive and negative cells.  
 
All three MSC types exhibited adipogenic and osteogenic differentiation potential in vitro, 
however, variation in differentiation capability between depots was observed. Adipogenic 
differentiation potential was lower in bmMSCs compared to either scADSCs or pvADSCs. 
This observation is consistent with previous findings, which indicated that scADSCs have a 
greater adipogenic differentiation potential than bmMSCs (Yoshimura et al., 2007). The in 
vitro adipogenic differentiation, assessed by lipid accumulation, of pvADSCs was greater 
than that of scADSCs, which is also consistent with findings in the literature (Sadie-Van 
Gijsen et al., 2012; van de Vyver et al., 2014).   
 
In contrast to adipogenic differentiation, bmMSC mineralisation was much more rapid and 
extensive in vitro compared with either scADSCs or pvADSCs, a finding which is confirmed 
by previous studies. Yoshimura et al. found that bmMSCs from Sprague-Dawley rats had a 
greater osteogenic differentiation potential in comparison to scADSCs, when mineralisation 
was measured by Alizarin Red staining and alkaline phosphatase (ALP) activity assay 
(Yoshimura et al., 2007). Hayashi et al. also reported that in vitro osteogenic differentiation 
capability was higher in bmMSCs than scADSCs, by quantification of mineralised matrix, 
ALP activity and osteocalcin levels (Hayashi et al., 2008). Mineralisation in scADSCs and 
pvADSCs was only detectable after 21 days of culture, which is in range of values obtained 
in the literature (Yoshimura et al., 2007; Hayashi et al., 2008). The levels of mineralisation 
observed in scADSCs and pvADSCs under osteogenic conditions were found to be similar to 
one another, which is in keeping with previous findings (Arrigoni et al., 2009; van de Vyver 
et al., 2014).  
 
Weiser et al. found that ascorbic acid enhanced adipogenesis in the bmMSCs isolated from 
Sprague-Dawley rats, and they proposed that the mechanism by which ascorbic acid 
enhanced lipid accumulation in these cells was due to an increase in collagen synthesis 
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(Weiser et al., 2009). Analysis of the expression of the adipogenic marker genes, PPARγ, aP2 
and Adipsin in scADSCs, pvADSCs and bmMSCs showed an increase in the relative 
expression of these genes throughout adipogenic induction, in comparison to time-matched 
control samples. PPARγ is expressed early on in the adipocyte differentiation pathway, as 
mentioned in Section 3.2.4.1, is the master regulator of adipogenesis, and along with 
C/EPBα, are the main drivers of expression of adipocyte-specific genes (MacDougald and 
Mandrup, 2002). In contrast to lipid accumulation data, which indicated that lipid 
accumulation was slightly higher in pvADSCs compared to scADSCs, scADSCs appeared to 
have the highest levels expression of adipogenic markers, followed by pvADSCs and lowest 
levels overall were found in bmMSCs. Expression of PPARγ in rat bmMSCs and scADSCs 
after four days of in vitro adipogenic induction has previously been reported (Yoshimura et 
al., 2007). An increase in PPARγ expression was also found in human bmMSCs and 
scADSCs after 21 days  incubation in adipogenic differentiation medium, where PPARγ 
expression levels were similar for MSCs from both depots (Noel et al., 2008). In contrast to 
the results reported with ADSCs from rat subcutaneous and visceral depots, a study 
comparing human ADSCs derived from various adipose depots including subcutaneous and 
visceral (omental) depots, found that subcutaneous ADSCs were more adipogenic than 
visceral ADSCs (Russo et al., 2014). The difference between the adipogenic potential of 
human and rat scADSCs and visceral ADSCs may be related to the precise source of the 
visceral ADSCs, as the rat pvADSCs were derived from the fat pad surrounding the kidney, 
while human visceral ADSCS in the study by Russo et al. (2014) were derived from the 
omentum. Van de Vyver et al. also reported an increase in the relative expression of aP2 and 
adipsin in rat scADSCs and pvADSCs between days 7 and 10 of adipogenic induction, which 
is consistent with the present findings as expression of all adipogenic markers increased most 
notably between days 7 and 10 of adipogenic induction (van de Vyver et al., 2014). Taken 
together, the literature reports an increase in the expression of adipogenic marker genes 
PPARγ, aP2 and adipsin in MSCs during adipogenic induction, which is consistent with the 
findings in the present study, indicating that adipogenesis is occurring.   
 
Osteogenic differentiation was evaluated by measuring the relative expression of the 
osteogenic marker genes, Runx2, BSP and ALP. Runx2, as mentioned in Section 3.2.4.2, is a 
key regulator of osteoblast differentiation and also functions in mature osteoblasts. BSP is 
also found almost exclusively in mineralised bone matrix, and is product of mature 
osteoblasts (Ducy, 2000). Increased ALP expression is also characteristic of osteoblast 
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differentiation (Kuroda et al., 2005). Expression of osteogenic markers was significantly 
higher in bmMSCs compared to time-matched controls, confirming that osteogenesis was 
taking place in these cells.. Mineralisation proceeded rapidly in bmMSCs during osteogenic 
differentiation, resulting in an overabundance of mineral deposits by day 7 of differentiation, 
which prevented sufficient quantities of RNA to be obtained from these samples. Expression 
of osteogenic markers in scADSCs and pvADSCs was not significantly different compared to 
undifferentiated time-matched control samples, and no trends were apparent. This finding is 
supported by previous studies, one of which found no significant differences in relative 
Runx2 expression between time-matched undifferentiated controls and cells incubated in 
osteogenic differentiation medium for both rat scADSCs and pvADSCs (Sadie-Van Gijsen et 
al., 2012). A later study also found no statistically significant increase in relative ALP 
expression levels in rat scADSCs and pvADSCs between day 7 and 10 of osteogenic 
induction, and also reported that there was no increase in expression mRNA levels of the 
osteogenic markers Msx2 and collagen I between days 7 and 10 in the same cells (van de 
Vyver et al., 2014). It is therefore proposed that the osteogenic differentiation capacity in rat 
scADSCs and pvADSCs is lower than that of bmMSCs, despite the observation that these 
cells have the ability to form mineralised calcium deposits under osteogenic induction 
conditions.    
 
The results from the present study are supportive of the conclusion that the cells isolated from 
bone marrow, subcutaneous and peri-renal visceral adipose depots are mesenchymal stromal 
cells. Surface marker expression is consistent with the literature for rat-derived MSCs and the 
cells isolated from all three depots studied have been shown to exhibit bipotentiality in vitro. 
The data also suggest that cells isolated from adipose and bone-marrow tissue retain 
characteristics of the tissue of origin. Both scADSCs and pvADSCs were observed to have a 
greater capacity for adipogenic differentiation than bmMSCs, as quantified by both lipid 
accumulation and relative expression levels of adipogenic marker genes. Conversely, 
bmMSCs differentiated more readily towards an osteogenic phenotype, with more rapid and 
extensive formation of mineralised matrix, as well as higher relative expression of osteogenic 
marker genes, compared to ADSCs, where mineralisation required more than double the 
amount of time to occur and was marginal in comparison to that observed for bmMSCs. 
Osteogenic induction did not significantly increase expression of osteogenic marker genes in 
either scADSCs or pvADSCs, indicating that osteogenesis may be poorly or incompletely 
induced in these cells, under the differentiation conditions assessed. Taken together, rat 
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bmMSCs, scADSCs and pvADSCs provide adequate in vitro cellular models for gathering 
insight into the interplay between adipogenesis and osteogenesis. Due to MSCs from each 
depot retaining characteristics of the tissue of origin, MSCs from a single depot may not 
provide the best model for investigating both osteogenic and adipogenic differentiation 
pathways, as demonstrated by the limited capacity for osteogenic differentiation in scADSCs 
and pvADSCs compared to bmMSCs as well as the limited capacity for adipogenic 
differentiation in bmMSCs compared to either scADSCs and pvADSCs. Increased 
understanding of the differences in the behaviour of MSCs from various depots provides 
better insight into choice of model for future investigations, and for possible clinical use with 
regards to tissue-engineering. 
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CHAPTER 4 
Effects of TNAP inhibitors on lipid 
accumulation, mineralisation and ALP 
activity levels of MSCs undergoing 
adipogenic or osteogenic induction. 
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4.1 Introduction  
Tissue non-specific ALP is highly expressed in skeletal, hepatic and renal tissues, and also at 
low levels in most other tissues. TNAP has a well established role in skeletal mineralisation, 
however very little is known about the function of TNAP in other tissues. The presence of 
TNAP in a variety of different tissues, and the existence of multiple isoforms of TNAP, 
indicates that there may be a variety of physiological roles for this enzyme (Sharma et al., 
2014). TNAP has also been identified as a mesenchymal stem cell marker and is also known 
as Mesenchymal stem cell antigen-1 (MSCA-1), which further indicates the possible diverse 
roles for this enzyme (Sobiesiak et al., 2010).   
 
Recent research has indicated a role for TNAP during adipogenesis in the 3T3-L1 murine 
preadipocytic cell line. Ali et al. (2005) noted that ALP activity increased over the course of 
adipogenic induction in these cells, while the addition of either of the TNAP inhibitors, 
levamisole or histidine during adipogenesis was found to significantly reduce lipid 
accumulation within the cells. The research also found that alkaline phosphatase activity was 
spatially associated with the lipid membrane which surrounds these lipid droplets that are 
characteristically present in adipocytes. Similar results were obtained using primary human 
preadipocytes, derived from mammary tissue, where the presence of histidine during 
adipogenic induction resulted in a concomitant drop in lipid accumulation and ALP activity, 
compared to samples where histidine was absent (Ali et al., 2006).   
 
A further study by Ali et al. (2013) using human adipose-derived preadipocytes found that the 
addition of levamisole during adipogenic induction produced a decrease in lipid accumulation 
compared to control samples, while an increase in ALP activity was observed (Ali et al., 
2013). It was proposed that in human preadipocytes that levamisole blocked adipogenesis at a 
point downstream from TNAP (Ali et al., 2013). 
 
TNAP expression has previously been identified in rat adipose tissue (Wallach and Ko, 1964), 
and we questioned whether inhibition of TNAP had a similar effect on lipid accumulation 
during adipogenesis in rat-derived MSCs, as seen in 3T3-L1 and human preadipocytes. 
Consequently, rat MSCs were harvested from bone-marrow as well as visceral and 
subcutaneous adipose depots and expanded in vitro. Bone marrow-derived MSCS (bmMSCs) 
are able to readily differentiate into either osteoblasts or adipocytes within the marrow cavity, 
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and the age-related disease, osteoporosis, is thought to be due, at least in part, to the skewing 
of the differentiation of marrow-derived MSCs from an osteogenic towards the adipocytic 
lineage (Bruedigam et al., 2010). This results in a reduction in the number of bone-forming 
osteoblasts, a subsequent imbalance in bone turnover and loss of bone. For this reason, 
investigation into the role of TNAP in bmMSCs undergoing adipogenic induction may 
provide insight into the mechanisms of osteoporosis.  
 
Differences between MSCs derived from different tissues, as well as between adipose-derived 
stromal cells (ADSCs) from different adipose depots, have been well documented (Sadie-Van 
Gijsen et al., 2010; Strioga et al., 2012; Elahi et al., 2016). Differences between adipocytes 
from different adipose depots can be illustrated by the finding that in humans, increased 
visceral adiposity, as opposed to subcutaneous adiposity, is related to a greater risk for 
metabolic disorders such as diabetes (Boyko et al., 2000). In Chapter 3 of this study it was 
shown that differences exist between scADSC and pvADSC differentiation in both levels of 
adipogenic marker genes expressed during adipogenic differentiation as well as in lipid 
accumulation levels. As TNAP has been previously shown to be involved in adipogenesis, the 
question may be asked whether TNAP is differentially expressed in the various adipose 
depots, as TNAP expression differences may contribute to the depot specific differences in 
differentiation. 
 
 ALP activity levels in bmMSCs, scADSCs and pvADSCs during both osteogenesis and 
adipogenesis were investigated, with the addition of TNAP-specific inhibitors levamisole, L-
histidine and L-homoarginine, added separately or in combination, during either osteogenic or 
adipogenic induction. Three inhibitors were used because each inhibitor is not specific for 
TNAP alone, and may have other off-target effects within the cell. Combinations of each 
inhibitor allowed for any additive effects of the inhibitors to be observed. The resulting 
mineralisation or lipid accumulation was measured over the course of the differentiation 
period, as well as the corresponding levels of ALP activity for each treatment.  
 
Certain L-amino acids have commonly been found to selectively inhibit TNAP, among these 
are L-homoarginine and L-histidine (Bodansky and Schwartz, 1963; Kozlenkov et al., 2004; 
Ali et al., 2005). L-homoarginine is found in circulation and can function as a substrate for 
nitric oxide synthesis by nitric oxide synthases in brain and other tissues (Bernstein et al., 
2015). Histidine is an essential amino acid which is involved in the biosynthesis of proteins. 
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Other TNAP inhibitor compounds, not related to amino acids, exist, such as levamisole and 
theophylline (Kozlenkov et al., 2004). Levamisole, the L-isomer of tetramisole, is used as an 
antihelmintic, targeting the nicotinic acetylcholine receptors of parasitic nematodes, and is 
also an allosteric modulator of human nicotinic acetylcholine receptors in the brain 
(Levandoski et al., 2003), but is also a potent selective inhibitor of TNAP (Kozlenkov et al., 
2004). Levamisole, as well as L-homoarginine, are uncompetitive inhibitors of TNAP, and 
although levamisole is close to one hundred times more potent than L-homoarginine, both 
inhibitors have a weak binding affinity for TNAP and have other off-target effects 
(Kozlenkov et al., 2004). The exact mechanism and binding sites for levamisole and L-
homoarginine inhibition of ALP are currently unknown (Kozlenkov et al., 2004).The 
mechanism of inhibition for L-histidine is considered to be mixed (Bodansky and Schwartz, 
1963). 
 
The levels of TNAP mRNA expression in all three cell types above, during adipogenesis and 
osteogenesis and in the presence of the TNAP inhibitors, levamisole, L-histidine and L-
homoarginine, were measured. This was done in order to assess what effect TNAP inhibition 
during differentiation has on the gene expression. Biological repeats of between n=3 to n=5 
were performed for each set of experiments, where each experiment consisted of 3 technical 
(internal) repeats.  
 
4.2 Results 
Due to the large number of treatment conditions assessed, Table 4.2.1 is presented to 
summarise the statistically significant results obtained for the treatment of bmMSCs, 
scADSCs and pvADSCs with levamisole, histidine or L-homoarginine, both alone or in 
combination with one another, while the cells were undergoing either adipogenic or 
osteogenic induction. The response to each treatment was assessed by measurement of the 
change in percentage area of mineralisation or lipid accumulation for each treatment, relative 
to untreated control cells, in cells cultured in either OM or AM. No significant response in 
mineralisation or ALP activity in the presence of any of the inhibitors was observed in 
pvADSCs undergoing osteogenic induction. Briefly, treatment with levamisole, alone or in 
combination, was able to decrease mineralisation significantly in bmMSCs and scADSCs, 
while histidine and L-homoarginine had no effect on mineralisation during osteogenic 
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induction. No significant effect on ALP activity, in the presence of any of the inhibitors, was 
observed in either bmMSCs or scADSCs undergoing osteogenic induction.  
 
During adipogenesis, levamisole treatment alone did not decrease lipid accumulation in any 
cell type tested. A significant decrease in lipid accumulation compared to control was 
observed with treatment of all cell types with either L-homoarginine alone or in combination 
with histidine or levamisole. Histidine was only able to decrease lipid accumulation in 
bmMSCs. ALP activity was only decreased significantly in bmMSCs treated with levamisole 
alone or in combination with histidine. Levamisole in combination with L-homoarginine 
significantly increased ALP activity in scADSCs and pvADSCs, while treatment with L-
homoarginine alone or in combination with histidine resulted in a significant increase in ALP 
activity in scADSCs only.  
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Table 4.2.1: Summary of statistically significant effects of levamisole (Lev), histidine (His) and L-homoarginine (Arg) on lipid accumulation, mineralisation and 
alkaline phosphatase (ALP) activity in bmMSCs, scADSCs and pvADSCs undergoing either osteogenic or adipogenic induction. 
Cell type Differentiation Inhibitor Mineralization or lipid 
accumulation response to 
inhibitor compared to control 
ALP activity response to 
inhibitor compared to control 
bmMSC Osteogenic Lev 
His 
Arg 
Lev + His 
Lev + Arg 
His + Arg 
Decreased 
- 
- 
Decreased 
Decreased 
- 
- 
- 
- 
- 
- 
- 
 Adipogenic Lev 
His 
Arg 
Lev + His 
Lev + Arg 
His + Arg 
- 
Decreased 
Decreased  
- 
Decreased 
Decreased  
Decreased 
- 
- 
Decreased  
- 
- 
scADSC Osteogenic Lev 
His 
Arg 
Lev + His 
Lev + Arg 
His + Arg 
Decreased  
- 
- 
Decreased  
Decreased  
-  
- 
- 
- 
- 
- 
- 
 Adipogenic Lev 
His 
Arg 
Lev + His 
Lev + Arg 
His + Arg 
- 
- 
Decreased 
- 
Decreased 
Decreased 
- 
- 
Increased 
- 
Increased 
Increased 
pvADSC Osteogenic All inhibitors tested No significant response No significant response 
 Adipogenic Lev 
His 
Arg 
Lev + His 
Lev + Arg 
His + Arg 
- 
- 
Decreased 
- 
Decreased  
Decreased  
- 
- 
- 
- 
Increased  
- 
Responses to treatment in either the relative percentage area of mineralisation or lipid accumulation, as well as ALP activity, in treated compared to control untreated cells. 
Statistical significance was assumed when p < 0.05. Only statistically significant results are shown. Quantification is shown in subsequent graphs. 
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4.2.1 Selection of TNAP inhibitor concentrations 
The proliferation rate of bmMSCs, scADSCs and pvADSCs cultured in in the presence of the 
TNAP inhibitors, levamisole (Lev), histidine (His) and L-homoarginine (Arg) was assayed 
using the BrdU cell proliferation ELISA kit (Roche) to determine the maximum concentration 
of each inhibitor which would not hinder cellular proliferation. All inhibitors were 
reconstituted in SGM, at stock concentrations of 100 mM (Lev), 200 mM (His) and 500 mM 
(Arg). Briefly, proliferation is measured by incorporation of BrdU, an analogue of thymidine, 
into the new DNA strands during DNA replication prior to cell division. After fixing and 
denaturing the DNA, an anti-BrdU monoclonal antibody conjugated to peroxidase is used to 
bind to the incorporated BrdU in the newly synthesized DNA strands. Cleavage of a substrate 
by the peroxidase produces a coloured product, which is quantified by absorbance using an 
ELISA plate reader. Proliferation in bmMSCs, scADSCs and pvADSCs was measured at 24 
and 48 hr time points (Fig. 4.2.1.1). Ali et al. (2005) used a concentration of 2.5 mM 
levamisole and 50 mM histidine with 3T3-L1 cells to study the effects of TNAP inhibitors on 
lipid accumulation and ALP activity (Ali et al., 2005). However, these concentrations proved 
to be toxic to the rat-derived MSCs used in the present study, and so a lower range of 
concentrations were compared. At the time of writing we are aware of only one study that has 
used L-homoarginine applied to live cells, where it was reported that long term cellular 
proliferation was inhibited at a concentration of 22.3 mM L-homoarginine (Kikuchi et al., 
1982). Proliferation in the presence of levamisole was measured with inhibitor concentrations 
of 0.1, 0.5 and 1.0 mM. In all cell types, at both 24 and 48 hr time points 1.0 mM levamisole 
appeared to reduce cell proliferation when compared to control sample. The only  statistically 
significant effect for levamisole was observed in scADSCs treated with 1.0 mM levamisole 
compared to untreated controls, at 24 hr (Fig. 4.2.1.1 A, D and G). A concentration of 0.5 mM 
levamisole was chosen for further experiments as this was the highest concentration which did 
not inhibit cell proliferation in either bmMSCs, scADSCs or pvADSCs. At the highest 
concentration measured (20 mM) for both histidine and L-homoarginine, no significant 
decrease in proliferation after either 24 and 48 hr in all three cell types was observed (Fig 
4.2.1.1 B, C, E, F, H and I), however the presence of histidine or L-homoarginine at 20 mM 
did result in observable morphological differences in all cell types during longer periods of 
culture such as during treatment with AM or OM. For this reason, histidine and L-
homoarginine were each used at a concentration of 10 mM for further experiments, as this 
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concentration did not inhibit cellular proliferation or result in apparent morphological changes 
of the cells.  
 
 
Figure 4.2.1.1: BrdU cell proliferation ELISA of bmMSCs, scADSCs and pvADSCs in the presence of TNAP 
inhibitors. Cells were either cultured in SGM, as controls (no inhibitors), or in the presence of levamisole (Lev) at 
0.1, 0.5 or 1.0 mM (A, D and G), histidine (His) at 5, 10 or 20 mM (B, E and H) and L-homoarginine (Arg) at 5, 10 
or 20 mM (C, F and I). n=3. Statistical analysis was performed using one-way ANOVA and Tukey post-test to 
determine statistical differences where p < 0.05 (* represents p < 0.05). Error bars are representative of standard 
error (SE).  
 
4.2.2 Evaluation of the effect TNAP inhibitors on bmMSC osteogenesis and 
adipogenesis  
Bone marrow-derived MSCs were induced to differentiate into either an osteogenic or 
adipogenic phenotype as previously described (Sections 2.2.5 and 2.2.7), in the presence of 
the TNAP inhibitors levamisole (0.5 mM), histidine (10 mM) and L-homoarginine (10 mM), 
added separately or in combination with one another. Inhibitors were added to cell cultures at 
the start of osteogenic or adipogenic induction and maintained throughout the differentiation 
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period. Table 4.2.2.1 provides a summary of the overall effects of TNAP inhibitors on the 
percentage of mineralisation, lipid accumulation and ALP activity levels on bmMSCs induced 
towards an osteogenic or adipogenic phenotype.  
 
Table 4.2.2.1: Overall effects of tissue nonspecific alkaline phosphatase (TNAP) inhibitors on percentage 
mineralisation, lipid accumulation and alkaline phosphatase (ALP) activity on bmMSCs induced towards 
an osteogenic or adipogenic phenotype.  
 Osteogenic phenotype   Adipogenic phenotype  
Inhibitor  Mineralisation  ALP activity    Lipid accumulation  ALP activity  
Lev Decreased ++ Increased  No effect  Decreased++ 
His  No effect Increased  Decreased ++ Increased   
Arg  No effect  No effect  Decreased ++ Decreased  
Lev+His Decreased ++ Increased  Decreased Decreased++  
Lev+Arg  Decreased ++ Decreased  Decreased ++ Decreased  
His+Arg  No effect  Increased  Decreased ++ Decreased  
Inhibitors used include levamisole (Lev) (0.1 mM), histidine (His) (10 mM) and L-homoarginine (Arg) (10 
mM), and the differentiation period was 10 and 14 days for osteogenic and adipogenic differentiation, 
respectively. Where a possible trend was noticed, it is indicated by either “Increased” or “Decreased”,  “++” 
statistically significant p<0.05.  Quantification is shown in subsequent graphs. 
 
4.2.2.1 Bone marrow MSC osteogenesis  
In bmMSCs, mineralisation was typically first observed by day 5 of osteogenic induction, 
although this varied from between day 3 to 7 in some instances, and was typically complete 
by day 10 (Fig. 4.2.2.1.1). No mineralisation was observed in bmMSCs cultured in SGM with 
vehicle controls (the addition of an equal volume of inhibitor solvent into the control cells) 
throughout the differentiation period (Fig. 4.2.2.1.1 A, B and C), however dense clusters of 
cells were observed by day 10 on control samples (Fig. 4.2.2.1.1C). Image analysis results 
show that mineralisation in OM reaches a mean value of 50% of the cell culture surface by 
day 10, significantly higher than day 5 in OM, with a mean of 15% (Fig. 4.2.2.1.3 A), 
however individual biological repeats displayed considerable variation of mineralisation by 
day 10, ranging from approximately 12 to 77% (See Addendum B, Fig. B1, F and I). 
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Figure 4.2.2.1.1: Osteogenic differentiation of bmMSCs. Bone marrow-derived MSCs were cultured in 
standard growth medium (SGM) (A, B and C) and osteogenic differentiation medium (OM) (D, E and F), and 
differentiation progression is shown on day 5 (A and D), day 7 (B and E) and day 10 (C and F). Cells were 
stained with Alizarin Red S to visualise mineralisation (Red). These images were acquired using an Olympus 
(CKX41) microscope at x10 magnification. 
 
By day 10 of osteogenic induction, no mineralisation was observed in bmMSCs cultured in 
the presence of levamisole alone (Fig 4.2.2.1.2 A) or when used in combination with either 
histidine (Fig. 4.2.2.1.2 D) or L-homoarginine (Fig. 4.2.2.1.2 E). Image analysis confirmed 
that the presence of levamisole was sufficient to block mineralisation completely in all 
samples by day 10 (Fig. 4.2.2.1.3 F and G). The presence of histidine or L-homoarginine, 
alone or in combination with one another during osteogenic induction resulted in 
mineralisation which was frequently indistinguishable from control at day 10 (Fig 4.2.2.1.2, 
B, C and F). No significant differences in mineralisation were detected in the presence of 
histidine and/or L-homoarginine by the end (day 10) of the osteogenic induction period (Fig. 
4.2.2.1.3 F and G).   
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Figure 4.2.2.1.2: Osteogenic differentiation of bmMSCs in the presence of TNAP inhibitors.  Bone marrow-
derived MSCs cultured in osteogenic differentiation medium containing levamisole (Lev) (A), histidine (His) 
(B), L-homoarginine (Arg) (C), Lev+His (D) Lev+Arg (E) and His+Arg (F) for 10 days and stained with 
Alizarin Red S to visualise mineralisation. See Fig. 4.2.2.1.1 (F) for control osteogenic differentiation image. 
These images were acquired using an Olympus (CKX41) microscope at x10 magnification. 
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Figure 4.2.2.1.3: Image analysis to determine percentage area of mineralisation of bmMSCs cultured in 
osteogenic differentiation medium (OM) in the presence and absence of levamisole (Lev), histidine (His) 
and L-homoarginine (Arg). Percentage mineralisation of cells cultured in standard growth medium (SGM) 
(Control) or OM, at day 5, 7 and 10, animal 1 – 6, n=6 (A). Pooled data for animals 1 – 3 is shown in panel B, D 
and F, with relative % mineralisation at day 5, 7 and 10 in the presence of Lev, His or Lev+His. Pooled data for 
animal 4 – 6 are shown in panels C, E and G, with relative % mineralisation at day 5, 7 and 10 in the presence of 
Arg, Lev+Arg and His+Arg. Statistical analysis was performed using Student’s t test, and Bonferroni’s 
correction, where p < 0.05 (* represents p < 0.05, ** represents p < 0.01, *** represents p < 0.001). Error bars 
are representative of standard error (SE). Control OM was set to 100% for each inhibitor experiment.     
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TNAP is essential for mineralisation during osteogenesis. The effect of the addition of TNAP 
inhibitors, levamisole, histidine and L-homoarginine on total ALP activity of bmMSCs 
undergoing osteogenic induction was investigated. The question was asked whether a 
decrease or increase in percentage mineralisation observed upon addition of TNAP inhibitors 
would result in a corresponding decrease or increase in ALP activity. This would confirm the 
role of TNAP in mineralisation and allow for the effects of the various inhibitors to be 
compared with one another.  
 
ALP activity levels remained fairly constant throughout the osteogenic induction period, with 
no significant difference between control samples and those cultured in OM (Fig. 4.2.2.1.4 
A). Addition of levamisole and histidine resulted in a non-significant increase in ALP activity 
compared to only treated with OM (control OM) in samples taken at day 5, 7 and 10. A 
combination of levamisole and histidine appeared to produce an additive effect on ALP 
activity at day 5 and 7, but the effect was lost by day 10 (Fig. 4.2.2.1.4 B, D and F). L-
homoarginine had no statistically significant effect on ALP activity levels compared to 
control OM at days 5, 7 and 10 (Fig. 4.2.2.1.4 C, E and G). The combination of levamisole 
and L-homoarginine had no effect on ALP activity at days 5 and 7, however, by day 10 a 
decrease in activity was observed which was not significantly different to control OM. The 
combination of L-homoarginine and histidine produced an increase in ALP activity above 
control OM in day 5, 7 and 10 samples, and appeared to have an additive effect compared to 
the effect of either L-homoarginine or histidine alone. Overall, histidine appeared to increase 
activity when used in combination with either levamisole or L-homoarginine, although 
statistical significance was not observed.  
 
While the presence of levamisole alone, or in combination, was able to block mineralisation 
during osteogenic induction, total cell ALP activity was slightly increased in the presence of 
levamisole or when in combination with histidine. Histidine and L-homoarginine alone had 
no effect on mineralisation or total cell ALP activity compared to control OM samples. The 
combination of L-homoarginine with levamisole blocked mineralisation and produced a 
concomitant decrease in ALP activity at day 10, while L-homoarginine in combination with 
histidine had no effect on mineralisation but an increase in ALP activity was observed in 
comparison to untreated controls.   
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Figure 4.2.2.1.4: Alkaline phosphatase (ALP)  assay to determine total cell ALP activity of bmMSCs 
cultured in osteogenic differentiation medium (OM) in the presence and absence of levamisole (Lev), 
histidine (His) and L-homoarginine (Arg). ALP activity (U/mg) of cells cultured in standard growth medium 
(SGM) (Control) or OM, at day 5, 7 and 10, n=6 (A). Pooled data for animals 1 – 3 are displayed in panel B, D 
and F, showing relative % ALP activity at days 5, 7 and 10 in the presence of Lev, His or Lev+His. Pooled data 
for animals 4 – 6 are displayed in panels C, E and G, showing relative % ALP activity at day 5, 7 and 10 in the 
presence of Arg, Lev+Arg and His+Arg. Statistical analysis was performed using Student’s t test, and 
Bonferroni’s correction, where p < 0.05. Error bars are representative of standard error (SE). Control OM was 
set to 100% for each inhibitor experiment.     
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4.2.2.2 Bone marrow MSC adipogenesis  
Cells containing lipid droplets were typically visible by day 7 of adipogenic induction and 
increased in number and size throughout the differentiation period (Fig. 4.2.2.2.1 D – F). 
bmMSCs cultured in SGM with solvent vehicle as a control did not produce any visible lipid 
accumulation throughout the differentiation period, however dense clusters of cells were 
visible by day 14 (Fig. 4.2.2.2.1 A – C). Results from image analysis showed that cells 
containing lipid droplets reached a mean value of 10.1% of the culture surface area by day 14, 
a significant increase from day 7, with a mean value of 2.6% (Fig, 4.2.2.2.3 A). Maximum 
lipid accumulation by day 14 of adipogenic induction varied considerably between animals, 
with a range of between 2.5% and 30.7% (n=9) (Addendum B, Fig. B2, F and I).  
 
 
Figure 4.2.2.2.1: Adipogenic differentiation of bmMSCs. Bone marrow-derived MSCs were cultured in 
standard growth medium (SGM) (A, B and C) and adipogenic differentiation medium (AM) (D, E and F), and 
differentiation progression is shown on day 7 (A and D), day 10 (B and E) and day 14 (C and F). Cells were 
stained with Oil Red O to visualise lipid droplets (Red). These images were acquired using an Olympus 
(CKX41) microscope at x10 magnification. 
 
The addition of levamisole to bmMSCs undergoing adipogenic induction had no discernible 
effect on lipid accumulation, as the lipid droplets were visually observable (Fig. 4.2.2.2.2 A) 
and image analysis results showed no significant differences between AM control (cells 
grown in AM without inhibitors) and levamisole samples at days 7, 10 and 14 (Fig. 4.2.2.2.3 
B, D and F). The presence of histidine during adipogenic induction resulted in a statistically 
significant decrease in the number of cells containing lipid droplets compared to AM control 
or cells cultured with levamisole (Fig. 4.2.2.2.2 B). The combination of levamisole and 
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histidine during adipogenic induction resulted in a visually observable decrease in the number 
of cells containing lipid droplets compared to AM control (Fig. 4.2.2.2.2 D). Image analysis 
showed that the decrease in lipid accumulation produced by the combination of levamisole 
and histidine was intermediate between the effects of histidine or levamisole alone by day 14 
but similar to the effect of histidine alone at days 7 and 10 (Fig. 4.2.2.2.3 B, D and F). L-
homoarginine alone was sufficient to block adipogenesis by day 14 (Fig. 4.2.2.2.2 C), as few 
to no cells containing lipid droplets were visible. The combination of L-homoarginine with 
either histidine or levamisole (Fig. 4.2.2.2.2 E and F) had a similar effect to treatment with L-
homoarginine alone, as confirmed by image analysis (Fig. 4.2.2.2.3 C, E and G) which shows 
a statistically significant reduction in lipid accumulation compared to control AM in all 
samples where L-homoarginine was present (Fig. 4.2.2.2.3 C, E and G).   
 
 
Figure 4.2.2.2.2: Adipogenic differentiation of bmMSCs in the presence of TNAP inhibitors. Bone marrow-derived 
MSCs cultured in Adipogenic differentiation medium (AM) containing levamisole (Lev) (A), histidine (His) (B), L-
homoarginine (Arg) (C), Lev+His (D) Lev+Arg (E) and His+Arg (F) for 14 days and stained with Oil Red O to 
visualise lipid droplets (red). See Fig. 4.2.2.2.1 (F) for control adipogenic differentiation image. These images were 
acquired using an Olympus (CKX41) microscope at x10 magnification. 
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Figure 4.2.2.2.3: Image analysis to determine percentage area of lipid accumulation in bmMSCs cultured 
in adipogenic differentiation medium (AM) in the presence and absence of levamisole (Lev), histidine 
(His) and L-homoarginine (Arg).  Percentage area of lipid accumulation of cells cultured in standard growth 
medium (SGM) (Control) or AM, at day 7, 10 and 14, n=9 (A). Pooled data for animals 1 – 5 are displayed in 
panel B, D and F, showing relative % lipid accumulation at days 7, 10 and 14 in the presence of Lev, His or 
Lev+His. Pooled data for animal 6 - 9 are displayed in panels C, E and G, showing relative % lipid accumulation 
at day 7, 10 and 14 in the presence of Arg, Lev+Arg and His+Arg. Statistical analysis was performed using 
Student’s t test, and Bonferroni’s correction, where p < 0.05 (* represents p < 0.05, ** represents p < 0.01, *** 
represents p < 0.001). Error bars are representative of standard error (SE).  Control AM was set to 100% for each 
experiment.  
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Total cell ALP activity increased in bmMSCs undergoing adipogenic induction 
throughout the differentiation period, while that of bmMSCs maintained in SGM with 
vehicle (control) experienced a slight decrease in activity over the same period (Fig. 
4.2.2.2.4 A). The ALP activity of cells cultured in AM was significantly higher than that 
of control cells by day 14 of adipogenic induction, with mean values of 1.4 U/mg and 
0.31 U/mg respectively (Fig. 4.2.2.2.4 A).  
 
In the presence of levamisole, a progressive decrease in ALP activity, in both absolute 
and relative values, was observed over days 10 and 14, with the greatest difference 
present at day 14 of adipogenic induction (Fig. 4.2.2.2.4 B, D and F and Addendum B, 
Fig. B4). The decrease in ALP activity in the presence of levamisole was observed in all 
biological repeats (Addendum B, Fig. B4, D – F). Addition of histidine resulted in a 
slight, non-statistically significant increase in ALP activity compared to AM control 
samples, observed across all time points (Fig. 4.2.2.2.4 B, D and F). The combination of 
levamisole and histidine resulted in partial rescue of ALP activity by histidine, but ALP 
activity was still significantly reduced compared to control AM by day 14 (Fig. 4.2.2.2.4 
F). L-homoarginine resulted in a slight but non-significant reduction of ALP activity 
compared to control AM, however ALP activity appeared to be similar to control AM 
when L-homoraginine was present in combination with levamisole or hisitidine (Fig. 
4.2.2.2.4 C, E and G).  
 
Results show that the presence of levamisole during adipogenic induction in bmMSCs 
does not decrease lipid accumulation, but does result in a decrease of total cell ALP 
activity compared to untreated controls. Conversely, the addition of histidine during 
adipogenic induction results in a decrease in lipid accumulation and a slight increase in 
total cell ALP activity, compared to untreated controls. In contrast to both levamisole 
and histidine, the presence of L-homoarginine during adipogenic induction, alone or in 
combination, results in significant decrease in lipid accumulation, as well as a slight 
decrease in total cell ALP activity (Addendum B, Fig. B4).  
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Figure 4.2.2.2.4 Alkaline phosphatase (ALP)  assay to determine total cell ALP activity of bmMSCs 
cultured in adipogenic differentiation medium (AM) in the presence and absence of levamisole (Lev), 
histidine (His) and L-homoarginine (Arg). ALP activity (U/mg) of cells cultured in standard growth medium 
(SGM) (Control) or AM, at day 7, 10 and 14, n=7 (A). Pooled data for animals 1 – 4 are displayed in panels B, 
D and F, showing relative % ALP activity at days 7, 10 and 14 in the presence of Lev, His or Lev+His. Pooled 
data for animal 5 – 7 are displayed in panels C, E and G, showing relative % ALP activity at days 7, 10 and 14 
in the presence of Arg, Lev+Arg or His+Arg. Statistical analysis was performed using Student’s t test, and 
Bonferroni’s correction, where p < 0.05 (* represents p < 0.05, ** represents p < 0.01). Error bars are 
representative of standard error (SE).  Control AM was set to 100% for each experiment. 
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 4.2.3 Evaluation of TNAP inhibitors on scADSC osteogenesis and 
adipogenesis  
Subcutaneous ADSCs were induced to differentiate into either an osteogenic or adipogenic 
phenotype as previously described (Chapter 2, Sections 2.6 and 2.8), in the presence of the 
TNAP inhibitors levamisole (0.5 mM), histidine (10 mM) and L-homoarginine (10 mM), 
added separately or in combination with one another. Inhibitors were added to cell cultures at 
the start of osteogenic or adipogenic induction and maintained throughout the differentiation 
period. 
 
Table 4.2.3.1: Overall effects of tissue nonspecific alkaline phosphatase (TNAP) inhibitors on percentage 
mineralisation, lipid accumulation and alkaline phosphatase (ALP) activity on subcutaneous adipose 
derived stromal cells (scADSCs) induced towards an osteogenic or adipogenic phenotype.  
 Osteogenic phenotype   Adipogenic phenotype  
Inhibitor  Mineralisation  ALP activity    Lipid accumulation  ALP activity  
Lev Decreased ++ No effect No effect  Decreased  
His  Increased  No effect Decreased  No effect  
Arg  Decreased  No effect  Decreased++ Increased++ 
Lev +His Decreased ++ Increased  No effect  No effect  
Lev +Arg  Decreased ++ Increased Decreased ++ Increased ++ 
His+Arg  No effect  Increased Decreased ++  Increased ++ 
Inhibitors used include levamisole (Lev) (0.1 mM), histidine (His) (10 mM) and L-homoarginine (Arg) (10 
mM), and the differentiation period was 21 and 10 days for osteogenic and adipogenic differentiation, 
respectively.  Where a possible trend was noticed, it is indicated by either “Increased” or “Decreased”,  “++” 
statistically significant p<0.05.   Quantification is shown in subsequent graphs. 
 
4.2.3.1 Subcutaneous ADSC osteogenesis  
Mineralisation was typically first detectable by staining with Alizarin Red S at day 14 of 
osteogenic induction in scADSCs and reached quantifiable levels by day 21, although 
morphological changes were already visible in cells at day 7 of osteogenic induction, in 
comparison to time-matched controls maintained in SGM with vehicle (Fig. 4.2.3.1.1). No 
mineralisation was detected in time-matched controls throughout the differentiation period 
(Fig. 4.2.3.1.1 A – C). Image analysis showed that scADSCs had a mean 17.7% surface area 
mineralisation by day 21 of osteogenic induction, significantly higher in comparison to mean 
values of only 2.4% and 0.5% at days 14 and 7, respectively (Fig. 4.2.3.1.3 A). The 
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percentage of mineralisation at day 21 ranged from 8.4% to 30.8%  between biological 
repeats (Addendum B, Fig. B5, F and I).  
 
 
Figure 4.2.3.1.1: Osteogenic differentiation of scADSCs. Subcutaneous ADSCs were cultured in standard 
growth medium (SGM) (A, B and C) and osteogenic differentiation medium (OM) (D, E and F), and 
differentiation progression is shown on day 7 (A and D), day 14 (B and E) and day 21 (C and F). Cells were 
stained with Alizarin Red S to visualise mineralisation (red). These images were acquired using an Olympus 
(CKX41) microscope at x10 magnification. 
 
Subcutaneous ADSCs undergoing osteogenic induction in the presence of levamisole formed 
cell clusters which appeared darker than surrounding areas upon staining with Alizarin Red S 
(Fig. 4.2.3.1.2 A), in contrast to the more homogenous appearance of untreated control cells 
(Fig. 4.2.3.1.1 C).  Similar darkly staining cell clusters were observed when levamisole was 
added in combination with histidine or L-homoarginine (Fig. 4.2.3.1.2 D and E). 
Mineralisation was completely inhibited in all samples where levamisole was present, as 
evidenced by the lack of red staining in these samples (Fig 4.2.3.1.2 A, D and E). While 
visual analysis confirmed a lack positively stained mineralisation in samples containing 
levamisole, image analysis detected a small percentage of positive staining for these groups 
(Addendum B, Fig. B5, B, D – F). This appears to be a false positive result due to the darker 
stained cell clusters present in these samples. The stained cell clusters are considered to be 
false positives, as these have a brown appearance after staining, in contrast to the red colour 
present in OM treated cultures, which identifies the presence of calcified mineral.    
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The addition of histidine alone had the surprising effect of increasing mineralisation in 
scADSCs compared to OM controls. The increased mineralisation in the presence of histidine 
was confirmed by visual observation (Fig. 4.2.3.1.2 B) as well as image analysis, which 
showed an increase in percentage mineralisation at all time points, with a significant increase 
observed on day 7 (Fig. 4.2.3.1.3 B, D and F). Image analysis data showed that  a mean value 
of 55.2% mineralisation was observed in samples containing histidine in comparison to 
16.5% for OM samples at day 21 (Addendum B, Fig. B5, B, D – F). L-homoarginine alone 
was sufficient to inhibit mineralisation in scADSCs, with no mineralisation observed at day 
21 (Fig. 4.2.3.1.2 C). The combination of L-homoarginine with histidine during osteogenic 
induction resulted in a slight increase in mineralisation compared to control OM at day 14, 
however by day 21 percentage mineralisation in the presence of L-homoarginine and 
histidine were approximately equal to control OM (Fig. 4.2.3.1.3 C, E and G).  
 
 
Figure 4.2.3.1.2: Osteogenic differentiation of scADSCs in the presence of TNAP inhibitors.  Subcutaneous 
ADSCs were cultured in osteogenic differentiation medium (OM) containing levamisole (Lev) (A), histidine 
(His) (B), L-homoarginine (Arg) (C), Lev+His (D) Lev+Arg (E) and His+Arg (F) for 21 days and stained with 
Alizarin Red S to visualise mineralisation (red). See Fig. 4.2.3.1.1 (F) for control osteogenic differentiation 
image. These images were acquired using an Olympus (CKX41) microscope at x10 magnification. 
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Figure 4.2.3.1.3: Image analysis to determine percentage area of mineralisation of scADSCs cultured in 
osteogenic differentiation medium (OM) in the presence and absence of levamisole (Lev), histidine (His) 
and L-homoarginine (Arg). Percentage mineralisation of cells cultured in standard growth medium (SGM) 
(Control) or OM, at day 7, 14 and 21, n=7 (A). Pooled data for animals 1 – 4 are displayed in panels B, D and F, 
showing relative % mineralisation at days 7, 14 and 21 in the presence of Lev, His or Lev+His. Pooled data for 
animal 5 – 7 are shown in panels C, E and G, showing relative % mineralisation at days 7, 14 and 21 in the 
presence of Arg, Lev+Arg or His+Arg. Statistical analysis was performed using Student’s t test, and 
Bonferroni’s correction, where p < 0.05 (* represents p < 0.05, ** represents p < 0.01). Error bars are 
representative of standard error (SE). Control OM was set to 100% for each inhibitor experiment.         
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Considerable variation in total cell ALP activity was detected between biological repeats in 
scADSCs undergoing osteogenic induction. ALP activity in cells undergoing osteogenic 
induction displayed no significant difference compared to time-matched controls maintained 
in SGM with OM vehicle. Total cell ALP activity of OM treated cells appeared to peak at day 
14, with the lowest levels observed at day 21 (Fig. 4.2.3.1.4 A).  
 
The addition of levamisole, histidine or L-homoarginine did not decrease ALP activity levels, 
but rather resulted in a slightly discernible increase in ALP activity levels, most noticeable by 
day 14 of osteogenic induction (Fig. 4.2.3.1.4 B – G). The combination of histidine with 
levamisole, levamisole and L-homoarginine and histidine with L-homoarginine resulted in a 
more noticeable increase in ALP activity compared to control OM, most noticeably at day 14, 
where the combination of levamisole and L-homoarginine was statistically significant (Fig. 
4.2.3.1.4 B - G). 
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Figure 4.2.3.1.4: Alkaline phosphatase (ALP)  assay to determine total cell ALP activity of scADSCs 
cultured in osteogenic differentiation medium (OM) in the presence and absence of levamisole (Lev), 
histidine (His) and L-homoarginine (Arg).  ALP activity (U/mg) of cells cultured in standard growth medium 
(SGM) (Control) or OM, at day 7, 14 and 21, n=6 (A). Pooled data for animals 1 – 3 are displayed in panel B, D  
and F, showing relative % ALP activity at days 7, 14 and 21 in the presence of Lev, His or Lev+His. Pooled 
data for animal 4 – 6 are displayed in panels C, E and G, showing relative % ALP activity at day 7, 14 and 21 in 
the presence of Arg, Lev+Arg or His+Arg. Statistical analysis was performed using Student’s t test, and 
Bonferroni’s correction, where p < 0.05 (* represents p < 0.05). Error bars are representative of standard error 
(SE). Control OM was set to 100% for each inhibitor experiment.        
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4.2.3.2 Subcutaneous ADSC adipogenesis  
Cells containing lipid droplets were typically visible by day 5 of adipogenic induction, where 
after lipid accumulation increased steadily  and was typically complete by day 10, where 
most cells present had visible intracellular lipid droplets (Fig. 4.2.3.2.1 D – F). By day 10 of 
adipogenic induction, scADSCs had an average value of 12.4% of surface area positively 
stained for lipid with Oil Red O (Fig. 4.2.3.2.3 A), however this ranged from 6.9% to 24.0% 
between biological repeats (n=8) (Addendum B, Fig. B7). Subcutaneous ADSCs maintained 
in SGM with vehicle control did not produce any visible lipid droplets throughout the 
differentiation period (Fig. 4.2.3.2.1 A – C).   
 
 
Figure 4.2.3.2.1: Adipogenic differentiation of scADSCs. Subcutaneous ADSCs were cultured in standard 
growth medium (SGM) (A, B and C) and adipogenic differentiation medium (AM) (D, E and F), and 
differentiation progression is shown on day 5 (A and D), day 7 (B and E) and day 10 (C and F). Cells were 
stained with Oil Red O to visualise lipid droplets (red). These images were acquired using an Olympus 
(CKX41) microscope at x10 magnification.  
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Figure 4.2.3.2.2: Adipogenic differentiation of scADSCs in the presence of TNAP inhibitors. Subcutaneous 
ADSCs were cultured in adipogenic differentiation medium (AM) containing levamisole (Lev) (A), histidine 
(His) (B), L-homoarginine (Arg) (C), Lev+His (D) Lev+Arg (E) and His+Arg (F) for 10 days and stained with 
Oil Red O to visualise lipid droplets (red). See Fig. 4.2.3.2.1 (F) for control adipogenic differentiation image. 
These images were acquired using an Olympus (CKX41) microscope at x10 magnification.  
 
The addition of levamisole to scADSCs undergoing adipogenic induction had no apparent 
visible effect on lipid accumulation compared to control AM samples (Fig. 4.2.3.2.2 A). 
Image analysis results confirmed that the presence of levamisole had little effect on lipid 
accumulation, as percentage surface area of lipid in samples containing levamisole was only 
slightly below that of control AM at days 5, 7 and approximately equal to control AM at day 
10 (Fig. 4.2.3.2.3 B, D and F). The presence of histidine during adipogenic induction 
produced a slight drop in lipid accumulation, a trend present in all biological repeats (n=3). 
The combination of histidine and levamisole resulted in lipid accumulation at similar levels 
to those observed in control AM and levamisole (Fig. 4.2.3.2.3 B, D and F).  
 
In the presence of L-homoarginine, a slight decrease in lipid accumulation was noticeable by 
day 7 and statistically significant by 10 (Fig. 4.2.3.2.3 C, E and G). The decrease in lipid 
accumulation was visibly apparent by day 10 in comparison to control AM samples (Fig. 
4.2.3.2.3 A). The combination of L-homoarginine with levamisole had a similar effect to L-
homoarginine alone, while the combination of L-homoarginine with histidine resulted in an 
even greater decrease in lipid accumulation compared to L-homoarginine alone, when viewed 
in comparison to lipid accumulation in control AM cells  by day 10 (Fig. 4.2.3.2.3 C, E and 
G).  
Stellenbosch University  https://scholar.sun.ac.za
 117 
 
 
Figure 4.2.3.2.3: Image analysis to determine percentage area of lipid accumulation in scADSCs cultured 
in adipogenic differentiation medium (AM) in the presence and absence of levamisole (Lev), histidine 
(His) and L-homoarginine (Arg). Percentage area of lipid accumulation of cells cultured in standard growth 
medium (SGM) (Control) or AM, at day 5, 7 and 10, n=8 (A). Pooled data for animals 1 – 3 are displayed in 
panels B, D and F, showing relative % lipid accumulation at days 5, 7 and 10 in the presence of Lev, His or 
Lev+His respectively. Pooled data for animal 4 – 8 are displayed in panels C, E and G, showing relative % lipid 
accumulation at days 5, 7 and 10 in the presence of Arg, Lev+Arg or His+Arg. Statistical analysis was 
performed using Student’s t test, and Bonferroni’s correction, where p < 0.05 (* represents p < 0.05, ** 
represents p < 0.01, *** represents p < 0.001). Error bars are representative of standard error (SE). Control AM 
was set to 100% for each inhibitor experiment.         
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The highest level of total cell ALP activity in scADSCs undergoing adipogenic induction was 
observed at day 5, at a mean value of 0.0271 U/mg, and decreased significantly with time 
until the lowest level was reached at day 10, where the average ALP activity was 0.0080 
U/mg, approximately equal to ALP activity levels in time-matched controls maintained in 
SGM with vehicle, at an average of 0.0078 U/mg (Fig. 4.2.3.2.4 A). The ALP activity 
detected in time-matched controls, was slightly lower than in cells undergoing adipogenic 
induction at days 5 and 7, but showed a similar decreasing trend over time (Fig. 4.2.3.2.4 A). 
 
The ALP activity of scADSCs undergoing adipogenic induction in the presence of levamisole 
was slightly lower in comparison to AM control samples at days 5 and 10 and significantly 
lower at day 7 only (Fig. 4.2.3.2.4 B, D and F). The presence of histidine alone resulted in a 
slight increase in ALP activity compared to control AM at days 5 and 7, however by day 10 it 
was similar to control AM. Histidine in combination with levamisole had no apparent effect 
on ALP activity when compared to AM controls at all time points measured (Fig. 4.2.3.2.4 B, 
D and F). ALP activity in the presence of levamisole, histidine and in combination decreased 
similarly to that of control AM over the differentiation period (Addendum B, Fig. B8).  
 
The presence of L-homoarginine during adipogenic induction resulted in a significant increase 
in ALP activity in comparison to control AM samples, visible over all time-points 
investigated (Fig. 4.2.3.2.4 C, E and G). The combination of L-homoarginine with either 
levamisole or histidine resulted in increasing levels of ALP activity over the differentiation 
period, exceeding that for L-homoarginine alone, indicating an additive effect (Fig. 4.2.3.2.4 
C, E and G). The combination of L-homoarginine and histidine resulted in a significantly 
greater amount of ALP activity in comparison to control AM at day 10 (Fig. 4.2.3.2.4 C, E 
and G).  
 
The combined image analysis and ALP activity results show that levamisole did not inhibit 
lipid accumulation in scADSCs undergoing adipogenic induction, whereas a slight inhibition 
of ALP activity was observed. Conversely, the presence of histidine produced a slightly lower 
percentage of lipid accumulation, while ALP activity levels were not affected when compared 
to control AM samples. L-homoarginine resulted in a decrease in lipid accumulation and a 
concomitant increase in ALP activity, and effect which was intensified when L-homoarginine 
was combined with levamisole or histidine, with the combination with histidine having the 
greatest effect on lipid accumulation and ALP activity. 
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Figure 4.2.3.2.4: Alkaline phosphatase (ALP) assay to determine total cell ALP activity of scADSCs 
cultured in adipogenic differentiation medium (AM) in the presence and absence of levamisole (Lev), 
histidine (His) and L-homoarginine (Arg). ALP activity (U/mg) of cells cultured in standard growth medium 
(SGM) (Control) or AM, at day 5, 7 and 10, n=7 (A). Pooled data for animals 1 – 3 are displayed in panels B, D 
and F, showing relative % ALP activity at days 5, 7 and 10 in the presence of Lev, His or Lev+His. Pooled data 
for animal 4 – 7 are displayed in panels C, E and G, showing relative % ALP activity at days 5, 7 and 10 in the 
presence of Arg, Lev+Arg or His+Arg. Statistical analysis was performed using Student’s t test, and 
Bonferroni’s correction, where p < 0.05 (* represents p < 0.05). Error bars are representative of standard error 
(SE). Control AM was set to 100% for the inhibitor experiments.     
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4.2.4 Evaluation of TNAP inhibitors on pvADSC osteogenesis and 
adipogenesis  
Peri-renal visceral ADSCs were induced to differentiate into either an osteogenic or 
adipogenic phenotype as previously described (Chapter 2, Sections 2.6 and 2.8), in the 
presence of the TNAP inhibitors levamisole (0.5 mM), histidine (10 mM) and L-
homoarginine (10 mM), added separately or in combination with one another. Inhibitors were 
added to cell cultures at the start of osteogenic or adipogenic induction and maintained 
throughout the differentiation period. 
 
Table 4.2.4.1: Overall effects of tissue nonspecific alkaline phsosphatase (TNAP) inhibitors on percentage 
mineralisation, lipid accumulation and alkaline phosphatase (ALP) activity on peri-renal visceral 
adipose-derived stromal cells (pvADSCs) induced towards an osteogenic or adipogenic phenotype.  
 Osteogenic phenotype   Adipogenic phenotype  
Inhibitor  Mineralisation  ALP activity    Lipid accumulation  ALP activity  
Lev Decreased  No effect  No effect  Decreased  
His  No effect  Increased  Decreased Decreased  
Arg  Decreased  No effect  Decreased ++ Increased  
Lev +His Decreased  Increased  No effect  No effect  
Lev +Arg  Decreased  No effect  Decreased ++ Increased ++ 
His+Arg  Increased  Increased  Decreased ++  Increased  
Inhibitors used include levamisole (Lev) (0.1 mM), histidine (His) (10 mM) and L-homoarginine (Arg) (10 
mM), and the differentiation period was 10 and 14 days for osteogenic and adipogenic differentiation, 
respectively.  Where a possible trend was noticed, it is indicated by either “Increased” or “Decreased”, “++” 
statistically significant p<0.05. Quantification is shown in subsequent graphs. 
 
4.2.4.1 Peri-renal visceral ADSC osteogenesis.  
Mineralisation in pvADSCs was typically only apparent by day 21 of osteogenic induction, 
although the presence of a small amount of mineralisation was detectable by day 14 in some 
samples (Fig. 4.2.4.1.1 D – F). Mineralisation was not detected in pvADSCs maintained in 
SGM with vehicle as control after 21 days in culture (Fig. 4.2.4.1.1 A – C). Successful 
mineralisation of pvADSCs was variable, with mineralisation ranging from a maximum of 
35.8% to a minimum of 1.35% – similar to levels measured in control samples, at day 21 
(Fig. 4.2.4.1.3 A and Addendum B, Fig. B9).  
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Figure 4.2.4.1.1: Osteogenic differentiation of pvADSCs. Peri-renal visceral ADSCs were cultured in standard 
growth medium (SGM) (A, B and C) and osteogenic differentiation medium (OM) (D, E and F), and 
differentiation progression is shown on day 7 (A and D), day 14 (B and E) and day 21 (C and F). Cells were 
stained with Alizarin Red S to visualise mineralisation (red). These images were acquired using an Olympus 
(CKX41) microscope at x10 magnification. 
 
The addition of levamisole to pvADSCs, alone or in combination with histidine and L-
homoarginine, prevented mineralisation from occurring by day 21 of osteogenic induction 
(Fig. 4.2.4.1.2 A, D and E). Similar to the observation in scADSCs, clusters of cells which 
appeared darker than surrounding areas when stained with Alizarin Red S were apparent in 
samples where levamisole was present, and resulted in a slight false postive result for 
mineralisation during image analysis. (Fig. 4.2.4.1.3 B, D and F; Addendum B, Fig. B9).  
 
Histidine alone, or in combination with L-homoarginine, resulted in an increase in 
mineralisation in comparison to OM control cells by day 21 of osteogenic induction (Fig. 
4.2.4.1.2 B and F, and Fig. 4.2.4.1.3 F and G), although this trend was not present in all 
biological repeats (Addendum B, Fig. B9, F and I). Mineralisation in the presence of histidine 
and L-homoarginine was higher than with L-homoarginine alone. L-homoarginine appeared 
to inhibit mineralisation in pvADSCs during osteogenic induction, however this inhibition 
was not as complete as that observed for levamisole, due to the observeration of slight red-
stained mineral present in these samples (Fig 4.2.4.1.2 C).  
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Figure 4.2.4.1.2: Osteogenic differentiation of pvADSCs in the presence of TNAP inhibitors. Peri-renal 
visceral ADSCs were cultured in osteogenic differentiation medium (OM) containing levamisole (Lev) (A), 
histidine (His) (B), L-homoarginine (Arg) (C), Lev+His (D) Lev+Arg (E) and His+Arg (F) for 21 days and 
stained with Alizarin Red S to visualise mineralisation (red). See Fig. 4.2.4.1.1 (F) for control osteogenic 
differentiation image. These images were acquired using an Olympus (CKX41) microscope at x10 
magnification. 
 
Stellenbosch University  https://scholar.sun.ac.za
 123 
 
 
Figure 4.2.4.1.3: Image analysis to determine percentage area of mineralisation of pvADSCs cultured in 
osteogenic differentiation medium (OM) in the presence and absence of levamisole (Lev), histidine (His) 
and L-homoarginine (Arg). Percentage mineralisation of cells cultured in standard growth medium (SGM) 
(Control) or OM, at day 7, 14 and 21, n=7 (A). Pooled data for animals 1 – 4 are displayed in panels B, D and F, 
showing relative % mineralisation at days 7, 14 and 21 in the presence of Lev, His or Lev+His. Pooled data for 
animal 5 – 7 are displayed in panels C, E and G, showing relative % mineralisation at days 7, 14 and 21 in the 
presence of Arg, Lev+Arg or His+Arg. Statistical analysis was performed using Student’s t test, and 
Bonferroni’s correction, where p < 0.05 (* represents p < 0.05, ** represents p < 0.01). Error bars are 
representative of standard error (SE). Control OM was set to 100% for the inhibitor experiments.     
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Similarly to scADSCs, the total cell ALP activity of pvADSCs undergoing osteogenic 
induction was observed to decrease over the differentiation period of 21 days. The total cell 
ALP activity of cells maintained in SGM with vehicle control was higher than that of cells 
undergoing osteogenic induction for all time points measured (Fig. 4.2.4.1.4 A). The lowest 
ALP activity levels were observed in pvADSCs in comparison to scADSCs and bmMSCs, 
with a maximum average value of 0.0015 U/mg (1.5 mU/mg) at day 7 in cells undergoing 
osteogenic induction, and dropping to an average of 0.00085 U/mg (0.85 mU/mg) on day 21 
(Fig. 4.2.4.1.4 A). The biological variation in ALP activity of pvADSCs undergoing 
osteogenic induction was not as pronounced as that of scADSCs, however a day 14 sample 
(animal 1) did have markedly higher ALP activity compared to other samples at the same 
time point, where control OM had 0.0043 U/mg (4.3 mU/mg) compared to values of less than 
0.001 U/mg for the remaining 5 biological repeats at the same time point (Addendum B, Fig. 
B10, E and H).  
 
The addition of levamisole or histidine to cells undergoing osteogenic induction did not have 
any apparent effect on ALP activity levels compared to OM control, however the 
combination of levamisole and histidine resulted in a slightly higher ALP activity, indicating 
an additive effect in pvADSCs undergoing osteogenic induction (Fig. 4.2.4.1.4 B, D and F). 
L-homoarginine alone, or in combination with levamisole had little discernible effect on ALP 
activity, whereas the combination of L-homoarginine with histidine resulted in an increase in 
ALP activity compared to control OM for all three time points sampled, with statistical 
significance on day 7 and 21 (Fig. 4.2.4.1.4 C, E and G).  
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Figure 4.2.4.1.4: Alkaline phosphatase (ALP)  assay to determine total cell ALP activity of pvADSCs 
cultured in osteogenic differentiation medium (OM) in the presence and absence of levamisole (Lev), 
histidine (His) and L-homoarginine (Arg). ALP activity (U/mg) of cells cultured in standard growth medium 
(SGM) (Control) or OM, at day 7, 14 and 21, n=6 (A). Pooled data for animals 1 – 3 are displayed in panela B, 
D and F, showing relative % ALP activity at days 7, 14 and 21 in the presence of Lev, His or Lev+His. Pooled 
data for animal 4 – 6 are displayed in panels C, E and G, showing relative % ALP activity at days 7, 14 and 21 
in the presence of Arg, Lev+Arg and His+Arg. Statistical analysis was performed using Student’s t test, and 
Bonferroni’s correction, where p < 0.05 (* represents p < 0.05, ** represents p < 0.01). Error bars are 
representative of standard error (SE). Control OM was set to 100% for the inhibitor experiments.   
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 4.2.4.2 Peri-renal visceral ADSC adipogenesis  
By day 5, pvADSCs undergoing adipogenic induction typically produced visible intracellular 
lipid droplets, where after lipid droplets increased in size and number until day 10 where the 
majority of cells contained droplets (Fig. 4.2.4.2.1 D – F). No lipid accumulation was visible 
in cells maintained in SGM with vehicle control over the differentiation period, and instead 
maintained a homogenous lawn appearance (Fig. 4.2.4.2.1 A – C). By day 10, pvADSCs 
reached an average of 14.3 % surface area lipid when stained with Oil Red O, however, the 
maximum lipid accumulation achieved varied between biological repeats, with a range from 
5.9% to 22.6% (Addendum B, Fig. B11, F and I).  
 
 
Figure 4.2.4.2.1: Adipogenic differentiation of pvADSCs. Peri-renal visceral ADSCs were cultured in 
standard growth medium (SGM) (A, B and C) and adipogenic differentiation medium (AM) (D, E and F), and 
differentiation progression is shown on day 5 (A and D), day 7 (B and E) and day 10 (C and F). Cells were 
stained with Oil Red O to visualise lipid droplets (red). These images were acquired using an Olympus 
(CKX41) microscope at x10 magnification.. 
 
By day 10 of adipogenic induction, it could be seen that the presence of levamisole, alone or 
in combination with histidine, did not appear to visibly inhibit lipid accumulation in 
pvADSCs (Fig. 4.2.4.2.2 A and D), and image analysis data showed that the percentage 
surface area of lipid was slightly higher in these samples than for control AM (Fig. 4.2.4.2.3 
F). Histidine alone resulted in a very slight visible decrease in lipid accumulation (Fig. 
4.2.4.2.2 B), an observation that was confirmed by image analysis data (Fig. 4.2.4.2.3 B and 
D).  
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The presence of L-homoarginine alone, or in combination with either levamisole or histidine 
resulted in a significant decrease in lipid accumulation compared to AM control, with the 
greatest reduction observed with L-homoarginine was combined with histidine (Fig. 4.2.4.2.3 
C, E and G).  
 
 
Figure 4.2.4.2.2: Adipogenic differentiation of pvADSCs in the presence of TNAP inhibitors. Peri-renal 
visceral ADSCs were cultured in adipogenic differentiation medium (AM) containing levamisole (Lev) (A), 
histidine (His) (B), L-homoarginine (Arg) (C), Lev+His (D) Lev+Arg (E) and His+Arg (F) for 10 days and 
stained with Oil Red O to visualise lipid droplets (red). See Fig. 4.2.4.2.1 (F) for control adipogenic 
differntiation image. These images were acquired using an Olympus (CKX41) microscope at x10 magnification. 
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Figure 4.2.4.2.3: Image analysis to determine percentage area of lipid accumulation in pvADSCs cultured 
in adipogenic differentiation medium (AM) in the presence and absence of levamisole (Lev), histidine 
(His) and L-homoarginine (Arg). Percentage area of lipid accumulation of cells cultured in standard growth 
medium (SGM) (Control) or AM, at day 5, 7 and 10, n=9 (A). Pooled data for animals 1 – 4 are displayed in 
panels B, D and F, showing relative % lipid accumulation at days 5, 7 and 10 in the presence of Lev, His or 
Lev+His. Pooled data for animal 5 – 9 are displayed in panels C, E and G, showing relative % lipid 
accumulation at days 5, 7 and 10 in the presence of Arg, Lev+Arg or His+Arg. Statistical analysis was 
performed using Student’s t test, and Bonferroni’s correction, where p < 0.05 (* represents p < 0.05, ** 
represents p < 0.01, *** represents p < 0.001). Error bars are representative of standard error (SE). Control AM 
was set to 100% for the inhibitor experiments.     
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The total cell ALP activity of pvADSCs undergoing adipogenic induction was highest at day 
5 at 0.0060 U/mg and decreased over the course of the differentiation period, to levels of 
0.0022 U/mg at day 10, while the total cell ALP activity of cells maintained in SGM with 
vehicle control remained fairly constant over the same period (Fig. 4.2.4.2.4 A). In contrast to 
pvADSCs undergoing osteogenic induction, ALP activity in cells undergoing adipogenic 
induction was significantly higher than control cells at day 5, and also significantly higher at 
day 5 than at day 7 or 10 of differentiation (Fig. 4.2.4.2.4 A).  
 
The presence of levamisole or histidine alone during adipogenic induction appeared to 
decrease ALP activity very slightly compared to control AM at days 5 and 7 but were similar 
to control AM by day 10. The combination of levamisole and histidine resulted in levels of 
ALP activity very similar to control AM at all time points sampled (Fig. 4.2.4.2.4 B, D and 
F).  
 
The addition of L-homoarginine alone or in combination with levamisole and histidine 
resulted in either similar or higher ALP activity levels compared to control AM at all time 
points investigated. The combination of L-homoarginine with levamisole resulted in the 
highest levels of ALP activity at day 7 and 10, and were significantly higher than control AM 
at day 10, while ALP activity levels of L-homoarginine alone or in combination with 
histidine were largely similar to one another (Fig. 4.2.4.2.4 C, E and G). The ALP activity of 
both L-homoarginine combinations were found to increase over time compared to control 
AM, which was observed to decrease over the same period.  
 
In pvADSCs, levamisole alone or in combination with L-homoarginine or histidine seemed to 
be able to block mineralisation, but this was not statistically significant. Levamisole had no 
effect on lipid accumulation. The presence of histidine alone, or and in combination with L-
homoarginine, had no significant effect on mineralisation in comparison to control OM. 
However, a trend towards an increase was noticeable. Levamisole or histidine alone did not 
decrease ALP activity in cells undergoing osteogenic induction; however the combination of 
the two inhibitors resulted in a slight increase in ALP activity, although again this was not 
statistically significant. L-homoarginine in combination with levamisole was seen to inhibit 
mineralisation, and resulted in a slight increase in ALP activity, while L-homoarginine in 
combination with histidine resulted in an increase in mineralisation during osteogenic 
induction, and a concomitant increase in ALP activity in these samples. 
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Levamisole alone, or in combination with histidine had little to no effect on lipid 
accumulation or ALP activity, while histidine alone resulted in a slight reduction in lipid 
accumulation with a similar slight reduction on ALP activity. L-homoarginine, alone or in 
combination with levamisole or histidine, resulted in a significant reduction in lipid 
accumulation compared to control AM samples, while conversely, causing a significant 
increase in ALP activity in comparison on control AM samples.  
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Figure 4.2.4.2.4: Alkaline phosphatase (ALP) assay to determine total cell ALP activity of pvADSCs 
cultured in adipogenic differentiation medium (AM) in the presence and absence of levamisole (Lev), 
histidine (His) and L-homoarginine (Arg). ALP activity (U/mg) of cells cultured in standard growth medium 
(SGM) (Control) or AM, at day 5, 7 and 10, n=7 (A). Pooled data for animals 1 – 4 are displayed in panels B, D 
and F, showing relative % ALP activity at days 5, 7 and 10 in the presence of Lev, His or Lev+His. Pooled data 
for animal 5 – 7 are displayed in panels C, E and G, showing relative % ALP activity at days 5, 7 and 10 in the 
presence of Arg, Lev+Arg or His+Arg. Statistical analysis was performed using Student’s t test, and 
Bonferroni’s correction, where p < 0.05 (* represents p < 0.05). Error bars are representative of standard error 
(SE). Control AM was set to 100% for the inhibitor experiments.     
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4.2.5 ALP mRNA levels during osteogenesis and adipogenesis in the 
presence of TNAP inhibitors  
The mRNA expression levels of TNAP in bmMSCs, scADSCs and pvADSCs undergoing 
either adipogenic or osteogenic induction in the presence of TNAP inhibitors levamisole, 
histidine and L-homoarginine were investigated. The question posed was whether the 
presence of the various inhibitors would alter TNAP mRNA during adipogenic or osteogenic 
induction, and whether this change would correspond to the changes in lipid accumulation or 
mineralisation and ALP activity previously observed.  Time points used for gene expression 
analysis corresponded to the time points previously found to have the overall highest TNAP 
mRNA expression, this being days 5 and 7 for both adipogenic and osteogenic induction, 
except for bmMSCs where day 3 and 5 time points were investigated, as insufficient RNA 
could be extracted from later time points.  The highest relative TNAP expression levels were 
observed in bmMSCs, in which the average expression levels were never below 75 fold, 
followed by scADSCs and finally pvADSCs, in which TNAP mRNA expression was 
comparatively extremely low, where no samples were observed to reach even a 2-fold 
increase.  
 
The relative expression of TNAP mRNA compared to the housekeeping gene, ARBP, in 
bmMSCs between days 3 and 5 of osteogenic induction remained fairly stable, with average 
values of 83 and 75 fold, respectively. Levamisole resulted in a slight drop in TNAP mRNA, 
to levels of 76 and 56 fold on days 3 and 5 of osteogenic induction, respectively. The 
presence of histidine and L-homoarginine resulted in an increase in TNAP mRNA 
expression, with the greatest increase being that of L-homoarginine with an average level of 
186 fold on day 3 and 167 fold on day 5. This data is in contrast to ALP activity data, where 
treatment with levamisole resulted in a slight increase in ALP activity, while L-homoarginine 
had no apparent effect compared to control OM samples. Treatment with histidine resulted in 
an increase in ALP activity and TNAP mRNA expression (Fig. 4.2.2.1.4 B – G).  
 
During adipogenic induction of bmMSCs, relative TNAP mRNA expression more than 
doubled, from an average level of 89 fold to 242 fold on days 5 and 7, respectively. On both 
days 5 and 7, the presence of levamisole resulted in a decrease in TNAP mRNA expression 
compared to AM control, with a significant decrease on day 7 at an average level of 76 fold 
(Fig. 4.2.5.1 B). The presence of histidine and L-homoarginine resulted in an increase in 
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TNAP mRNA compared to control AM samples, peaking on day 7 at 343 and 297 fold, 
respectively. The mRNA data for levamisole and histidine correspond to ALP activity data, 
which showed a decrease and an increase in ALP activity in the presence of levamisole and 
histidine respectively. L-homoarginine resulted in a decrease in ALP activity, compared to 
the increase in TNAP mRNA expression observed under the same conditions (Fig. 4.2.5.1 B).  
 
 
Figure 4.2.5.1: Relative expression of TNAP mRNA in bmMSCs, scADSCs and pvADSCs during osteogenic 
or adipogenic induction in the presence of TNAP inhibitors. TNAP mRNA expression relative to house-
keeping gene Arbp, in cells cultured in either adipogenic differentiation medium (AM) or osteogenic 
differentiation medium (OM) in the presence of the TNAP inhibitors levamisole (Lev), histidine (His) and L-
homoarginine (Arg). Statistical analysis was performed using one-way ANOVA and Tukey post-test to determine 
statistical differences where statistical significance was given when p < 0.05 (* represents p < 0.05, # represents p 
< 0.05 differences between treatments at the same time point). Error bars are representative of standard error (SE). 
(n=3). 
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TNAP mRNA levels in scADSCs undergoing osteogenic differentiation in OM were fairly 
similar at day 5 and 7, with average expression levels of 1.94 and 1.89-fold, respectively. 
TNAP mRNA levels in samples where levamisole and histidine were present were both lower 
than control OM on day 5, and higher than control OM on day 7. Samples containing L-
homoarginine had similar TNAP mRNA levels at day 5 and 7, both of which were slightly 
higher than control OM (Fig. 4.2.5.1 C). The ALP activity data for scADSCs suggested that 
neither the presence of levamisole, histidine nor L-homoarginine had any effect on ALP 
activity during osteogenic induction.  
 
The levels of TNAP mRNA expression in scADSCs during adipogenesis were higher on day 
5, and dropped on day 7, similar to that observed with ALP activity data for scADSCs. The 
levels of TNAP mRNA in levamisole,  histidine and L-homoarginine samples were similar on 
both day 5 and 7, with all three at lower levels than control AM samples on day 5 and 
levamisole and L-homoarginine being higher than control AM on day 7 (Fig. 4.2.5.1 D). ALP 
activity data indicated that the presence of levamisole resulted in a decrease in ALP activity, 
while histidine had no effect, and L-homoarginine increased ALP activity during adipogenic 
induction. 
 
The relative expression of TNAP mRNA appeared to increase from day 5 to day 7 in samples 
of pvADSCs undergoing osteogenic induction; however this increase was only from an 
average level of 0.86 to 1.47-fold, respectively. At both day 5 and 7 time points, the presence 
of levamisole and histidine resulted in a decrease in TNAP mRNA compared to control OM, 
while L-homoarginine presented a slight increase in comparison to controls in OM (Fig. 
4.2.5.1. E). ALP activity data for pvADSCs indicated that levamisole and L-homoarginine 
had no effect of ALP activity levels, while the presence of histidine increased ALP activity 
during osteogenic induction.  
 
TNAP mRNA expression levels during adipogenic induction of pvADSCs increased between 
the day 5 and 7 time points assessed, and were similarly low, with average values of 0.08 and 
1.77-fold, respectively. The average TNAP mRNA expression levels of levamisole, histidine 
and L-homoarginine remained fairly similar between day 5 and 7 time points, and were all 
higher than controls in AM at day 5, while only L-homoarginine was higher than control at 
day 7 (Fig. 4.2.5.1 F). The TNAP mRNA expression data at day 7 of adipogenic induction 
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most closely compare to the ALP activity data for the same conditions, where levamisole and 
histidine decreased ALP activity, and L-homoarginine was found to increase it.  
 
4.2.6 Alkaline phosphatase activity assay after osteogenic or adipogenic 
induction in the presence of TNAP inhibitors 
Previous experiments investigated whether the addition of TNAP inhibitors to cells 
undergoing adipogenic or osteogenic induction would inhibit differentiation, as assessed by 
either lipid accumulation or mineralisation, respectively, as well as the resulting effect on 
ALP activity. The question was asked whether the ALP activity of the cells would be 
inhibited when the various inhibitors were added to samples of total cell lysate from control 
cells maintained in SGM, or cells that had undergone adipogenic or osteogenic induction. 
Samples were collected at time points where ALP activity was previously found to be 
highest, namely day 5 and 14 for ADSCs and bmMSCs during adipogenic induction and days 
5 and 7 for ADSCs and bmMSCs during osteogenic induction. Cell lysate samples from 
control cells were taken at day 7 from the point where differentiation was initiated. The 
inhibitors were added to the cell lysate prior to the addition of substrate, at 0.5 mM for 
levamisole and 10 mM each for histidine and L-homoarginine, which were the same 
concentrations of the inhibitors applied to live cell cultures. The reason for this was to 
investigate the effectiveness of the inhibitors used at these concentrations to inhibit ALP 
activity under ALP activity assay conditions, as opposed to cell culture conditions. 
 
ALP activity assay confirmed that levamisole was able to inhibit ALP activity in bmMSCs, 
scADSCs and pvADSCs, in control, adipogenic and osteogenic samples, although inhibition 
was not statistically significant in some bmMSC and scADSC samples (Fig. 4.2.6.1 A – I).  
Histidine partially inhibited ALP activity in scADSCs and pvADSCs in control, adipogenic 
and osteogenic samples, and in the bmMSC osteogenic group. Surprisingly, in bmMSC 
control and adipogenic samples, histidine appeared to increase ALP activity in comparison to 
the untreated controls in each group (Fig 4.2.6.1 A and C). This corresponds to the increased 
ALP activity observed in bmMSCs undergoing adipogenesis and osteogenesis where histidine 
was present during the differentiation period (see Section 4.2.2).  
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L-homoarginine was able to inhibit ALP activity in bmMSCs and scADSCs, when added to 
control, adipogenic and osteogenic samples, to an equal or greater extent than levamisole 
(Fig. 4.2.6.1). Conversely, in pvADSCs levamisole inhibited more strongly than L-
homoarginine (Fig. 4.2.6.1 G – I).   
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Figure 4.2.6.1: ALP activity in lysates of naïve undifferentiated control cells (Ctrl) and cells after having undergone adipogenic (AM) and osteogenic (OM) 
differentiation in the presence of TNAP inhibitors levamisole (Lev), histidine (His) and L-homoarginine (Arg). Control (ctrl) samples were taken from day 7 cell 
cultures, while OM samples were taken at day 5 for bmMSCs and day 7 for scADSCs and pvADSCs. AM samples were taken from day 14 for bmMSCs and day 5 for 
scADSCs and pvADSCs. ALP activity is presented as U/mg of total cell protein. n =3. Statistical analysis was performed using Student’s t test and Bonferroni’s correction to 
determine statistical differences where p < 0.05 (* represents p < 0.05, ** represents p < 0.01, *** represents p < 0.001). Error bars are representative of standard error (SE). 
Controls were set to 100%.
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4.3 Discussion 
In order to determine the effect that TNAP inhibitors would have on differentiation of MSCs 
from bone marrow and adipose tissue, the maximum, non-cytotoxic, concentration of each 
inhibitor was assessed for each cell type. In contrast to previous studies using 3T3-L1 and 
primary cultured human mammary preadipocytes, the rat-derived MSCs used in this study 
were noted to be more sensitive to both levamisole and histidine. Previous studies found that 
3T3-L1 cells could tolerate levamisole at 2.5 mM (Ali et al., 2005), while the data presented 
here showed that rat-derived MSCs were not able to tolerate greater than 0.5 mM levamisole 
over the course of the differentiation period, which ranged from 10 to 21 days. Similarly, 
histidine was not well tolerated above 10 mM in rat-derived MSC cultures, while 3T3-L1 
cells were able to tolerate 50 mM histidine (Ali et al., 2005). We found that rat MSCs were 
able to tolerate an L-homoarginine concentration of 10 mM during culture. Under ALP 
activity assay conditions, 8 mM L-homoarginine was previously found to be sufficient to 
inhibit ALP activity by 80%, where pH was also found to have no effect on inhibition (Lin 
and Fishman, 1972). Since in vitro ALP assay conditions are typically at an alkaline pH 
(Section 2.2.4.3) and are optimised for ALP activity where cell lysates or extracts are used, 
the percentage of ALP inhibition in these conditions may be different to that when the 
inhibitors are added exogenously to intact cells at concentrations optimised for cell survival. 
In spite of this, previous data showing that 8 mM L-homoarginine is sufficient to inhibit 80% 
of ALP, and that pH did not affect the ability of L-homoarginine to inhibit ALP activity, 
indicates that some inhibition can be expected at a concentration of 10 mM L-homoarginine 
in live cell culture. 
 
During osteogenic induction, the presence of levamisole, alone or in combination with 
histidine or L-homoarginine successfully inhibited mineralisation in bmMSCs, scADSCs and 
pvADSCs, and resulted in slightly increased ALP activity in bmMSCs and no apparent effect 
on activity in either scADSCs or pvADSCs. Increased ALP activity in cells undergoing 
osteogenic differentiation in the presence of levamisole has been observed before in a rat-
derived bone marrow stromal cell model where mineralisation was simultaneously inhibited 
(Klein et al., 1993). It was proposed by Klein et al. that levamisole may prevent 
mineralisation by inhibition of calcium accumulation. This may be by a mechanism other 
than by the inhibition of ALP activity, as the D-isomer of levamisole has been observed to 
inhibit mineralisation, but does not inhibit ALP activity (Klein et al., 1993). The increase in 
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ALP activity observed by Klein et al. was hypothesized to be due to a compensatory 
mechanism, where the cells are increasing synthesis of TNAP in response to the inhibition by 
levamisole. A similar compensatory mechanism may be present here in bmMSCs where 
increased ALP activity was observed in the presence of levamisole, while mineralisation was 
simultaneously inhibited.   
 
 Levamisole alone had no apparent effect on lipid accumulation, but resulted in a decrease in 
ALP activity in all three cell types during adipogenic induction, compared to AM controls. 
This is in contrast to the effect of levamisole observed on cells undergoing osteogenic 
induction, and also in a separate study, the effect of levamisole on human preadipocytes, 
where levamisole significantly reduced lipid accumulation and increased ALP activity (Ali et 
al., 2013). Another recent study reported that adipogenic potential in human adipocyte 
precursor cells derived from subcutaneous adipose tissue was highest in a subset of the 
population that expressed TNAP on the surface membrane, and this subset of cells also had 
the highest ALP activity in comparison to the subset of adipocyte precursors which did not 
express TNAP as a cell surface marker (Esteve et al., 2015). In the TNAP-positive subset, 
lipid accumulation was inhibited and adipocytic marker gene expression was lowered in the 
presence of tetramisole, a racemate of L-tetramisole (levamisole) and D-tetramisole, as well 
as with RNA interference against TNAP. This same study concluded that TNAP activity was 
necessary for triglyceride accumulation in human white and brite (Browned white) 
preadipocytes (Esteve et al., 2015). It is worthwhile to note that only levamisole is known to 
have an inhibitory effect on TNAP, while D-tetramisole has no effect (Borgers, 1973; Nowak 
et al., 2015). It is possible that tetramisole and levamisole have effects beyond inhibition of 
TNAP in living MSCs, as experiments examining the inhibition of TNAP in cells from 
mouse brain cortex by tetramisole and levamisole found that the effects were not 
stereospecific, and that tetramisole had at least four other targets in the nervous system apart 
from TNAP (Nowak et al., 2015). The same authors cautioned the use of levamisole and 
tetramisole in living excitable cells for the sole aim of inhibiting TNAP, due to the numerous 
off-target effects (Nowak et al., 2015).  
 
Levamisole has also be found to reduce lipid accumulation in the murine preadipocyte cell 
line, 3T3-L1, along with a reduction in ALP activity (Ali et al., 2005). The lack of response 
of lipid accumulation to levamisole observed in rat-derived MSCs found here may be due to 
several factors, including possible heterogeneity of the cell cultures, compared to the more 
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homogenous 3T3-L1 cell line, or the human adipocyte precursors, which were selected for 
specific surface markers. The human adipocyte precursors were selected using cell depletion 
kits to select for markers CD31, CD45 and immuno-magnetic selection kits for CD34, 
CD271 and MSCA-1 (TNAP), followed by flow cytometry analysis to analyse purity of 
populations (Ali et al., 2005; Esteve et al., 2015). The effect of levamisole may also be 
obscured in rat-derived MSCs, as a 5 x lower concentration of levamisole was used in 
comparison to that used on 3T3-L1 cells. We also suggest that the different responses in ALP 
activity to levamisole treatment observed between human adipocyte precursors (Ali et al., 
2013) where ALP activity increases, and the murine 3T3-L1 cells (Ali et al., 2005) and rat-
derived MSCs, where ALP activity decreased, may be the result of species-specific 
differences, as rat and mouse are more closely biologically related to one another than to 
humans. Levamisole also resulted in a slight decrease in TNAP mRNA levels during 
adipogenic induction of bmMSCs, while levamisole had no apparent effect on TNAP mRNA 
in scADSCs and pvADSCs 
 
Histidine did not inhibit mineralisation or ALP activity during osteogenic induction in 
bmMSCs, scADSCs and pvADSCs. The inability of histidine to inhibit ALP activity and 
consequentially mineralisation may be related to the observation that at pH 7.5, 
approximately the pH of cell culture media, the inhibitory effect of histidine on the hydrolysis 
of adenosine 5`-phosphate by ALP was negligible, while the inhibition of ALP activity by 
histidine was maximal at pH 9.5 (Bodansky and Schwartz, 1963). This may indicate that at 
physiological pH, the inhibitory effect of histidine at 10 mM on rat-derived TNAP during in 
vitro cell culture is low or nonexistent, which may explain the lack of inhibition of ALP 
activity or mineralisation by histidine. The lack of inhibition of TNAP by histidine may be 
due in some part to the sub-optimal conditions of the cell culture environment, such as lower 
pH, for histidine binding to TNAP.   
 
The mechanism by which histidine inhibits TNAP is described as mixed type, that is, the 
inhibitor may bind to the enzyme both when the substrate is bound and when it is not  
(Bodansky and Schwartz, 1963), however inhibition by histidine may possibly be 
uncompetitive (where the inhibitor is only able to bind to the enzyme when the substrate is 
also bound), due to the observation that other L-amino acids inhibit TNAP by this method 
(Kozlenkov et al., 2004). Inhibition assay data using cell lysates showed that histidine was 
the weakest of the three inhibitors examined here, and surprisingly, even increased ALP 
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activity in bmMSC control and adipogenic samples, but not osteogenic samples. TNAP 
mRNA expression data indicated that histidine increased TNAP mRNA levels compared to 
OM control in bmMSCs and scADSCs, but not in pvADSCs. In cells treated with AM, 
histidine resulted in an increase in TNAP mRNA levels compared to control AM in bmMSCs 
only. Although during osteogenic induction the substrate for TNAP is β-glycerophosphate, 
the primary substrate for TNAP is not known for cells undergoing adipogenic induction. It 
may be possible, as previously described for levamisole, that inhibition of TNAP by histidine 
causes the cells to compensate, by increasing synthesis of TNAP enzyme molecules. The 
increased amount of TNAP in the cells may then be enough to overcome the partial inhibition 
by histidine, allowing mineralisation to proceed, albeit at a slower rate. This appears to be 
confirmed by the observation that while the percentage mineralisation of bmMSC samples 
containing histidine lags behind OM control samples at days 5 and 7, the levels are 
approximately equal to OM control by day 10. The ALP activity levels of bmMSCs in the 
presence of histidine are found to increase over time in comparison to OM control, such that 
the increased enzyme activity in the presence of histidine was able to overcome the partial 
inhibition of TNAP by histidine. 
 
Similarly, in all three cell types, the combination of levamisole and histidine resulted in an 
increase in ALP activity, even though mineralisation was still completely inhibited, which 
may further indicate that a compensatory mechanism is occurring, as TNAP mRNA 
expression levels increased in the presence of histidine, in comparison to control OM, for 
bmMSCs and scADSCs, but was not observed in pvADSCs, where TNAP mRNA expression 
levels were lowest.  
 
Histidine treatment during adipogenic induction was able to decrease lipid accumulation in 
all three cell types, although this decrease was only statistically significant in bmMSCs. 
Histidine treatment resulted in a very slight increase in ALP activity in bmMSCs, and no 
apparent effect in scADSCs or pvADSCs. Previous research has found that histidine causes a 
significant decrease in lipid accumulation and in ALP activity in both 3T3-L1 cells and 
human preadipocytes (Ali et al., 2005; Ali et al., 2013). The discrepancy may be due to the 
lower concentration of histidine used in this study (10 mM) compared to the higher 
concentrations of 50 and 20 mM used on 3T3-L1 and human preadipocytes, respectively. 
However, due to the sensitivity of the rat-derived MSCs to histidine concentrations above 10 
mM, higher concentrations could not be used under the current experimental conditions. Due 
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to the observation that histidine is a weak inhibitor of TNAP in comparison to levamisole and 
L-homoarginine (Fig. 4.2.6.1), future studies on TNAP from rat-derived MSCs may wish to 
exclude this inhibitor, although the effect of histidine on adipogenesis is still of great interest.  
 
The combination of levamisole and histidine in bmMSCs undergoing adipogenic induction 
appeared to have an intermediate effect, as lipid accumulation and ALP activity decreased to 
levels between that observed for either inhibitor, indicating that levamisole and histidine have 
different effects to one another during adipogenic differentiation, and that levamisole may be 
able to partially rescue the inhibition of lipid accumulation by histidine. In scADSCs and 
pvADSCs, the combination of levamisole and histidine during adipogenic induction had no 
effect when compared to AM control, while histidine alone resulted in a small decrease in 
lipid accumulation, indicating that here again levamisole may be able to rescue the histidine-
induced decrease in lipid accumulation, which may be a consequence of depot specific 
differences between rat-derived MSCs from bone marrow and adipose tissue. It appears that 
under adipogenic conditions, levamisole decreases ALP activity, and enhances lipid 
accumulation; while histidine has the opposite effect in rat-derived MSCs. Histidine has been 
reported to have mixed inhibition towards TNAP, while levamisole has uncompetitive 
inhibition. Histidine may be more inhibitory towards TNAP as it is able to bind to TNAP 
both when the substrate is bound in the active site, as well as when no substrate is bound, 
while levamisole is only able to bind to TNAP when the substrate is bound at the active site. 
It is presently unclear how the presence of levamisole is able to rescue the inhibition of lipid 
accumulation by histidine.   
 
At the time of writing, we are aware of only one study that looked at the effects of L-
homoarginine on ALP activity of live cells in culture. In murine osteosarcoma (OS) cells, L-
homoarginine at 44.5 mM was able to inhibit the cellular proliferation, as measured by a 
reduction in [
3
H]thymidine uptake, to 9% of untreated controls at 24 hr, and 17% of untreated 
controls at 48hr. At 22.3 mM L-homoarginine, proliferation of OS cells was not affected at 
24 and 48 hr, but proliferation in long-term OS cell cultures was inhibited (Kikuchi et al., 
1982). No inhibition of proliferation was detected in rat MSCs incubated with 20 mM L-
homoarginine in the study presented here, in comparison to untreated controls in a short-term 
proliferation assay (Fig. 4.2.1.1). This is similar to the findings of Kikuchi et al. using OS 
cells treated with L-homoarginine at 22.3 mM for 25 and 48 hr, who reported no significant 
reduction in cell viability or proliferation during these time periods (Kikuchi et al., 1982). 
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Kikuchi et al. also reported that L-homoarginine at 11.2 mM was capable of inhibiting ALP 
activity substantially during ALP activity assay, consistent with the inhibition of ALP activity 
in rat MSCs in the presence of 10 mM L-homoarginine found here (Fig. 4.2.6.1) (Kikuchi et 
al., 1982). 
 
L-homoarginine, like histidine, was not able to block mineralisation or decrease ALP activity 
in bmMSCs undergoing osteogenic induction. In bmMSCs the percentage of mineralisation 
in the presence of L-homoarginine was similar to OM control at all time points sampled, 
unlike histidine which caused a lag in mineralisation compared to OM control samples. In 
scADSCs and pvADSCs however, L-homoarginine appeared to inhibit mineralisation. In 
bmMSCs, scADSCs and pvADSCs, the addition of L-homoarginine during osteogenic 
induction resulted in ALP activity that was noted to be similar to – or marginally higher than, 
OM control samples, and again this may be due to a compensation reaction by the cell to 
TNAP inhibition. Inhibition assay data indicated that L-homoarginine was a more potent 
inhibitor of ALP activity than histidine under assay conditions, which may explain why 
mineralisation as impaired in scADSCs and pvADSCs but not in bmMSCs, in the presence of 
L-homoarginine.   
 
 In the presence of histidine alone, an increase in mineralisation of scADSCs, and no effect 
on mineralisation of pvADSCs, in comparison to OM control was observed. L-homoarginine 
was able to block mineralisation in scADSCs and pvADSCs, however when L-homoarginine 
was in combination with histidine, mineralisation was similar to, or higher than control, 
respectively. In all three cell types the combination of histidine with L-homoarginine resulted 
in an increase in ALP activity, above levels observed for either histidine or L-homoarginine 
separately. This observation appears to confirm that L-homoarginine and histidine partially 
inhibit TNAP. L-homoarginine and histidine may also cause the cell to compensate by 
increasing TNAP synthesis, as TNAP mRNA levels were approximately equal to or higher 
than control levels in all three MSC cell types cultured in either OM or AM (Fig. 4.2.5.1).  
 
In the presence of levamisole, L-homoarginine blocked mineralisation in all cell types, with a 
variable effect on ALP activity. As levamisole or L-homoarginine alone had no discernible 
effect on ALP activity, it was expected that the combination of the two inhibitors would 
similarly have little effect on ALP activity. In line with expectations, the combination of 
levamisole and L-homoarginine resulted in only a slight increase in ALP activity in scADSCs 
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and pvADSCs, and unexpectedly, a decrease in ALP activity in bmMSCs, where levamisole 
and L-homoarginine separately had produced a slight increase in ALP activity. Levamisole 
and L-homoarginine cannot act simultaneously on TNAP, as a common amino acid residue 
binds them in the binding site pocket, with His-434 and Tyr-371 binding levamisole, while 
the residues at position 108 as well as Tyr-371 are necessary for L-homoarginine binding,  
and yet the effects of the two inhibitors have been found to be additive (Kozlenkov et al., 
2004). It is also known that levamisole is a more potent inhibitor than L-homoarginine, by 
nearly 100 times, and the higher potency of levamisole has been confirmed by enzyme assay 
data (Fig. 4.2.6.1) (Kozlenkov et al., 2004). Further work will be needed to confirm this 
result; however, this data may suggest depot-specific differences between MSCs derived 
from bone marrow and adipose tissue with regards to TNAP isozyme expression.  
 
L-homoarginine was able to significantly inhibit lipid accumulation across all cell types 
undergoing adipogenic induction, but surprisingly, decreased ALP activity compared to AM 
control in bmMSCs and increased ALP activity compared to AM control in scADSCs and 
pvADSCs. The combination of L-homoarginine with levamisole resulted in decreased lipid 
accumulation similar to that observed with L-homoarginine alone; along with increased ALP 
activity in scADSCs and pvADSCs, however no effect on ALP activity was observed in 
bmMSCs. This data may indicate that TNAP activity is linked to lipid accumulation during 
adipogenesis, and that differences exist between the isoform of TNAP present in bmMSCs 
and ADSCs, which leads to different effects of L-homoarginine and other inhibitors of TNAP 
in these cells. 
 
The combination of L-homoarginine with histidine showed the greatest reduction in lipid 
accumulation of all inhibitors and their combinations, in all three cell types. Similar to the 
combination of L-homoarginine with levamisole, the combination of L-homoarginine with 
histidine resulted in an increase, which was not statistically significant in all cases, in ALP 
activity in scADSCs and pvADSCs, and no apparent effect on ALP activity in bmMSCs. In 
each cell type the increased ALP activity for the combinations with L-homoarginine was 
higher than for L-homoarginine alone, with the highest activity mainly observed in 
combination with histidine. During adipogenic induction, an additive effect was observed 
between L-homoarginine and either histidine or levamisole, and a decrease in lipid 
accumulation and an increase in ALP activity is observed. These observations confirm that L-
homoarginine, levamisole and histidine have different effects to one another when applied to 
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live rat-derived MSCs, and these effects may be due to interactions of the inhibitors with 
TNAP, but may also be due to other currently unknown off-target effects.   
 
A major difficulty in interpreting the data lay in the biological variation detected between 
experimental batches, most notably being the large variation observed in ALP activity in 
scADSCs during osteogenic induction. Heterogeneity of MSCs cultured in vitro has been 
discussed and is a well-known feature of these cells (Section 3.3) with several precursor cell 
populations possibly present in the initial cultures. Ho et al. observed that slight variations in 
culture conditions may preferentially support the growth of certain subsets of the culture 
population, and this may result in genetic instability of the cell culture or malignant 
transformation (Ho et al., 2008). A study investigating the genomic stability of rat bmMSCs 
discovered a high degree of chromosome instability during in vitro culture in comparison to 
mouse and human MSCs, although the rat bmMSCs were still capable of differentiation into 
osteoblast, adipocyte and chondrocyte phenotypes (Foudah et al., 2009). Therefore, factors 
such as heterogeneity, minor variations in cell culture conditions between experiments, and 
possible chromosomal abnormality may have contributed to the observed biological 
variation. Together with biological variation, and low repeat number of between n=3 and n=5 
for each experiment makes it difficult to draw clear conclusions from the statistical analyses 
in all experiments. Thus, future work should include a higher number of repeats in order to 
firmly establish the current findings. 
 
 In addition to increased biological repeats, the effects of biological variation may be reduced 
by stricter selection criteria, which may involve the selection of surface markers in rat-
derived MSCs which identify cells that will reliably differentiate towards an adipogenic or 
osteogenic phenotype in vitro, as the current method of plastic adherence, while commonly 
used to select for MSC populations, is known to possibly result in heterogeneous cell 
populations (Bianco et al., 2008; Strioga et al., 2012). 
 
Bone marrow-derived MSCs cultured in OM had fully mineralised by day 10. In bmMSC 
samples where mineralisation had occurred, deposited mineral was prone to detach or wash 
off the culture surface during media changes, or during staining and sample preparation for 
the ALP assay. Therefore, later time points experience variations that are difficult to control 
for. For this reason, multiple time points are necessary for a more accurate assessment of the 
effect of inhibitors on osteogenic differentiation, and day 7 may give a more accurate 
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assessment in bmMSC samples. Similar behaviour between scADSCs and pvADSCs was 
observed during osteogenic induction, but as discussed previously, together had a far more 
limited capacity for mineralisation than bmMSCs (Wu et al., 2015). 
 
The ALP activity of control undifferentiated pvADSCs was markedly higher than the ALP 
activity of osteogenic differentiated pvADSC samples. Peri-renal visceral ADSCs also 
displayed the lowest levels of ALP activity and low levels of mineralisation. Subcutaneous 
ADSCs displayed a slightly higher percentage area of mineralisation at day 21, ALP activity 
levels and TNAP mRNA expression compared to pvADSCs; however, both were still far less 
than the levels observed in bmMSCs. We therefore put forward that rat-derived pvADSCs 
and scADSCs are a less efficient model for in vitro osteogenesis in comparison to bmMSCs; 
however, the in vivo osteogenesis of scADSCs and pvADSCs compared to bmMSCs should 
be ideally investigated. This data also highlights the need to screen various depots for 
suitability if cells are going to be used for bone tissue engineering, due to existing depot 
specific differences.  
 
Interestingly, while treatment with the various inhibitors and their combinations during both 
osteogenic or adipogenic induction resulted in similar effects across the three rat-derived 
MSCs with regards to either mineralisation or lipid accumulation percentage, differences 
were noted in mainly between the bmMSCs and the ADSCs (scADSCs and pvADSCs) 
regarding ALP activity. Noticeably, under adipogenic conditions, histidine and L-
homoarginine, alone or in combination with one another and levamisole, produced an 
opposite response in either bmMSCs or ADSCs. This may indicate that the TNAP isozyme 
present in bmMSCs and ADSCs undergoing adipogenic induction may be different 
depending on the tissue depot from where the cells were isolated. The existence of 
differences between TNAP isoforms from bone, liver and kidney is well established, and 
various TNAP bone isoforms have also been discovered (Halling Linder et al., 2009). 
Therefore, it may be possible that differences observed between cell types under the same 
conditions are due to the expression of different TNAP isoforms intrinsic to these cell types. 
ALP activity was found to vary between MSCs from the same depot, in the presence of the 
same inhibitors, depending on whether the cells were undergoing adipogenic or osteogenic 
induction, which may also indicate that different isoforms of TNAP may be expressed in 
MSCs from the same source, depending on whether the cells are induced to differentiate 
towards either an osteogenic or adipogenic phenotype. This conclusion may be verified by 
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investigating whether TNAP enzymes isolated from cells from a single MSC source, when 
undergoing adipogenic and osteogenic differentiation, had differing glycosylation patterns 
which would indicate the existence of different TNAP isoforms.  
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CHAPTER 5 
Sub-cellular localisation and characterisation of 
tissue-nonspecific alkaline phosphatase 
(TNAP) transcript and glycosylation 
differences, as well as knockdown of TNAP in 
rat-derived mesenchymal stromal cells 
(MSCs) undergoing differentiation. 
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5.1 Introduction  
That alkaline phosphatase (ALP) is present in adipose tissue and adipocyte precursors from 
various species, including human and rat, has been known for many years (Wallach and Ko, 
1964; Okochi et al., 1987; Bianco et al., 1988). The ALP expressed in adipose tissue has 
been identified as TNAP, and while the role of TNAP in mineralisation and its presence in 
osteoblasts and osteoblast progenitors is well known, the function of TNAP in adipocytes and 
adipocyte progenitors is less well established (Ali et al., 2005; Ali et al., 2013). Much work 
remains to elucidate the function of TNAP in adipocytes, as well as other cell types where 
TNAP is expressed.  
 
In osteoblasts, TNAP is known to be an ectoenzyme, attached to the outer layer of the plasma 
membrane of cells or vesicles by GPI anchors (Millán et al., 2006). The presence of ALP has 
been detected in rat adipose tissue as early as 1964 (Wallach and Ko, 1964) as well as in 
adipocytes found in human bone marrow (Bianco et al., 1988). Kodama et al. identified ALP 
activity in mouse bone marrow-derived fibroblasts, converted to adipocytes in vitro (Kodama 
et al., 1983). A later study using the murine preadipocyte cell line, 3T3-L1, found that ALP 
activity was exclusively present on the lipid droplet membrane, while no ALP activity was 
detected on the plasma membrane after these cells were induced towards adipogenesis. The 
same study proposed that ALP on the lipid droplet membrane would be involved with either 
altering the phosphorylation state of other proteins and enzymes anchored to the lipid droplet 
membrane, or in the hydrolysis of ATP, as TNAP is known to have adenosine triphosphatase 
(ATPase) activity (Ali et al., 2005). Ali et al. identified the ALP in differentiated 3T3-L1 
cells as TNAP, as the ALP activity in these cells was only inhibited in the presence of the 
TNAP-specific inhibitors levamisole and histidine, and not the tissue-specific ALP inhibitor, 
Phe-Gly-Gly (Ali et al., 2005). We hypothesized that the subcellular location of TNAP 
present in primary rat-derived MSCs differentiated towards adipocytic phenotype in vitro 
would also be on the surface of the lipid droplet membrane, similar to that found in 3T3-L1 
cells (Ali et al., 2005; Ali et al., 2013).  
 
Several isoforms of TNAP exist, and are preferentially expressed in various tissues such as 
bone, liver and kidney. These isoforms consist of the same primary amino acid sequence, but 
differ to one another based on various posttranslational modifications, in the form of N- and 
O-linked glycosylations (Nosjean et al., 1997). Differences in glycosylation pattern are 
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thought to be the main factor contributing to the differences that exist between the various 
TNAP isoforms (Nosjean et al., 1997; Millán et al., 2006). Initially, it was thought there was 
one TNAP isoform specific to each tissue, however it appears that further variations exist 
within each tissue-specific TNAP isoform, as four different bone-specific TNAP isoforms 
have been discovered in humans (Halling Linder et al., 2009) along with several liver-
specific TNAP isoforms in rat (Dziedziejko et al., 2005). The glycosylation pattern of the 
TNAP present in adipocytes is to the best of our knowledge, currently unknown, and an 
understanding of this may help to further establish the function of TNAP in adipose tissue.  
 
The TNAP gene in rats, designated Alp1,  is found on a single locus, and consists of 13 exons 
– 11 protein-coding exons and 2 non-coding exons in the 5’-untranslated region (UTR), 
designated as 1a or 1b, with each having different promoter regions (Toh et al., 1989a). The 
mature TNAP mRNA therefore consists of 11 coding exons, and either exon 1a or 1b, which 
are incorporated into the mRNA sequence via alternative transcription initiation (Toh et al., 
1989b; Brun-Heath et al., 2011). In bone, transcription is preferably initiated with the 1a 
exon, while in liver and kidney the 1b exon is preferred. In rat liver, it has been found that 
both bone and liver TNAP mRNA transcripts are present, with the bone transcript 
predominating (Brun-Heath et al., 2011). It is currently unclear as to which TNAP mRNA 
transcript is preferentially expressed in rat-derived MSCs from bone-marrow (bmMSCs,), 
subcutaneous adipose (scADSCs) and peri-renal visceral adipose (pvADSCs) depots, when 
differentiated towards an adipogenic phenotype. Brun-Heath et al. were able to amplify both 
rat TNAP mRNA transcripts by designing forward PCR primers specific for either the 1A or 
1B exon, which allowed them to determine which exon was preferentially expressed in rat 
brain tissue (Brun-Heath et al., 2011). We have used the same primers designed by Brun-
Heath et al. to amplify a reverse transcribed TNAP cDNA sequence from rat-derived 
bmMSCs, scADSCs and pvADSCs, which were differentiated towards either an osteogenic 
or adipogenic phenotype.  Conventional PCR amplification of  the TNAP cDNA using the 
primers specific for either bone or liver-type TNAP transcripts was performed in order to 
determine the leader exon preferentially expressed in these cells, as well as to determine 
whether the leader exon usage changes when cells are differentiated between an osteogenic or 
adipogenic phenotype.  
 
RNA interference (RNAi) is a process used naturally by cells to regulate the expression of 
targeted mRNA molecules, and is used as a cellular mechanism to protect the genome from 
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aberrant or harmful RNA resulting from viral infections or transposons. It may also be a 
mechanism for regulating post-transcriptional gene expression. RNAi involves the cleavage 
of double-stranded RNA (dsRNA) by the enzyme Dicer, into dsRNA of approximately 21 to 
23 nucleotides in length, with 3′ overhangs of 1 to 2 nucleotides, which are termed short 
interfering RNA (siRNA). Double-stranded RNA may be exogenous, in the form of viral 
RNA or introduced into the cell in the laboratory, or it may be endogenous, in the form of 
microRNA (miRNA) or certain types of transposable elements. Double-stranded RNA 
produced endogenously is formed from stem-loop structures which are further processed into 
dsRNA by Dicer. The double-stranded siRNA molecules bind to Argonaute proteins, where 
the dsRNA is denatured into single-strands, with the antisense strand, also known as the 
guide strand, remaining bound to the Argonaute protein, now known as the RNA-induced 
silencing complex (RISC), while the remaining sense strand, also known as the passenger 
strand, is degraded by the RISC complex. This complex is then targeted to a region on the 
native mRNA molecule complementary to the antisense RNA strand in the RISC. Once the 
RISC binds to the complementary region of the mRNA target, the enzyme Argonaute, which 
is part of the RISC, degrades the mRNA, thus preventing translation of the mRNA and 
effectively silencing gene expression. If the guide strand incorporated into the RISC is not 
completely complementary to the target mRNA molecule to which it is bound, the RISC 
cannot degrade the target mRNA and translation is only repressed instead of silenced (Tuschl 
et al., 1999; Elbashir et al., 2001; Nakanishi, 2016). 
 
RNAi has been utilised as a way to study gene function; by delivering exogenous double-
stranded siRNA molecules specific to a target gene within a cell, the target gene is silenced 
by the endogenous RNAi silencing system and the effects of gene knockdown on the cell can 
be analysed (Moore et al., 2010). Cells may be transfected with siRNA molecules, using 
either reagent- or instrument-based methods, however many cell types are resistant to 
transfection, or have low transfection efficiency (Luft and Ketteler, 2015). siRNA transfected 
into the cell cytoplasm has only transient effects, and is therefore often only useful for short 
term, in vitro studies (Moore et al., 2010).  
 
Another technique which makes use of the RNAi mechanism involves the introduction into 
the cell of short hairpin RNAs (shRNAs), and usually mediated by infection with viral or 
plasmid vectors. In order to produce the shRNA, a DNA sequence is inserted into the vector 
consisting of two complementary strands of DNA of approximately 20 nucleotides in length, 
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connected to one another by a short stretch of four to eleven nucleotides, which when 
expressed will produce the shRNA molecule (Moore et al., 2010).  The vector construct is 
delivered into the cell either by transfection, in the case of plasmids, or by infection of the 
cell with the viral vectors containing the construct. The viral-mediated transfection is also 
known as transduction.  Once inside the cell, the construct DNA is stably integrated into the 
host cell genome, leading to transcription of the encoded shRNA molecule. Once transcribed, 
the shRNA sequence forms the dsRNA hairpin structure, due to the inbuilt complementarity 
of the sequence. The double-stranded shRNA is recognized by the enzyme Dicer, which 
cleaves off the interconnecting nucleotides to form a siRNA molecule. The siRNA produced 
from the cleavage of the shRNA is then bound to an Argonaute protein, leading to formation 
of the RISC complex, and to the degradation of the target mRNA (Moore et al., 2010). This 
allows for a stable long-term knockdown of the target mRNA, as opposed to short-term 
knockdown which results from transfection of the cell directly with siRNA molecules.   
 
As TNAP in adipocytes is thought to play a role in lipid accumulation, reducing the levels of 
TNAP expression during adipogenic induction by RNAi should produce a concomitant 
reduction in lipid droplet formation. Transduction of MSCs with shRNA targeting TNAP 
mRNA should allow for a stable knock-down of TNAP expression, and test the hypothesis 
that TNAP is involved in lipid accumulation.  
 
The aim of this chapter was to further characterise the expression of alkaline phosphatase 
(ALP) in rat-derived MSCs, in particular when these cells were differentiated towards an 
adipogenic phenotype. The sub-cellular localisation of TNAP in bmMSCs, scADSCs and 
pvADSCs differentiated towards an adipogenic phenotype was investigated using confocal 
microscopy and the endogenous phosphate substrate ELF-97, in order to visualise ALP 
activity within the cell. PCR amplification was used to determine whether the bone- or liver-
specific TNAP mRNA transcript is present in bmMSCs, scADSCs and pvADSCs when 
differentiated towards either an osteogenic or adipogenic phenotype. Differences in 
glycosylation between the ALP molecules from undifferentiated bmMSCs or those 
differentiated towards either an osteogenic or adipogenic phenotype was investigated and 
compared to the ALP from scADSCs differentiated towards an adipogenic phenotype, by 
means of agarose electrophoresis in the presence of wheat germ lectin (WGL), which binds 
selectively to sialic acid residues. As the bone-specific TNAP isoform is known to have the 
highest degree of sialation of the various ALP isozymes, WGL is able to bind preferentially 
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to this isozyme, allowing it to be identified. Finally, we attempted to knock-down TNAP 
expression by transduction of scADSCs with shRNA molecules targeting TNAP mRNA, and 
assessed the levels of lipid accumulation and TNAP mRNA during adipogenic differentiation 
of these cells.   
 
5.2 Results  
5.2.1 Subcellular localisation of ALP activity in rat-derived MSCs 
undergoing adipogenesis. 
It was hypothesized that the TNAP present in adipocytes is localised on the lipid droplet 
membrane, where it may play a role in lipid transport. A suitable anti-TNAP antibody to 
detect the presence of TNAP within adipogenically induced cells is not currently 
commercially available; therefore ALP activity in the cell was measured using a fluorescent 
substrate for ALP. The subcellular localisation of ALP in bmMSCs, scADSCs and pvADSCs 
was investigated using the endogenous phosphatase substrate, ELF-97, where cells were also 
immunolabelled for Perilipin A, a protein associated with the lipid droplet membrane. 
Labelling with Perilipin A allows the lipid droplet membrane to be easily identified, and 
provides a frame of reference when looking at the location of ALP activity.  According to the 
hypothesis that TNAP within lipid-containing cells is localised to the lipid droplet membrane, 
as seen in 3T3-L1 cells (Ali et al., 2005), the fluorescent signal resulting from the cleavage of 
the ELF-97 substrate by ALP enzyme activity was expected to localise in the same area as  
perilipin A.  
 
Cells were fixed and labelled with the perilipin A primary antibody, and the signal (red) 
detected using Alexa Fluor 594 conjugated goat anti-rabbit secondary antibody, as previously 
described (Section 2.2.13.1). Perilipin A was positively detected in bmMSCs, scADSCs and 
pvADSCs undergoing adipogenic induction, where perilipin A staining corresponded with 
the outline of lipid droplets visible in phase contrast images. Perilipin A appeared to be more 
strongly detected in scADSCs and pvADSCs in comparison to bmMSCs (Fig. 5.2.2.1, 5.2.1.2 
and 5.2.1.3). Cells that contained lipid droplets, or were in the process of forming lipid 
droplets, were observed to have the most positive perilipin A signal, with cells that did not 
have any visible lipid droplets having little to no perilipin A signal. Primary antibody 
controls, which were stained with only the secondary antibody and ELF-97, yielded faint 
nonspecific background staining (Fig. 5.2.1.4 K – O). 
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The ELF-97 fluorescent signal appeared as small bright yellow/green dots, indicating the 
position of ALP activity. ELF-97 signal was observed in bmMSCs, scADSCs and pvADSCs, 
but most abundantly in bmMSCs. ELF-97 signal was observed most strongly in association 
with perilipin A staining, where it appeared to be associated with the surface of the lipid 
droplet in all cell types. In bmMSCs, ELF-97 signal was also observed within the cell 
cytoplasm, although the signal here was less bright than the ELF-97 signal associated with 
lipid droplets. Interestingly, ELF-97 signal was not uniformly present across all lipid droplet-
containing cells, but appeared to be more abundant on some cells and on some lipid droplets 
compared to others, appearing as distinct, bright green points in the location of the lipid 
droplet membrane. The outer cell plasma membrane was not stained for visualisation; 
therefore the presence of ELF-97 signal at this region could not be defined, however, in 
scADSCs and pvADSCs, ELF-97 signal was not observed apart from surrounding lipid 
droplets.     
 
As a negative control for ELF-97, the TNAP-specific inhibitor, levamisole, was included 
during the incubation with the ELF-97 substrate, resulting in a near total reduction in ELF-97 
signal within this sample (Fig. 5.2.1.4 A – E). An additional negative control, from which 
ELF-97 substrate was excluded, resulted in no ELF-97 signal detected, indicating that the 
positive signal observed was not the result of background staining (Fig. 5.2.1.4 F – J)
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Figure 5.2.1.1: Confocal microscopy images of bmMSCs after 14 days of adipogenic induction, showing lipid droplets  and staining with ELF-97 and perilipin 
ASingle and merged images for each channel are shown. Single channels for  ELF-97 (yellow) (A), and Perilipin A (red) (B), and phase contrast (D) are shown, while 
panel (C) is a merged image of (A) and (B), (E) is merged channel D and A and panel F is merged image of panels A, B and D. Magnification x60. 
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Figure 5.2.1.2: Confocal microscopy images of scADSCs after 5 days of adipogenic induction, showing lipid droplets and staining with ELF-97 and perilipin A. 
Single and merged images for each channel are shown. Single channels for  ELF-97 (yellow) (A), and Perilipin A (red) (B), and phase contrast (D) are shown, while panel 
(C) is a merged image of (A) and (B), (E) is merged channel D and A and panel F is merged image of panels A, B and D. Magnification x60. 
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Figure 5.2.1.3: Confocal microscopy images of pvADSCs after 5 days of adipogenic induction, showing lipid droplets and staining with ELF-97 and perilipin A. 
Single and merged images for each channel are shown. Single channels for  ELF-97 (yellow) (A), and Perilipin A (red) (B), and phase contrast (D) are shown, while panel 
(C) is a merged image of (A) and (B), (E) is merged channel D and A and panel F is merged image of panels A, B and D. Magnification x60. 
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Figure 5.2.1.4: Control samples for ELF-97 and perilipin A staining. Panel A – E, ELF-97+ and perilipin A primary and secondary antibody staining in the presence of the 
TNAP inhibitor, levamisole; F – J, perilipin A staining, and ELF-97-  control; K – O, ELF-97+ and primary antibody control.  Magnification x60. 
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5.2.2 Identification of the TNAP mRNA transcripts expressed in bmMSC, 
scADSC and pvADSCs 
Either the 1A or 1B untranslated leader exons are preferred in TNAP mRNA transcripts from 
cells of different tissues. TNAP mRNA molecules containing exon 1A are preferentially 
transcribed in osteoblasts, as well as in neural tissue, and is designated as bone-type TNAP 
mRNA, while the 1B exon has been found in TNAP mRNA transcripts from liver tissue, and 
is designated as liver-type TNAP mRNA (Brun-Heath et al., 2011). To the best of our 
knowledge, no information is available for which exon, 1A or 1B, is preferably incorporated 
into the TNAP mRNA from rat-derived MSCs when differentiated into an adipogenic 
phenotype. Using PCR primer sets specific for either bone- or liver-type TNAP mRNA, we 
attempted to determine the preferred TNAP mRNA type using cDNA isolated from rat-
derived MSCs, which had been treated with OM or AM.      
 
PCR primers were synthesized using previously published sequences for forward primers 
specific for regions on either the bone- or liver-specific non-coding exons, as well as a single 
reverse primer corresponding to a coding region on TNAP mRNA, which would be common 
to all TNAP mRNA sequences (Brun-Heath et al., 2011). These primer sequences were used 
as query sequences in a database search, and two separate entries for rat TNAP mRNA 
sequences were identified, with accession numbers, NM_013059.1 and XM_006239136.2, 
which were identified as the bone and liver mRNA isoforms, respectively. A sequence 
alignment was constructed using the two identified TNAP mRNA sequences (Addendum C, 
Fig. C1) in order to determine the non-coding exon/coding exon boundary, as well as to 
confirm that the forward primers did indeed correspond to regions which were not common 
to both bone and liver mRNA transcripts.  
 
The expected lengths of the bone and liver amplicons were 1595 bp and 1607 bp, 
respectively. Amplification of TNAP from bmMSCs using the bone isoform-specific primers 
yielded a band at approximately 1600 bp, which corresponded to the expected length of the 
product, in adipogenic samples from three separate animals (n=3) (Fig. 5.2.2.1, lane 5 – 7), 
while a band corresponding to the expected size was detected in only one osteogenic sample 
(Fig. 5.2.2.1, lane 2 – 4). Rat liver RNA was isolated and reverse transcribed into cDNA for 
use as a positive control for the detection of the liver transcript in mRNA isolated from rat-
derived MSCs. As predicted, the amplification of rat liver cDNA with the bone type-specific 
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primer set did not produce any bands (Fig. 5.2.2.1, lane 8). Multiple non-specific bands were 
observed in all test samples, which could not be resolved by adjusting PCR conditions 
(Addendum C, Fig C2). A control reaction using the bmMSC OM sample 1 as template, 
which came up as positive for TNAP when used as the template in the presence of bone 
forward and reverse primers in lane 2, along with only the forward primer resulted in the 
detection of several bands (Fig. 5.2.2.1, lane 9), indicating that the forward primer was able 
to act as a forward and reverse primer, allowing for the formation of nonspecific products, 
whereas the reverse primer alone did not have this effect (Fig. 5.2.2.1, lane 10). Bone 
marrow-derived MSC OM sample 1 was used as a positive control for subsequent PCR 
amplifications using the bone-type primer set with either scADSC or pvADSC samples, 
because although nonspecific bands were present in this sample, a band at the predicted size 
for the bone-type transcript was present.   
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Figure 5.2.2.1: PCR amplification of bone-type TNAP cDNA in bmMSCs differentiated towards an (OM) 
osteogenic or adipogenic (AM) phenotype. Lane 1 and 13, molecular size marker (NEB, 1kb DNA ladder); 
lanes 2 – 4, bmMSC OM samples 1 – 3; lanes 5 – 7, bmMSC AM samples 1 – 3; lane 8, rat liver cDNA; lane 9, 
bmMSC OM sample 1 with forward primer only; lane 10, bmMSC OM sample 1 with reverse primer only; lane 
11, no cDNA control; lane 12, no cDNA control with forward primer only.    
 
 
Figure 5.2.2.2: Amplification of the liver-type TNAP cDNA in bmMSCs differentiated towards either an 
osteogenic (OM) or adipogenic (AM) phenotype. Lanes 1 and 10, molecular size marker (NEB, 1kb DNA 
ladder); lanes 2 – 4, bmMSC OM samples 1 – 3; lanes 5 – 7, bmMSC AM samples 1 – 3; lane 8, rat liver 
cDNA; lane 9, no cDNA control.  
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Neither adipogenic nor osteogenic bmMSC samples produced any bands when template was 
amplified using the TNAP liver isoform-specific PCR primer set. A single non-specific band 
was observed in adipogenic sample 3, while no other bands were detected in any other test 
samples (Fig.5.2.2.2). A single band of the expected size was observed in the rat liver cDNA 
sample, which served as a positive control (Fig. 5.2.2.2, lane 8).    
 
 
Figure 5.2.2.3: Amplification of bone-type TNAP cDNA in scADSCs differentiated towards either an 
osteogenic (OM) or adipogenic (AM) phenotype. Lanes 1 and 10, molecular weight marker (NEB, 1kb DNA 
ladder); lane 2; bmMSC OM sample 1; lane 3 – 5, scADSC OM samples 1 – 3; lanes 6 – 8, scADSC AM 
samples 1 – 3; lane 9, no cDNA control.  
 
The amplification of the bone-type transcript of TNAP was performed in scADSCs 
differentiated towards either an osteogenic or adipogenic phenotype. Similar to bmMSCs, a 
band at the expected size was amplified in all three adipogenic samples (Fig. 5.2.2.3, lane 6 – 
8) and only one osteogenic sample (Fig. 5.2.2.3, lane 3 – 5). Nonspecific bands were also 
detected with this bone isoform primer set, however these bands were fewer in comparison to 
those observed in the bmMSC samples.  
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Figure 5.2.2.4 Amplification of the liver-type TNAP cDNA in scADSCs differentiated towards either an 
osteogenic (OM) or adipogenic (AM) phenotype. Lanes 1 and 10, molecular weight marker (NEB, 1kb DNA 
ladder); lane 2, rat liver cDNA; lane 3 – 5, scADSC OM; lanes 6 – 8, scADSC AM; lane 9, no cDNA control.  
 
The liver isoform primer set was not able to amplify any bands in the scADSC samples 
differentiated into an osteogenic phenotype, however a single band of the expected product 
size was observed in scADSC adipogenic sample 1 (Fig. 5.2.2.4, lane 6), which may have 
been due to contamination as it was not reproducible in subsequent PCR reactions.  
 
Stellenbosch University  https://scholar.sun.ac.za
 164 
 
 
Figure 5.2.2.5: Amplification of the bone-type TNAP cDNA in pvADSCs differentiated towards either an 
osteogenic (OM) or adipogenic (AM) phenotype. Lanes 1 and 10, molecular weight marker (NEB, 1kb DNA 
ladder); lane 2; bmMSC OM; lane 3 – 5, pvADSC OM samples 1 – 3; lanes 6 – 8, pvADSC AM samples 1 – 3; 
lane 9, no cDNA control.  
 
PCR amplification using both the bone and liver isoform PCR primer sets with pvADSC 
samples did not yield any bands at the expected sizes (Fig. 5.2.2.5 and Fig 5.2.2.6).  
Nonspecific faint bands were observed for pvADSC osteogenic sample 1 and adipogenic 
sample 2 with the bone isoform primer set (Fig. 5.2.2.5, lane 3 and 8).  
 
Due to the multiple nonspecific bands observed with the bone-type primers, it was deemed 
necessary to confirm the identity of the band located at the expected size for the product 
amplified using this primer set. The band corresponding to the expected product size for 
bmMSC adipogenic sample 1 was excised, sequenced and used as a query sequence for a 
database search. The database search aligned the sequenced fragment to a region on to the 
published rat Alpl gene sequence NM_013059.1, confirming the identity of the product as 
TNAP (Addendum C, Fig. C3).  
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Figure 5.2.2.6: Amplification of the liver-type TNAP cDNA in pvADSCs differentiated towards either an 
osteogenic (OM) or adipogenic (AM) phenotype. Lanes 1 and 10, molecular weight marker (NEB, 1kb DNA 
ladder); lane 2, rat liver cDNA; lane 3 – 5, pvADSC OM samples 1 – 3; lanes 6 – 8, pvADSC AM samples 1 – 
3; lane 9, no cDNA control.  
 
5.2.3 Analysis of the glycosylation pattern of TNAP from bmMSCs and 
scADSCs differentiated towards an adipogenic or osteogenic phenotype.  
Isoforms of TNAP, which all have the same primary amino acid sequence, are differentiated 
from one another by the amount and type of post-translational modifications, in the form of 
O- and N-linked glycosylations, which are present. The glycosylations present are 
responsible for the variation in the properties of the TNAP isoforms, such as heat stability 
and sensitivity to various inhibitors, as well as differences in electrophoretic migration and 
sensitivity to neuraminidase (Nosjean et al., 1997; Dziedziejko et al., 2005). The 
glycosylation pattern of the TNAP isoform present in rat-derived MSCs differentiated 
towards an adipogenic phenotype is unknown. Glycosylation differences between the various 
isozymes of ALP may be detected by agarose electrophoresis, as electrophoretic mobility is 
directly related to the molecular weight, which is altered by the amount of glycosylation of 
the enzyme. Once the enzymes have been subjected to electrophoresis, detection is achieved 
via the cleavage of a substrate by ALP enzyme activity to yield a coloured product in this 
zymogram.       
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Serum was collected from male Wistar rats (150 g) for use as a control, as serum ALP in rats 
is known to contain bone and intestinal ALP isoforms (Dziedziejko et al., 2005). Total cell 
ALP was prepared from bmMSCs, scADSCs and pvADSCs that were induced towards either 
adipogenic or osteogenic differentiation, as well as from undifferentiated naïve cells, as 
previously described (Section 2.2.4.1). In order for adequate detection within the zymogram, 
an activity of 150 mU/ml for ALP was required, a level which could not be achieved using 
the available ALP extraction method for either scADSCs or pvADSCs, treated with either 
AM, OM or naïve undifferentiated cells, with the exception of scADSCs treated with AM. 
Crude total cell lysates of bmMSCs contained sufficient ALP activity for glycosylation 
analysis to be performed, and therefore only the crude total cell lysates were used for 
glycosylation analysis of bmMSC samples of AM or OM treated, as well as naïve 
undifferentiated cells. Normal human serum was used as a running control for 
electrophoresis.  
 
Rat serum ALP was separated into bands which were identified as either bone or intestinal 
ALP, as well as a third band which may be the slow migratory (SM) band identified by 
Dziedziejko et al. (Fig. 5.2.3.1, A). In agreement with earlier reports, the bone ALP band 
appeared diffuse, while the intestinal ALP band was the most dominant band observed 
(Dziedziejko et al., 2005). The addition of wheat germ lectin (WGL) to the sample resulted in 
the precipitation of the bone ALP isoform at the anode, while the intestinal ALP isoform was 
not affected. Precipitation of the bone ALP isoform, but not the intestinal ALP isoform, with 
WGL has been previously reported (Dziedziejko et al., 2005).  Human serum was used as a 
control for the reaction, and showed a similar precipitation of the bone isoform in the 
presence of WGL, however the banding pattern between human and rat differs markedly, as 
previously found (Dziedziejko et al., 2005). 
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Figure 5.2.3.1:  Separation of the isozymes of serum and tissue-derived alkaline phosphatase (ALP) by 
lectin affinity electrophoresis. ALP isozymes were separated by wheat germ lectin (WGL) affinity on an 
alkaline buffered (pH 9.1) agarose (10 g/L) gel (Hydragel 7 ISO-PAL® kit, Hydrasys® electrophoresis system, 
Sebia, France). Samples were run, in the absence and presence of WGL, in adjacent wells. WGL-treated 
samples are denoted with an inverted comma. Panel A: lanes 1 and 2, human serum; lanes 3 and 4, rat 1 serum; 
lane 5 and 6, rat 2 serum; lane 7, human serum control (WGL absent). Panel B: lanes 1 and 2, ALP extract from 
scADSCs differentiated for 5 days in adipogenic medium (AM); lanes 3 and 4, whole cell lysate prepared from 
naïve undifferentiated bmMSCs at P3; lane 5, human serum control (WGL absent). Bands identified as the bone, 
intestinal and slow migratory (SM) ALP isozymes are labelled on panel A and B. Direction of migration is from 
anode to cathode.  
 
 
The ALP detected in adipogenically differentiated scADSCs ran further on the gel in 
comparison to undifferentiatied bmMSCs, while both were found to contain the bone ALP 
isoform, as this was precipitated in the presence of WGL (Fig. 5.2.3.1, B). Both 
adipogenically differentiated scADSCs and undifferentiated bmMSCs produced a band that 
remained after the precipitation of the bone ALP, which differed to one another in migration 
distance. It was unclear whether either of these bands could correspond to intestinal ALP, as 
rat serum and cell lysate ALP samples were run on different gels.  
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Lysate from both undifferentiated and osteogenically differentiated bmMSCs produced a 
single band which appeared to run similar distances to one another on the gel, and both also 
produced a band of precipitated ALP in the presence of WGL (Fig. 5.2.3.2 A). A single band 
was detected for lysates of adipogenically differentiated bmMSCs, which appeared to run a 
slightly shorter distance, in comparison to both undifferentiated and osteogenic bmMSC 
lysate samples. Interestingly, a band of precipitated ALP was not detected in the presence of 
WGL for the adipogenic bmMSC lysate samples (Fig. 5.2.3.2, A, lane 4 and B, lane 2). The 
quantity of ALP activity in the first adipogenic sample (Fig. 5.2.3.2 A, lanes 3 and 4) 
appeared to be low, which may have prevented a precipitation band from being visible (Fig. 
5.2.3.2 A, lane 4); however, the quantity of the adipogenic sample in the second gel was 
higher (Fig. 5.2.3.2 B, lanes 1 and 3), and no precipitated ALP band was visible here either. 
The ALP activity of the osteogenic bmMSC lysate sample in the second gel (Fig. 5.2.3.2 B, 
lanes 2 and 4) appeared markedly lower than the activity of the osteogenic sample in the first 
gel (Fig. 5.2.3.2 A, lanes 5 and 6), which may have resulted from an insufficient quantity of 
precipitated ALP in the presence of WGL to form a detectable band. In both gels however, 
the adipogenic samples migrated a shorter distance than the osteogenic or undifferentiated 
samples, which may indicate that the ALP from rat-derived bmMSCs, which have been 
differentiated towards an adipogenic phenotype, is differently glycosylated to either naïve 
undifferentiated or osteogenic differentiated bmMSCs.  
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Figure 5.2.3.2: Separation of alkaline phosphatase (ALP) from rat-derived bmMSC lysates by lectin 
affinity electrophoresis. ALP isozymes were separated by wheat germ lectin (WGL) affinity on an alkaline 
buffered (pH 9.1) agarose (10 g/L) gel (Hydragel 7 ISO-PAL® kit, Hydrasys® electrophoresis system, Sebia, 
France). Samples in panel A were run, in the absence and presence of WGL, in adjacent wells. WGL-treated 
samples are denoted with an inverted comma. Panel A: lanes 1 and 2, undifferentiated naïve bmMSC; lanes 3 
and 4, bmMSCs cultured in adipogenic differentiation medium (AM) for 14 days; lanes 5 and 6, bmMSCs 
cultured in osteogenic differentiation medium (OM) for 5 days; lane 7, human serum (WGL absent).  Panel B, 
bmMSCs cultured in AM for 14 days, WGL present (lane 1) and WGL absent (lane 3); bmMSCs cultured in 
OM for 5 days, WGL absent (lane 2) and WGL present (lane 4); lane 5, human serum control (WGL absent). 
Direction of migration is from anode to cathode.  
 
 
5.2.4 Knockdown of TNAP by shRNA interference.  
To determine whether knockdown of TNAP would induce a reduction in lipid accumulation, 
scADSCs were transduced with TNAP shRNA lentiviral vectors and subsequently induced to 
differentiate towards an adipogenic phenotype. Subcutaneous ADSCs (n=4) were transduced 
with control or TNAP shRNA lentiviral vectors at P1, and induced to differentiate after 
confluence was reached at P2. Cells were harvested after 5 days of culture in AM and either 
stained with Oil Red O or RNA was collected for analysis of TNAP gene expression.  
 
Transduction with shRNA and puromycin selection resulted in an increased duration of four 
days from seeding at P2 until confluence was reached, when compared to non-transduced 
control cells. Cells transduced with either control or TNAP shRNA did not appear to increase 
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in cell density after splitting and reseeding, and sparsely populated areas could still be 
observed amongst areas of higher cell density, in contrast to non-transduced control cells 
which appeared as a densely packed uniform lawn of cells by day two post confluence (Fig. 
5.2.4.1). Induction of differentiation resulted in a marked decrease in lipid accumulation in 
both control shRNA and TNAP shRNA samples in comparison to that observed in non-
transduced controls (Fig. 5.2.4.2). The decrease in lipid accumulation at day 5 in cells 
transduced with shRNA was accompanied by a decrease in overall cell number in comparison 
to non-transduced control cells. These observations indicated that the decrease observed was 
not due to the shRNA mediated knockdown of TNAP, but that the decrease was due to the 
effect of transduction and subsequent puromycin selection. The decreased viability of 
transduced cells in comparison to non-transduced control cells, which resulted in large 
sparsely populated areas on the culture surface precluded efforts to quantify lipid 
accumulation using image analysis.  
 
TNAP mRNA expression appeared to be lower in both undifferentiated and differentiated 
samples for cells transduced with TNAP shRNA compared to control shRNA (Fig 5.2.4.3), 
although this was not statistically significant.   
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Figure 5.2.4.1: Light microscopy images of control non-transduced, control shRNA and TNAP shRNA 
scADSCs at day 2 post confluence. Control non-transduced scADSCs (A), as well as scADSCs transduced with 
either control shRNA (B) or TNAP shRNA (C) at P1, were cultured in standard growth medium (SGM) until 2 
days post confluence was reached at P2, in preparation for adipogenic induction. Images were acquired 
immediately prior to initiation of adipogenic differentiation. Images were acquired using an Olympus (CKX41) 
microscope at x10 magnification. 
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Figure 5.2.4.2: Light microscopy images of control non-transduced, control shRNA and TNAP shRNA 
scADSCs on day 5 of adipogenic induction. Control non-transduced (A and B) and control shRNA transduced 
(C and D) as well as TNAP shRNA transduced cells were cultured in either SGM with vehicle (A, C and E), or 
in adipogenic differentiation medium (AM) (B, D and F) for 5 days, followed by staining with Oil Red O to 
visualise lipid droplets. These images were acquired using an Olympus (CKX41) microscope at x10 
magnification. 
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Figure 5.2.4.3: Relative expression of TNAP mRNA in scADSCs transduced with either control or TNAP-
specific shRNA, after 5 days of culture in either standard growth medium with vehicle (SGM) or 
adipogenic differentiation medium (AM).  Subcutaneous ADSCs were cultured in SGM until 2 days post 
confluence, followed by 5 days of culture in either SGM with vehicle or AM. Error bars are representative of 
standard error (SEM), n = 3 - 4.  
 
 
5.3 Discussion  
ELF-97 staining in bmMSCs, scADSCs and pvADSCs differentiated towards an adipogenic 
phenotype showed that the ALP activity in all these cell types was localised on the lipid 
droplet surface. This is in agreement with the pattern of ALP activity in 3T3-L1 cells 
demonstrated by Ali et al. using ELF-97 (Ali et al., 2005). ELF-97 staining appeared to be 
most intense in bmMSC samples, while the least amount of staining appeared to be within the 
pvADSCs, observations which corroborate earlier findings for ALP activity levels within 
these cells (See Chapter 4). Although a small amount of ELF-97 staining was observed in 
cells from the bmMSC sample which did not appear to have visible lipid droplets, ALP 
activity appeared to be almost exclusively present within cells containing lipid droplets, 
which confirms the previous literature findings (Ali et al., 2005).  
 
ALP activity does not appear to be evenly distributed across the surface of the lipid droplet 
membrane, but is rather present in distinct locations, visible as yellow/green spots, on the 
membrane.  ALP activity is also not uniformly present in all lipid droplet-containing cells, as 
ELF-97 staining appears to be more intense in some cells and lower in other cells. It was 
observed that ELF-staining appears to be more intense in cells with smaller lipid droplets, 
while cells with larger lipid droplets showed fewer areas of ALP activity. This finding is 
consistent with previous ALP activity assay data, which demonstrated that for scADSCs and 
pvADSCs, ALP activity is highest at day 5 of adipogenic differentiation, the initial phase of 
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small droplet formation, and decreases with time until day 10 of differentiation, where larger 
droplets have been formed. In contrast to scADSCs and pvADSCs, bmMSCs undergoing 
adipogenesis showed the highest ALP activity on day 14, which was the final time point for 
differentiation in this cell type. Previous findings show that mouse bone marrow-derived 
stromal cells capable of adipogenic differentiation have the highest levels of ALP activity 
during the earlier stages of differentiation, while ALP activity was virtually absent in mature 
adipocytes (Kodama et al., 1983). The increasing ALP activity of rat-derived bmMSCs over 
the course of the differentiation period may indicate that the bmMSCs have not yet peaked in 
ALP activity. In future studies ALP activity should be monitored in bmMSCs undergoing 
adipogenic differentiation over a longer period, as in this study the endpoint for experiments 
was determined when sufficient lipid accumulation had occurred to enable quantification and 
not according to ALP activity levels.  
   
The stem cell marker, mesenchymal stem cell antigen 1 (MSCA-1) was found to be identical 
to TNAP, which points to an important role for TNAP in differentiation (Sobiesiak et al., 
2010). The role of TNAP as a stem cell marker provides further evidence that TNAP may 
play a more major role during the early stages of adipogenesis, when cells are more stem-
like, than in maintenance of an adipocytic phenotype.   
 
PCR data revealed that the bone TNAP mRNA transcript was predominantly expressed in 
bmMSCs and scADSCs, while neither bone- or liver-type transcript could be detected in the 
pvADSCs. The same pvADSC cDNA samples were previously used in Chapters 3 and 4 for 
RT-qPCR experiments, in which TNAP as well as adipogenic and osteogenic marker genes 
were successfully detected, indicating that the cDNA was not degraded in these samples. Rat 
liver is known to express both the bone and liver TNAP transcripts, with the bone form being 
predominant (Brun-Heath et al., 2011), which indicates that expression and by influence, 
function of one particular TNAP isoform is not mutually exclusive of the other in a particular 
tissue.  For this reason, it may be possible that rat scADSCs express the liver TNAP transcript 
as well as the bone transcript, but at such low levels that detection of this transcript using 
conventional PCR is inconsistent, although this seems highly unlikely given the sensitivity of 
PCR run at 35 cycles. The number of TNAP mRNA transcripts appeared to be low in 
scADSCs and below detectable levels in pvADSCs under the growth conditions used. The 
detection of expression may have been missed as the template cDNA was prepared from 
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RNA isolated at day 5 of differentiation for all cell types; however it is possible that TNAP 
mRNA expression could have been maximal at an earlier or later time point.  
 
It was found that the previously published bone TNAP forward primer was not optimal, as it 
allowed the formation of nonspecific products. However there was a relatively short sequence 
available from which a primer could be designed before the sequence became common to 
both transcripts (exons 1a and 1b), the point presumably being the start of exon 2, which 
made redesign of the primers impractical. Primers for the bone TNAP transcript, taken from 
Brun-Heath et al., selectively amplified a product at the expected size in bmMSCs 
differentiated towards an osteogenic phenotype, which is consistent with the identification of 
this as the bone-specific TNAP mRNA transcript.  
 
TNAP mRNA was previously detected in pvADSCs, albeit at low levels compared to 
bmMSCs and scADSCs, using RT-qPCR (See Chapter 3 and 4), while no detection was 
possible with conventional PCR. Therefore, suitable primer sequences for use with RT-qPCR 
specific for the rat bone or liver TNAP mRNA transcript should be designed and tested, as 
this may provide a more sensitive method of detection and quantification. Difficulty in 
designing a forward primer for the bone transcript is anticipated, due to the relatively short 
stretch of sequence available from which a forward primer may be designed (Addendum C, 
Fig. C1).    
 
Detection of the bone isoform transcript produced more distinct and consistent bands in 
adipogenic samples compared to osteogenic samples, in both bmMSCs and scADSCs, which 
was surprising considering the well established role for TNAP in mineralisation. The highest 
expression of TNAP during in vitro osteogenic differentiation of bmMSCs may have 
occurred at an earlier time point than measured here (day 5), as mineralisation had already 
began to occur by the time RNA was collected, and may be the reason for the low levels of 
amplification in bmMSCs treated with OM in comparison to AM.   
 
The results indicate that for rat-derived bmMSCs and scADSCs, the bone-specific transcript 
is the predominant TNAP mRNA transcript expressed. Based on the results from the 
scADSCs, it may be possible that the TNAP mRNA expressed in pvADSCs is also likely to 
be predominantly the bone type, however additional work will be needed to confirm this. 
Future work should also include investigating temporal TNAP mRNA expression with levels 
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measured at daily intervals in order to determine the point where TNAP mRNA expression is 
highest in each cell type. It may also be of interest to investigate whether the bone transcript 
predominates at earlier time points compared to later time points. Due to the difficulty 
amplifying sufficient product using conventional PCR, future work should be undertaken 
using RT-qPCR, which would additionally allow for quantification.  
 
The presence of a single band of ALP in all cell lysate samples indicates that only one 
isozyme of ALP is present, in comparison to the multiple ALP bands typically present in rat 
serum (Dziedziejko et al., 2005). The failure of WGL to precipitate ALP in AM-treated 
bmMSCs was an unexpected result, as PCR data confirmed that both scADSCs and bmMSCs 
expressed the bone TNAP mRNA transcript during adipogenic differentiation. The ALP from 
AM-treated bmMSCs migrated a shorter distance compared to undifferentiated or OM-treated 
bmMSCs. The data indicate that the ALP present in AM-treated bmMSCs may be differently 
glycosylated, in comparison to either undifferentiated or OM-treated bmMSCs. The data 
further indicate that depot-specific glycosylation differences may exist between AM-treated 
scADSCs and AM-treated bmMSCs. Depot-specific differences have been observed between 
rat-derived MSCs (Sadie-Van Gijsen et al., 2010) including differences in in vitro 
differentiation potentials. The glycosylation pattern of ALP from adipocytes is relatively 
unknown. 
 
An ALP isozyme discovered in human adipose tissue had different biochemical properties 
compared to liver, intestinal and placental ALP (Okochi et al., 1987), providing evidence that 
adipose tissue-derived ALP is distinct from other isoforms of TNAP. Okochi et al. described 
the adipose-derived ALP isozyme as localized to the walls of capillaries within the adipose 
tissue, and absent from mature adipocytes. Adipose precursor cells are thought to have a 
perivascular localisation, and are found amongst cells lining the blood vessel walls in adipose 
tissue (Zannettino et al., 2008). This is consistent with the observation that ALP activity is 
highest in immature adipocytes and absent in mature adipocytes (Kodama et al., 1983).  
 
Aberrant glycosylation patterns of ALP are known to occur, and are indicative of malignancy 
(Nowrouzi and Yazdanparast, 2005). The hepatocarcinoma cell line HepG2, is known to 
accumulate lipid within lipid droplets (Ali et al., 2013). HepG2 cells were found to express 
an aberrantly glycosylated form of liver TNAP in the cell membrane, as well as another form 
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that was released into the extracellular medium (Nowrouzi and Yazdanparast, 2005). This 
indicates that a particular cell type may express more than one isoform of TNAP.  
 
The TNAP present in adipocytes has not yet been extensively characterized, and much 
remains to be discovered about the isoforms present in adipose tissue, including whether 
more than one isoform is known to occur. It cannot be stated with certainty that the TNAP 
isoforms present in in vitro differentiated rat-derived MSCs reflect accurately the isoforms 
found in native adipose tissue. The observation that oxidative stress is able to increase the 
expression and alter the glycosylation pattern of TNAP in enterocytes, suggests that 
environmental conditions may result in alterations to the TNAP isoform expressed (Lopez-
Posadas et al., 2011). The in vitro cell culture environment together with the various 
differentiation cocktails used, may present an environment much unlike the in vivo conditions 
where TNAP expression occurs, and may result in unknown effects on the glycosylation of 
TNAP. Future work should first aim to isolate and characterise TNAP from native adipose 
tissue, as this may provide the most accurate reflection of the natural glycosylation pattern 
present in this tissue and whether more than one TNAP isoform is expressed. The properties 
of the TNAP isolated from in vitro differentiated primary MSCs should be compared to that 
of native TNAP in order to determine whether the artificial culture environment has an effect 
on expression.     
 
Neuraminidase functions to remove terminal N-acetyl neuraminic acid (sialic acid) from the 
surface of glycoproteins (Cuatrecasas and Illiano, 1971). As demonstrated, WGL is able to 
bind to the sialic acid residues of ALP, forming a band of precipitated ALP enzymes, which 
retards the migration through the gel (Fig. 5.2.3.1 and 5.2.3.2). As the differences in 
molecular weight of TNAP isoforms is due to the presence of different glycosylations, 
cleavage of terminal sialic acid by neuraminidase is expected to produce bands of similar 
molecular weight when subjected to electrophoresis through an agarose gel. Future 
experiments will include treating differentiated MSC samples with neuraminidase, in order to 
see if removing the glycosylations from the ALP isozymes present in these samples will 
cause the ALP bands to migrate at the same distance on the gel. This would provide further 
evidence that the differences in migration distance of ALP are due to differences in  the 
amount of glycosylation present on the enzyme.   
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Caution should be used in applying rat data directly to humans, as species specific differences 
are known to exist; for example, rat serum does not contain liver ALP, while the liver ALP 
isoform forms a major component of human serum ALP (Dziedziejko et al., 2005). Rat 
serum also contains three intestinal ALP isoforms (Shidoji and Kim, 2004), which are not 
present in humans. The possibility of several isoforms of TNAP being present in adipose 
tissue cannot currently be ruled out, as WGL did not precipitate all the ALP present in the rat 
tissue samples. Four isoforms of human bone TNAP have been described (Halling Linder et 
al., 2009) which further indicates that more than one isoform of TNAP may be present in 
adipose tissue. The migration differences between scADSC-derived ALP and bmMSC-
derived ALP may also indicate that posttranslational differences exist between TNAP 
molecules expressed in MSCs derived from different tissues.  
 
In addition to electrophoresis, it may be desirable to characterise the TNAP isoforms from 
adipose tissue using high-performance liquid chromatography (HPLC), as this technique has 
been found to provide better resolution of ALP isoforms compared to electrophoresis. A 
combination of the two techniques is most desirable, as each technique provides information 
about the ALP isozymes present in a sample that may not be available from the other method 
(Dziedziejko et al., 2005). 
 
Bone marrow-derived MSCs express higher levels of TNAP during adipogenic differentiation 
than scADSCs, however the latter were selected for TNAP knockdown as these cells have a 
more consistent adipogenic differentiation potential in comparison to bmMSCs. The 
knockdown of TNAP in scADSCs proved to be unsuccessful. Although the viral transduction 
process did result in successful integration of the shRNA, as the transduced cells were 
puromycin resistant, these cells had an impaired capacity to proliferate and differentiate 
compared to non-transduced control cells. The reduction in cell viability and lipid 
accumulation observed in transduced cells was similar for cells transduced with both control 
shRNA as well as shRNA targeting TNAP. As a result, any reduction in lipid accumulation 
could not be attributed to the knockdown of TNAP. Transient expression of shRNA using 
plasmid vectors was not attempted, as it has previously been found in our labs that both 
bmMSCs and ADSCs are extremely sensitive to transfection, both chemical and 
electroporation, resulting in extremely low cell viability. Expansion in number of the few 
surviving cells was not sufficient for further experimentation.  
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Subcutaneous ADSCs cultured from the stromal vascular fraction (SVF) have previously 
been noted to have a limited number of expansions in vitro, and the heterogeneity of primary-
derived MSCs is well known (Bianco et al., 2008; Strioga et al., 2012). The scADSCs 
cultured from the SVF may include a mixture of cell types, some of which have limited 
proliferation and differentiation capacity. Transduction was performed at P1, and cells were 
used for experiments at P2. The P1 population may have been largely heterogeneous, and 
possibly cells with limited expansion capabilities were transduced along with more stem-like 
cells in the population. The appearance of cells capable of lipid accumulation with the 
transduced cell cultures may indicate that some cells within the population are capable of 
differentiating after being stably transduced, compared to other cells which took on a broad 
flattened appearance and displayed limited proliferation ability. To improve the success of 
future shRNA knockdown experiments involving scADSCs, better selection criteria should 
be applied, in order to isolate a clone of transduced cells which display a capacity for long 
term self renewal. Alternatively, as primary-derived MSCs have a more limited capacity for 
self renewal in culture, shRNA knockdown should be attempted using an established cell 
line, which has a more defined phenotype and unlimited self-renewal capacity, allowing for 
longer term experiments to be performed. 
 
In conclusion, we have demonstrated that ALP activity, as detected using the ELF-97 
substrate in bmMSCs, scADSCs and pvADSCs treated with AM, is predominantly associated 
with intracellular lipid droplets, in confirmation of previous work using 3T3-L1 cells. Using 
conventional PCR, we have also demonstrated that bone-type TNAP mRNA appears to be 
preferentially expressed in scADSCs and bmMSCs treated with both OM and AM. Neither 
TNAP mRNA transcript could be amplified from pvADSC cDNA using conventional PCR, 
indicating that expressional levels are below detectable levels in this cell type, when using 
this technique. Future work should include repeating the experiments performed using 
conventional PCR with RT-qPCR, as well as using samples collected at earlier time-points 
during differentiation in order to determine when peak levels of TNAP transcription occur.  
Glycosylation analysis data showed that possible differences may exist in the glycosylations 
present in TNAP from bmMSCs when treated with AM or OM, as well as between AM-
treated scADSCs and AM-treated bmMSCs, which warrants further investigation. 
Knockdown of TNAP in scADSCs using shRNA had limited success, as transduction of the 
cells with shRNA appeared to have a severe impact on cell viability. The results that were 
obtained indicated that shRNA knockdown of TNAP did not abolish lipid accumulation 
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completely in scADSCs, as some lipid containing cells were observed after treatment with 
AM. Future work may include repeating the knockdown of TNAP experiments using shRNA 
using a more robust model in which cell viability is not adversely affected by transduction 
with shRNA.  
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CHAPTER 6 
Conclusions and limitations 
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The aim of this project was to evaluate the role of tissue-nonspecific alkaline phosphatase 
(TNAP) in the differentiation of rat-derived mesenchymal stromal cells (MSCs) from bone 
marrow- and adipose tissue depots, with emphasis on adipogenic differentiation.  Rat MSCs 
were isolated from three tissue depots: bone marrow, subcutaneous adipose and peri-renal 
visceral adipose tissue, where the resulting MSC cultures were termed bone marrow-derived 
MSCs (bmMSCs), subcutaneous adipose-derived stromal cells (scADSCs) and peri-renal 
visceral adipose-derived stromal cells (pvADSCs). Cells isolated from all three tissue depots 
appeared similar in morphology, and analysis of surface marker expression by flow 
cytometry positively identified the cells as MSCs. Depot-specific differences were noted 
between cells from all depots, with the greatest differences between bmMSCs and cells from 
both adipose depots (ADSCs). Bone marrow-derived MSCs treated with osteogenic 
differentiation medium (OM) were observed to mineralise more rapidly, and osteogenic 
marker genes increased earlier and to higher levels than observed for either scADSCs or 
pvADSCs under the same conditions, relative to the house-keeping gene, Arbp. Conversely, 
lipid accumulation in scADSCs and pvADSCs treated with adipogenic differentiation 
medium (AM) occurred more rapidly and to higher levels than observed in bmMSCs, and 
also displayed a greater increase in adipogenic marker gene relative expression levels than 
bmMSCs. Between MSCs from adipose depots, pvADSCs accumulated slightly more lipid 
than scADSCs, while adipogenic marker gene expression levels were higher in scADSCs 
compared to pvADSCs.  
 
Alkaline phosphatase (ALP) activity assay data showed that ALP activity levels were highest 
overall in bmMSCs, followed by scADSCs, while pvADSCs had the lowest ALP activity. 
The ALP activity levels were highest in all cell types when treated with AM compared to 
OM, which was surprising as ALP activity is better known to be associated with osteogenesis 
rather adipogenesis, and this data is suggestive of a role for ALP activity in adipogenic 
differentiation and/or maintenance of an adipocyte phenotype.    
 
The key phenotypic feature of adipogenic differentiation is the accumulation of lipid in 
membrane-bound droplets within the cell, which coalesce into one or two large lipid droplets 
once the adipocyte has reached maturity. The isozyme of ALP present in bone as well as 
adipose tissue is tissue-nonspecific ALP (TNAP). Previous studies have found that inhibition 
of ALP activity in primary-derived human preadipocytes and the murine preadipocyte cell-
line 3T3-L1, using TNAP-specific inhibitors, resulted in a decrease in lipid accumulation 
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during in vitro adipogenic differentiation (Ali et al., 2005). We treated rat-derived bmMSCs, 
scADSCs and pvADSCs with the TNAP-specific inhibitors levamisole, histidine and L-
homoarginine, either alone or in combination with one another, while the cells were 
undergoing either adipogenic or osteogenic differentiation in vitro. The reduction of either 
mineralisation, during osteogenic induction or lipid accumulation during adipogenic 
induction, when in the presence of TNAP inhibitors, was taken to indicate that TNAP was 
involved in these processes. As TNAP is known to have a an essential role in the process of 
mineralisation during normal bone formation in vivo, we wanted to test the effect of TNAP 
inhibitors on mineralisation during osteogenic induction, in order to verify that the same 
inhibitors were able to reduce TNAP activity during in vitro adipogenic differentiation of 
MSCs.  
 
Levamisole, alone or in combination with either histidine or L-homoarginine, was found to 
completely inhibit mineralisation during osteogenic induction in all three cell types studied, 
while no statically significant effect on ALP activity was observed. In contrast, levamisole 
did not significantly decrease lipid accumulation during adipogenesis in any of the three cell 
types, and only significantly decreased ALP activity in bmMSCs when treated with either 
levamisole alone or in combination with histidine during adipogenesis. Treatment with 
levamisole alone was also found to significantly inhibit TNAP gene expression in bmMSCs 7 
days after initiation of adipogenic induction, in comparison to untreated control and cells 
treated with either histidine or L-homoarginine (Fig. 4.2.5.1). Histidine alone had no 
statistically significant effect on either mineralisation or lipid accumulation in any of the cell 
types, and only decreased ALP activity significantly in bmMSCs undergoing adipogenesis. 
L-homoarginine alone did not significantly affect mineralisation or ALP activity in cells 
undergoing osteogenic induction, however, during adipogenesis L-homoarginine, alone or in 
combination with levamisole and histidine, significantly decreased lipid accumulation in all 
three cell types. Interestingly, L-homoarginine treatment, alone or in combination with 
levamisole and histidine, during adipogenic induction resulted in a statistically significant 
increase in ALP activity in scADSCs, but not in bmMSCs. ALP activity increased 
significantly in pvADSCs during adipogenic induction only with the combination of 
levamisole and L-homoarginine. The low levels of ALP activity in pvADSCs in comparison 
to scADSCs and bmMSCs may have resulted in difficulty obtaining statistically significant 
effects within this cell type.  
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It appeared that, overall, treatment with levamisole was able to completely inhibit 
mineralisation in all cell types, but had no effect on lipid accumulation. Conversely, L-
homoarginine did not have a definite effect on mineralisation, but alone was sufficient to 
reduce lipid accumulation significantly in all cell types. Histidine significantly inhibited lipid 
accumulation in bmMSCs, but overall had no clearly discernible effect on differentiation or 
ALP activity.   
 
Levamisole is one of the best known inhibitors of TNAP, and is widely used to study ALP 
activity, however, levamisole has been found to have off-target effects which may obscure 
the results obtained when this compound is used solely as a means of inhibiting TNAP 
activity in live cells. In fact, one publication has advised against the use of levamisole for this 
sole purpose, due to off-target effects (Nowak et al., 2015). The results obtained here may 
differ from other studies, which have reported a significant decrease in lipid accumulation as 
a result of levamisole treatment, due to sensitivity of the rat-derived MSCs used in this study 
to levamisole, as these cells were only able to tolerate a maximum concentration of 0.5 mM 
levamisole over long-term culture, in comparison to 3T3-L1 cells, which were able to tolerate 
a 5 x higher dosage (2.5 mM) (Ali et al., 2005). It may be possible that the effect on lipid 
accumulation is only seen at higher concentrations of levamisole than were used in this study. 
However, this possibility is countered by the observation that mineralisation could be 
prevented in the rat-derived MSCs at 0.5 mM levamisole.  
 
L-homoarginine is a selective TNAP inhibitor, but surprisingly was not able to reduce 
mineralisation or ALP activity, even at 10 mM concentration, indicating that TNAP activity 
was not successfully inhibited during osteogenic induction. It is not known how effective L-
homoarginine is at inhibiting TNAP under cell culture conditions. The lack of inhibition may 
be due to suboptimal conditions in the cell culture environment, such as differences in pH and 
substrate composition when comparing in vitro assay conditions, with substrate composition 
and buffering capacity in vivo. L-homoarginine, while unable to inhibit mineralisation, was 
able to inhibit lipid accumulation during adipogenic differentiation. The reduction in lipid 
accumulation may be due to unknown off-target effects of L-homoarginine on the cells, 
resulting in a decrease in lipid accumulation. Another possible reason for the observed 
differences may be due to possible differences in the glycosylations present on TNAP 
molecules from cells with adipocyte and osteoblast phenotypes. Glycosylation differences, 
which are responsible for the main differences between TNAP isoforms, are known to affect 
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enzyme activity as well as inhibitor sensitivity. Therefore, it may be possible that the TNAP 
present in cells induced towards an adipocyte phenotype is more sensitive to inhibition by L-
homoarginine than cells differentiated towards osteoblastogenesis. Glycosylation analysis of 
the ALP isoforms present in bmMSCs differentiated towards an adipocyte and osteoblast 
phenotype using agarose electrophoresis and lectin precipitation, showed that some possible 
differences in TNAP isoform may exist between TNAP from adipocyte and osteoblast 
differentiated bmMSCs (Fig. 5.2.3.2).  
 
The observation that the presence of L-homoarginine was able to significantly increase ALP 
expression in scADSCs, but not in bmMSCs, undergoing adipogenic induction, may also 
point to a compensatory mechanism by scADSCs in response to L-homoarginine inhibition of 
TNAP, by raising ALP expression. Evidence of increased expression of TNAP in the 
presence of L-homoarginine can be seen in gene expression data, where levels of TNAP gene 
expression is similar to or slightly higher than control for all three cell types during 
adipogenic induction, although no statistical significance is present (Fig. 4.2.5.1). As 
mentioned, in bmMSCs L-homoarginine treatment did not increase ALP activity, which may 
again be due to differences in the glycosylations present in TNAP molecules between 
bmMSCs and scADSCs differentiated to an adipogenic phenotype. Glycosylation analysis 
also revealed that some differences may exist in the glycosylations between TNAP from 
scADSCs and bmMSCs after differentiation towards and adipocyte phenotype (Fig. 5.2.3.1 B 
and Fig 5.2.3.2 B).  
 
Histidine, at the highest concentration that the cells could tolerate in long term culture (10 
mM), had a limited effect on lipid accumulation as well as mineralisation and ALP activity, 
except in bmMSCs, where a statistically significant decrease in lipid accumulation was 
observed. The decrease may be due to the properties of TNAP in adipocyte differentiated 
bmMSCs, compared to ADSCs, although, it is also possible that the reduction in lipid 
accumulation in these cells was due to other unknown off-target effects in these cells. Out of 
the three inhibitors tested, inhibition by histidine was the weakest (Fig. 4.2.6.1), and future 
studies on TNAP from rat-derived MSCs may consider excluding this compound for use as 
TNAP inhibitor in either live cell culture or assay.   
 
Attempts to inhibit ALP activity in MSCs undergoing differentiation in culture using TNAP 
inhibitor compounds were limited by potential off-target effects, therefore another method of 
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examining the contribution of ALP to MSC differentiation was employed, in the form of 
knockdown of TNAP using lentiviral mediated transfection with short hairpin RNA (shRNA) 
targeting TNAP. A marked decrease in cell viability was observed in antibiotic selected cells 
following transduction of scADSCs with control vector, which contained a sequence not 
targeting any known mammalian genes, as well as test vector, which contained the TNAP-
specific shRNA, and subsequent antibiotic selection, in comparison to non-transduced control 
cells without selection at P1 and P2. Subcutaneous ADSCs were selected as the model for 
this experiment for financial reasons, due to limited available quantities of shRNA, and 
because while bmMSCs have the highest levels of ALP activity, scADSCs differentiate more 
readily and reliably towards an adipocyte phenotype. Despite the apparent lower cell viability 
of transduced scADSCs, treatment of these cells with adipogenic differentiation medium 
(AM) resulted in the production of cells containing lipid droplets after 5 days. Assessment of 
the gene expression levels of TNAP in transduced cells, showed a slight decrease in TNAP 
mRNA levels in cells transduced with shRNA targeting TNAP, compared to shRNA control. 
Differences in lipid accumulation could not be quantified due to the extremely poor 
differentiation of transduced cells. Expression of TNAP in non-transduced scADSCs treated 
with AM for 5 days was roughly 6-fold, relative to Arbp (Fig. 4.2.5.1, D), while TNAP gene 
expression levels in scADSCs transduced with TNAP-specific shRNA were less than 1-fold 
relative to Arbp (Fig. 5.2.4.3). This indicates that although TNAP expression was knocked 
down compared to non-transduced controls, some lipid accumulation was still able to occur.  
 
Viral vectors used for transfecting cells are known to insert randomly into the host genome, 
and may result in insertional mutations, which may possibly disrupt essential genes in the 
cell, resulting in cytotoxic effects on the cell (Kim and Eberwine, 2010). The reason for the 
apparent reduced viability of transduced scADSCs compared to non-transduced cells may be 
as a result of the transduction process. Nevertheless, the results indicate that knockdown of 
TNAP with TNAP-specific shRNA was not able to completely abolish lipid accumulation in 
scADSCs.  
 
Confocal microscopy demonstrated that ALP activity was present in lipid-containing cells 
produced after treatment of bmMSCs, scADSCs or pvADSCs with AM. The ALP activity 
appeared to be most prominently associated with the lipid droplet membrane in all three cell 
types, however, ALP activity was not present on all lipid droplets within a particular cell, 
while some lipid-containing cells appeared to have a higher amount of ALP activity than 
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others, and some had virtually no ALP activity. These results confirm that ALP activity, 
which in these cells is the result of TNAP activity, is likely to be associated with lipid 
accumulation and possibly also adipogenesis, however, the mechanism by which TNAP is 
able to stimulate adipogenic differentiation is not currently known (Esteve et al., 2015).  ALP 
activity was detected using the fluorescent substrate, ELF-97, because a suitable 
commercially available antibody against TNAP was not available at the time of the 
experiments. The possible future commercial availability of a suitable antibody against rat 
TNAP would be able to confirm the results obtained using ELF-97.  
 
The mRNA transcripts of TNAP are expressed in two forms, where each transcript type is 
composed of either one of two untranslated leader exons, designated 1a and 1b, followed by 
11 coding exons. Transcripts containing the 1a exon are predominant in cells from bone 
tissue and this is termed the bone-type TNAP transcript, while the 1b exon is largely found in 
liver tissue, and for this reason is known as the liver-type transcript. Knowledge of the TNAP 
transcripts in a particular tissue may identify which isoform of TNAP is preferentially 
expressed in these tissues. PCR revealed a preference for the expression of bone-type TNAP 
mRNA transcript was in bmMSCs and scADSCs, differentiated towards either an adipogenic 
or osteogenic phenotype. Published primer sequences for either bone- or liver-type TNAP 
transcripts were found in a paper by Brun-Heath et al. (2011), and a database search revealed 
that these were based on a relatively short stretch of available sequence data (Addendum C, 
Fig. C1) (Brun-Heath et al., 2011). Several non-specific bands were detected in scADSC and 
bmMSC samples, particularly when using the bone-type primer set. Due to the limited 
available sequence from which alternative primers could be designed, attempting to redesign 
more optimal primer sets was not considered to be feasible. More complete sequence data for 
both the bone- and liver-type TNAP mRNA from rat, each containing a longer sequence of 
both exon 1a or 1b, respectively, should allow for more optimal primers to be designed.  
 
Detection of bone-type transcript in bmMSCs and scADSCs treated with osteogenic 
differentiation medium (OM) was not consistent in all samples (n = 3) (Fig. 5.2.2.1 and Fig.   
5.2.2.3), which may be due to the lower expression of TNAP during osteogenic compared to 
adipogenic treatment, as has been previously observed (Fig. 4.2.5.1 A – D). Low numbers of 
TNAP mRNA transcript copies present in samples treated with OM may have been the 
reason for the inconsistent amplification in these samples, as the number of PCR cycles used 
were already at the recommended maximum of 35.  
Stellenbosch University  https://scholar.sun.ac.za
 188 
 
 
The expression of TNAP in pvADSCs was below detectable levels using conventional PCR 
and transcript-specific primers, but was detectable using RT-qPCR using a primer set which 
did not discriminate between transcripts. ALP assay and RT-qPCR data presented in this 
study showed that pvADSCs had low levels of TNAP expression, and therefore it is not 
surprising that conventional PCR failed to detect either the bone- or liver-type TNAP 
transcript in pvADSCs. 
 
Overall, more complete information on the sequences of exons 1a and 1b from rat TNAP 
mRNA transcripts will allow for improved primer design for both the bone- and liver-type 
transcripts for future work. In spite of the limited space for primer construction from the 
available sequence data, it was discovered that bone-type TNAP transcript appears to be 
preferred in rat-derived bmMSCs and scADSCs, while the preferred transcript in pvADSCs 
remains unclear.  
 
As mentioned previously, post-translational differences in the form of glycosylations account 
for the main differences between TNAP isoforms. While only two different TNAP mRNAs 
may be transcribed, several different TNAP isoforms may be expressed (Halling Linder et al., 
2009). Using agarose gel electrophoresis and lectin precipitation, differences were found 
between TNAP from OM and AM treated bmMSCs, as well as between AM treated 
bmMSCs and scADSCs. This data indicates that TNAP may possibly be differently 
glycosylated in osteoblasts and adipocytes, and that depot-specific differences in TNAP from 
cells with an adipocyte phenotype may occur. Limitations of this technique included the 
crude nature of the TNAP-containing samples, which included crude cell lysate in the case of 
bmMSCs, and ALP extract, in the case of scADSCs. ALP extraction was necessary for 
scADSCs, as ALP activity levels were too low in crude lysate of these cells, while even ALP 
extraction was not able to concentrate sufficient ALP activity in pvADSCs for glycosylation 
analysis. The crude nature of the samples resulted in the appearance of large diffuse bands. 
Future work will include purification of TNAP from crude cell lysates using column 
chromatography, followed by high performance liquid chromatography (HPLC) in addition 
to agarose electrophoresis. This will enable better resolution of the different isoforms present 
in the various samples, and will be necessary to confirm that glycosylation differences 
between rat MSCs when treated with OM or AM exist.  Additionally, TNAP may be released 
into the growth medium by certain cells and under certain conditions (Nowrouzi and 
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Yazdanparast, 2005). It may be worthwhile investigating whether TNAP is released by MSCs 
into the culture medium during differentiation, and, if present in sufficient quantities, to 
assess the glycosylation pattern present here. 
 
The inherent heterogeneity of primary-derived MSC cultures is a well-known phenomenon 
(Ho et al., 2008). This is likely to arise from the co-isolation of cells from the tissue of origin 
that may already be lineage committed with true MSCs that have multipotential 
differentiation capability. Attempts to reduce the amount of heterogeneity in primary-derived 
cultures include cell sorting, which is based on surface marker expression. Unfortunately, the 
number of reagents available for use with rat cells is currently extremely limited, and 
additionally, the yield of cells obtained after sorting is often greatly reduced. Consequently 
plastic adherence was used in this study as the sole method of selection for MSCs, and in 
spite of potential inherent heterogeneity, reports describing primary MSC cultures produced 
using plastic adherence alone are still very common. However, in this study phenotypic 
characterisation, by examining both known surface markers and differentiation potential, 
confirmed that the cells used in all investigations outlined here were MSCs.  
 
Difficulty was experienced when attempting to compare data gathered during this 
investigation with that published in the literature, due to a lack of standardisation of protocols 
used for isolation and culturing of MSCs, as well as for the methodologies used for 
assessment of cellular proliferation and differentiation. Universal standardization of protocols 
used for MSC studies is therefore necessary, and will increase the scientific value of 
published studies in this field.  
 
 In conclusion, this study has confirmed that TNAP is present in rat-derived bmMSCs, 
scADSCs and pvADSCs, and that ALP activity, which is identified to be from TNAP, is 
present in these cells undergoing adipogenic induction in vitro. ALP activity was higher in all 
three cell types when treated with AM in comparison to treatment with OM, which is further 
indicative of a role for this enzyme during adipogenesis, although the mechanism of action of 
TNAP in adipogenesis remains unknown. Depot-specific differences in TNAP expression 
were discovered, most markedly between bmMSCs and ADSCs, where bmMSCs had the 
highest levels of ALP activity. These differences indicate that care should be taken when 
selecting an MSC type for use as a model for investigating TNAP, as well as for bone or 
adipose tissue engineering studies. TNAP expression was also higher in scADSCs compared 
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to pvADSCs, and this observation may provide insight into the metabolic differences 
between subcutaneous and visceral adipose tissues, especially with regards to the contribution 
of these tissues to conditions such as diabetes and obesity. Despite having the lowest levels of 
TNAP, pvADSCs were able to successfully accumulate lipid and differentiate towards an 
adipocyte phenotype, which may indicate that only relatively low levels of TNAP may be 
required for lipid accumulation. Much still remains to be discovered about the exact function 
of TNAP during adipogenesis and in maintenance of the adipocyte phenotype, as well as in 
the myriad of other tissues where it is present; however, this study has provided insight into 
the expression of TNAP during in vitro adipogenic and osteogenic differentiation of rat-
derived MSCs.  
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Addendum A 
A1 Preparation of adipogenic differentiation medium (AM) cocktail components:  
 Dexamethasone was dissolved in ethanol (EtOH) (32221-2.5L, Sigma Aldrich) to 
give a stock solution of 10 mM, which was stored in aliquots at -20 °C.  
 Indomethacin was dissolved in EtOH to give a stock solution of 56 mM, which is the 
solubility limit of indomethacin. Stock solution was stored at RT.  
 3-isobutyl-1-methylxanthine (IBMX) was dissolved in dimethyl sulphoxide (DMSO) 
(1029873, Merck) to form a stock solution of 1 M, which was stored at -20 C. Stock 
solutions of IBMX was thawed no more than 3 times before being discarded.  
 Insulin was supplied in a ready to use stock of 10 mg/ml, which was stored at 4 °C.  
 Ascorbic acid powder was weighed out under sterile conditions and dissolved in 
sterile DMEM to give a stock solution of 50 mM. Aliquots of ascorbic acid were 
stored at -20 °C and discarded after a single use.  
 
   
Table A1: Cocktail for the induction of adipogenesis in scADSCs, pvADSCs and bmMSCs. 
Component  Vehicle  Stock 
concentration  
Final 
concentration  
Volume of stock added to make 
10 ml adipogenic differentiation 
medium (AM) 
Insulin HEPES 
buffer 
10 mg/ml 10 µM 57.2 µl  
Indomethacin EtOH 56 mM 56 µM 10µl 
3-isobutyl-1-
methylxanthine 
DMSO  1 M 0.5 mM  5µl 
Dexamethasone EtOH  10 mM 1 µM 1µl 
Ascorbic acid  DMEM  50 mM 50 µM  10µl  
 
A2 Preparation of osteogenic differentiation medium (OM) cocktail components: 
 β-glycerophosphate was dissolved in DMEM + 10% FBS to give a stock 
concentration of 25 mM, which was filter sterilised  and stored at -20 °C.  
 Dexamethasone was prepared by dilution of the 10 mM stock (See section 3.6.1) 
using 99% pure ethanol at a ratio of either 1:1000 or 1:100 to give stock solutions of 
10 μM or 100 μM, respectively.  
 Ascorbic acid stock was prepared the same as for the adipogenic differentiation 
cocktail.  
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Table A2: Cocktail components for the induction of osteogenesis in scADSCs, pvADSCs and bmMSCs 
Component  Vehicle Stock 
Concentration  
Final 
concentration  
Volume of stock added to make 
10 ml osteogenic differentiation 
medium  (OM) 
β-glycerophosphate DMEM+10
% FBS 
50 mM  10 mM 2 ml 
Dexamethasone 
(bmMSC OM) 
Ethanol 10 μM 10 nM 1 μl 
Dexamethasone 
(scADSC and 
pvADSC OM) 
Ethanol 100 μM 100 nM 1 μl 
Ascorbic acid DMEM 50 mM 50 μM 10 μl 
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Figure A: Compensation controls for 4 colour flow cytometry experiment for the analysis of cell surface 
marker expression in order to determine the purity of the isolated MSC populations. Regions of positive 
(green) staining in single fluorochrome stained control samples are demonstrated. These compensation control 
samples demonstrated that PE emissions were also detected in the FITC channel. A compensation matrix was 
created using the Flow Jo Vx (Treestar) software in order to correct for the spectral overlap between FITC and 
PE; gated regions of positive areas were set accordingly. Single fluorochrome stained control samples 
demonstrate no spectral overlap following compensation. Regions of positive staining following compensation 
in single stained controls (green) compared to a negative unstained control sample (blue) are given in the final 
column. 
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Addendum B 
 
Figure B1: Image analysis to determine percentage area of mineralisation of bmMSCs cultured in osteogenic differentiation medium (OM) in the presence and absence of 
levamisole (Lev), histidine (His) and L-homoarginine (Arg).  Percentage mineralisation of cells cultured in standard growth medium (SGM) (Control) or OM, at day 5, 7 and 10, 
n=6 (A). Pooled data for animal 1 – 3 at day 5 (D), 7 (E) and 10 (F) is represented in panel B, while pooled data for animal 4 – 6 at day 5 (G), 7 (H) and 10 (I) is represented as panel 
C. Statistical analysis was performed using one-way ANOVA and Tukey’s test to determine statistical differences where p < 0.05. Error bars are represented as standard error (SE).    
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Figure B2: Alkaline phosphatase (ALP)  assay to determine total cell ALP activity of bmMSCs cultured in osteogenic differentiation medium (OM) in the presence and 
absence of levamisole (Lev), histidine (His) and L-homoarginine (Arg).  ALP activity (U/mg) of cells cultured in standard growth medium (SGM) (Control) or OM, at day 5, 
7 and 10, n=6 (A). Pooled data for animal 1 – 3 at day 5 (D), 7 (E) and 10 (F) is represented in panel B, while pooled data for animal 4 – 6 at day 5 (G), 7 (H) and 10 (I) is 
represented as panel C. Statistical analysis was performed using one-way ANOVA and Tukey’s test to determine statistical differences where p < 0.05. Error bars are represented 
as standard error (SE).    
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Figure B3: Image analysis to determine percentage area of lipid accumulation in bmMSCs cultured in adipogenic differentiation medium (AM) in the presence and 
absence of levamisole (Lev), histidine (His) and L-homoarginine (Arg).  Percentage area of lipid accumulation of cells cultured in standard growth medium (SGM) (Control) 
or AM, at day 7, 10 and 14, n=9 (A). Pooled data for animal 1 – 5 at day 7 (D), 10 (E) and 14 (F) is represented in panel B, while pooled data for animal 6 – 9 at day 7 (G), 10 (H) 
and 14 (I) is represented as panel C. Statistical analysis was performed using one-way ANOVA and Tukey’s test to determine statistical differences where p < 0.05. Error bars are 
represented as standard error (SE).    
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Figure B4: Alkaline phosphatase (ALP) assay to determine total cell ALP activity of bmMSCs cultured in adipogenic differentiation medium (AM) in the presence and 
absence of levamisole (Lev), histidine (His) and L-homoarginine (Arg). ALP activity (U/mg) of cells cultured in standard growth medium (SGM) (Control) or AM, at day 7, 10 
and 14, n=7 (A). Pooled data for animal 1 – 4 at day 7 (D), 10 (E) and 14 (F) is represented in panel B, while pooled data for animal 5 – 7 at day 7 (G), 10 (H) and 14 (I) is 
represented as panel C. Statistical analysis was performed using one-way ANOVA and Tukey’s test to determine statistical differences where p < 0.05. Error bars are represented as 
standard error (SE).    
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Figure B5: Image analysis to determine percentage area of mineralisation of scADSCs cultured in osteogenic differentiation medium (OM) in the presence and absence of 
levamisole (Lev), histidine (His) and L-homoarginine (Arg).  Percentage mineralisation of cells cultured in standard growth medium (SGM) (Control) or OM, at day 7, 14 and 21, 
n=7 (A). Pooled data for animal 1 – 4 at day 7 (D), 14 (E) and 21 (F) is represented in panel B, while pooled data for animal 5 – 7 at day 7 (G), 14 (H) and 21 (I) is represented as panel 
C. Statistical analysis was performed using one-way ANOVA and Tukey’s test to determine statistical differences where p < 0.05. Error bars are represented as standard error (SE).    
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Figure B6: Alkaline phosphatase (ALP)  assay to determine total cell ALP activity of scADSCs cultured in osteogenic differentiation medium (OM) in the presence and 
absence of levamisole (Lev), histidine (His) and L-homoarginine (Arg).  ALP activity (U/mg) of cells cultured in standard growth medium (SGM) (Control) or OM, at day 7, 14 
and 21, n=6 (A). Pooled data for animal 1 – 3 at day 7 (D), 14 (E) and 21 (F) is represented in panel B, while pooled data for animal 4 – 6 at day 7 (G), 14 (H) and 21 (I) is 
represented as panel C. Statistical analysis was performed using one-way ANOVA and Tukey’s test to determine statistical differences where p < 0.05. Error bars are represented as 
standard error (SE).  
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Figure B7: Image analysis to determine percentage area of lipid accumulation in scADSCs cultured in adipogenic differentiation medium (AM) in the presence and 
absence of levamisole (Lev), histidine (His) and L-homoarginine (Arg).  Percentage area of lipid accumulation of cells cultured in standard growth medium (SGM) (Control) or 
AM, at day 5, 7 and 10, n=8 (A). Pooled data for animal 1 – 3 at day 5 (D), 7 (E) and 10 (F) is represented in panel B, while pooled data for animal 4 – 8 at day 5 (G), 7 (H) and 10 
(I) is represented as panel C. Statistical analysis was performed using one-way ANOVA and Tukey’s test to determine statistical differences where p < 0.05. Error bars are 
represented as standard error (SE).    
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Figure B8: Alkaline phosphatase (ALP) assay to determine total cell ALP activity of scADSCs cultured in adipogenic differentiation medium (AM) in the presence and 
absence of levamisole (Lev), histidine (His) and L-homoarginine (Arg).  ALP activity (U/mg) of cells cultured in standard growth medium (SGM) (Control) or AM, at day 5, 7 
and 10, n=7 (A). Pooled data for animal 1 – 3 at day 5 (D), 7 (E) and 10 (F) is represented in panel B, while pooled data for animal 4 – 7 at day 5 (G), 7 (H) and 10 (I) is represented 
as panel C. Statistical analysis was performed using one-way ANOVA and Tukey’s test to determine statistical differences where p < 0.05. Error bars are represented as standard 
error (SE). 
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Figure B9: Image analysis to determine percentage area of mineralisation of pvADSCs cultured in osteogenic differentiation medium (OM) in the presence and absence of 
levamisole (Lev), histidine (His) and L-homoarginine (Arg).  Percentage mineralisation of cells cultured in standard growth medium (SGM) (Control) or OM, at day 7, 14 and 21, 
n=7 (A). Pooled data for animal 1 – 4 at day 7 (D), 14 (E) and 21 (F) is represented in panel B, while pooled data for animal 5 – 7 at day 7 (G), 14 (H) and 21 (I) is represented as 
panel C. Statistical analysis was performed using one-way ANOVA and Tukey’s test to determine statistical differences where p < 0.05. Error bars are represented as standard error 
(SE).    
Stellenbosch University  https://scholar.sun.ac.za
Stellenbosch University  https://scholar.sun.ac.za
 223 
 
 
Figure B10: Alkaline phosphatase (ALP)  assay to determine total cell ALP activity of pvADSCs cultured in osteogenic differentiation medium (OM) in the presence and 
absence of levamisole (Lev), histidine (His) and L-homoarginine (Arg).  ALP activity (U/mg) of cells cultured in standard growth medium (SGM) (Control) or OM, at day 7, 14 
and 21, n=6 (A). Pooled data for animal 1 – 3 at day 7 (D), 14 (E) and 21 (F) is represented in panel B, while pooled data for animal 4 – 6 at day 7 (G), 14 (H) and 21 (I) is 
represented as panel C. Statistical analysis was performed using one-way ANOVA and Tukey’s test to determine statistical differences where p < 0.05. Error bars are represented 
as standard error (SE). 
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Figure B11: Image analysis to determine percentage area of lipid accumulation in pvADSCs cultured in adipogenic differentiation medium (AM) in the presence and 
absence of levamisole (Lev), histidine (His) and L-homoarginine (Arg).  Percentage area of lipid accumulation of cells cultured in standard growth medium (SGM) (Control) or 
AM, at day 5, 7 and 10, n=9 (A). Pooled data for animal 1 – 4 at day 5 (D), 7 (E) and 10 (F) is represented in panel B, while pooled data for animal 5 – 9 at day 5 (G), 7 (H) and 10 
(I) is represented as panel C. Statistical analysis was performed using one-way ANOVA and Tukey’s test to determine statistical differences where p < 0.05. Error bars are 
represented as standard error (SE). 
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Figure B12:  Alkaline phosphatase (ALP) assay to determine total cell ALP activity of pvADSCs cultured in adipogenic differentiation medium (AM) in the presence and 
absence of levamisole (Lev), histidine (His) and L-homoarginine (Arg). ALP activity (U/mg) of cells cultured in standard growth medium (SGM) (Control) or AM, at day 5, 7 
and 10, n=7 (A). Pooled data for animal 1 – 4 at day 5 (D), 7 (E) and 10 (F) is represented in panel B, while pooled data for animal 5 – 7 at day 5 (G), 7 (H) and 10 (I) is represented 
as panel C. Statistical analysis was performed using one-way ANOVA and Tukey’s test to determine statistical differences where p < 0.05. Error bars are represented as standard 
error (SE). 
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Addendum C 
 
Figure C1: Sequence alignment of Rattus norvegicus alkaline phosphatase, liver/bone/kidney (Alpl), 
mRNA, NM_013059.1 (ALP) and XM_006239136.2 (X1). The positions of the bone-type and liver-type 
forward and reverse primers are highlighted in grey. Clustal O (1.2.1) software was used to generate the 
alignment.  
 
X1       GATAGTCCCAGACCTCATGCCCAGCGCCTTCTGATTTCCAGTTCTGGTAGCCACGCCCTG 60 
ALP      ------------------------------------------------------------ 0 
                                                                      
 
X1       ACTTACGAAATAGAGCTGGTGACAAGGGTGAGGGATGGCACAAGCCAGGTCCTGCTTTGG 120 
ALP      ------------------------------------------------------------ 0 
                                                                      
 
X1       CTCCCTCAGGGCTACTCCAGGCCTCTCTGTCCTCAAACAACTGCTATGTGCTTGGCCGCT 180 
ALP      ------------------------------------------------------------ 0 
                                                                      
 
X1       GCCCCTGACTGAAATTCCTCGCATCCTGCCTCTCAGCTTCAGATCGTGCTGACCTTGCCA 240 
ALP      ------------------------------------------------------------ 0 
                                                                      
 
X1       CACTGCCAGCCTCACCGGTGACCTTTTAGATCACCCTTAGTTTTCTGTTCTGTAAGACGG 300 
ALP      ------------------------------------------------------------ 0 
                                                                      
 
X1       GGAAGAGCGTCACACCGCCTGGGGCTTGTATCTTCCCAGTGTGAATGGGACAGGACAGGA 360 
ALP      ------------------------------------------------------------ 0 
                                                                      
      Liver/kidney  
X1       GATGGGGACCTGTGACCAGCCTCATCCAGATGCTG--AAGGTTGAGCATTCTAGTGCAGG 418 
ALP      ----------------CACGGCGCTCCTTAGGGCCACCGCTCGGCGCGCCGGGACAGACC 44 
                         **      ***  * *           * **  Bone    *   
 
X1       ATAGACCATTTCAGCCTCAGGATCGGAACGTCAATTAACGGCTGACACTGCCCCCCACCT 478 
ALP      CTCCCCACTCCTGCCTGCAGGATCGGAACGTCAATTAACGGCTGACACTGCCCCCCACCT 104 
          *   *  *     *  ******************************************* 
 
X1       CTTCCCACCCATCTGGGCTCCAGCGAGGAACGGATCTCGGGGTACACCATGATCTTGCCA 538 
ALP      CTTCCCACCCATCTGGGCTCCAGCGAGGAACGGATCTCGGGGTACACCATGATCTTGCCA 164 
         ************************************************************ 
 
X1       TTTTTAGTACTGGCCATCGGCACCTGCCTTACCAACTCATTTGTGCCAGAGAAAGAGAAA 598 
ALP      TTTTTAGTACTGGCCATCGGACCCTGCCTTACCAACTCATTTGTGCCAGAGAAAGAGAAA 224 
         ********************  ************************************** 
 
X1       GACCCCAGTTACTGGCGACAGCAAGCCCAAGAGACCTTGAAAAATGCCCTGAAACTCCAA 658 
ALP      GACCCCAGTTACTGGCGACAGCAAGCCCAAGAGACCTTGAAAAATGCCCTGAAACTCCAA 284 
         ************************************************************ 
 
X1       AAACTCAACACCAACGTGGCCAAGAACATCATCATGTTCCTGGGAGATGGTATGGGCGTC 718 
ALP      AAACTCAACACCAACGTGGCCAAGAACATCATCATGTTCCTGGGAGATGGTATGGGCGTC 344 
         ************************************************************ 
 
X1       TCCACAGTGACAGCTGCCCGCATCCTTAAGGGCCAGCTACACCACAACACGGGCGAGGAG 778 
ALP      TCCACAGTGACAGCTGCCCGCATCCTTAAGGGCCAGCTACACCACAACACGGGCGAGGAG 404 
         ************************************************************ 
 
X1       ACACGGCTGGAGATGGACAAGTTCCCCTTTGTGGCTCTCTCCAAGACGTACAACACCAAC 838 
ALP      ACACGGCTGGAGATGGACAAGTTCCCCTTTGTGGCTCTCTCCAAGACGTACAACACCAAC 464 
         ************************************************************ 
 
X1       GCTCAGGTCCCCGACAGCGCGGGCACTGCCACTGCCTACTTGTGTGGCGTGAAGGCCAAC 898 
ALP      GCTCAGGTCCCCGACAGCGCGGGCACTGCCACTGCCTACTTGTGTGGCGTGAAGGCCAAC 524 
         ************************************************************ 
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X1       GAGGGCACCGTGGGAGTGAGCGCGGCCACTGAGCGCACGCGATGCAACACCACTCAGGGG 958 
ALP      GAGGGCACCGTGGGAGTGAGCGCGGCCACTGAGCGCACGCGATGCAACACCACTCAGGGG 584 
         ************************************************************ 
 
X1       AACGAGGTCACGTCCATCCTGCGCTGGGCCAAGGATGCTGGGAAGTCCGTGGGCATCGTG 1018 
ALP      AACGAGGTCACGTCCATCCTGCGCTGGGCCAAGGATGCTGGGAAGTCCGTGGGCATCGTG 644 
         ************************************************************ 
 
X1       ACCACCACTCGGGTGAACCACGCCACTCCCAGTGCAGCCTATGCGCACTCGGCCGATCGG 1078 
ALP      ACCACCACTCGGGTGAACCACGCCACTCCCAGTGCAGCCTATGCGCACTCGGCCGATCGG 704 
         ************************************************************ 
 
X1       GACTGGTACTCGGACAATGAGATGCCGCCAGAGGCTCTGAGCCAGGGCTGCAAGGACATC 1138 
ALP      GACTGGTACTCGGACAATGAGATGCGCCCAGAGGCTCTGAGCCAGGGCTGCAAGGACATC 764 
         *************************  ********************************* 
 
X1       GCCTATCAGCTAATGCACAACATCAAGGACATCGATGTGATCATGGGTGGCGGCCGGAAG 1198 
ALP      GCCTATCAGCTAATGCACAACATCAAGGACATCGATGTGATCATGGGTGGTGGCCGGAAG 824 
         ************************************************** ********* 
 
X1       TACATGTACCCCAAGAACAGAACTGATGTGGAATATGAACTGGATGAGAAGGCCAGGGGC 1258 
ALP      TACATGTACCCCAAGAACAGAACTGATGTGGAATATGAACTGGATGAGAAGGCCAGGGGC 884 
         ************************************************************ 
 
X1       ACCAGACTGGATGGCCTGGACCTCATCAGCATTTGGAAGAGCTTCAAACCTAGACACAAG 1318 
ALP      ACCAGACTGGATGGCCTGGACCTCATCAGCATTTGGAAGAGCTTCAAACCTAGACACAAG 944 
         ************************************************************ 
 
X1       CACTCCCACTATGTCTGGAACCGCACTGAACTGCTGGCCCTTGACCCCTCCAGGGTGGAC 1378 
ALP      CACTCCCACTATGTCTGGAACCGCACTGAACTGCTGGCCCTTGACCCCTCCAGGGTGGAC 1004 
         ************************************************************ 
 
X1       TACCTCTTAGGTCTCTTTGAGCCCGGGGACATGCAGTATGAGTTGAATCGGAACAACCTG 1438 
ALP      TACCTCTTAGGTCTCTTTGAGCCCGGGGACATGCAGTATGAGTTGAATCGGAACAACCTG 1064 
         ************************************************************ 
 
X1       ACTGACCCTTCCCTCTCGGAGATGGTGGAGGTGGCCCTCCGGATCCTGACAAAGAATCCC 1498 
ALP      ACTGACCCTTCCCTCTCGGAGATGGTGGAGGTGGCCCTCCGGATCCTGACAAAGAATCCC 1124 
         ************************************************************ 
 
X1       AAAGGCTTCTTCTTGCTAGTGGAAGGAGGCAGGATTGACCACGGGCACCATGAAGGCAAG 1558 
ALP      AAAGGCTTCTTCTTGCTAGTGGAAGGAGGCAGGATTGACCACGGGCACCATGAAGGCAAG 1184 
         ************************************************************ 
 
X1       GCCAAGCAGGCGCTGCATGAGGCCGTGGAGATGGATGAGGCCATCGGAAAGGCGGGCACC 1618 
ALP      GCCAAGCAGGCGCTGCATGAGGCCGTGGAGATGGATGAGGCCATCGGAAAGGCGGGCACC 1244 
         ************************************************************ 
 
X1       ATGACTTCCCAGAAAGACACGTTGACTGTGGTTACTGCTGATCACTCCCACGTTTTCACG 1678 
ALP      ATGACTTCCCAGAAAGACACGTTGACTGTGGTTACTGCTGATCACTCCCACGTTTTCACG 1304 
         ************************************************************ 
 
X1       TTTGGTGGCTACACCCCCAGGGGCAACTCCATTTTTGGTCTGGCTCCCATGGTGAGTGAC 1738 
ALP      TTTGGTGGCTACACCCCCAGGGGCAACTCCATTTTTGGTCTGGCTCCCATGGTGAGCGAC 1364 
         ******************************************************** *** 
 
 
X1       ACGGACAAGAAGCCCTTCACAGCCATCCTGTATGGCAACGGGCCTGGTTACAAGGTGGTG 1798 
ALP      ACGGACAAGAAGCCCTTCACAGCCATCCTGTATGGCAACGGGCCTGGTTACAAGGTGGTG 1424 
         ************************************************************ 
 
X1       GACGGTGAACGGGAGAACGTCTCCATGGTGGATTATGCTCACAACAACTACCAGGCCCAG 1858 
ALP      GACGGTGAACGGGAGAACGTCTCCATGGTGGATTATGCTCACAACAACTACCAGGCCCAG 1484 
         ************************************************************ 
 
X1       TCCGCTGTCCCCCTGCGGCACGAGACCCACGGTGGGGAAGATGTGGCGGTCTTTGCCAAG 1918 
ALP      TCCGCTGTCCCCCTGCGGCACGAGACCCACGGTGGGGAAGATGTGGCGGTCTTTGCCAAG 1544 
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         ************************************************************ 
 
X1       GGCCCTATGGCTCACCTGCTTCACGGCGTCCATGAGCAGAACTACATCCCCCACGTCATG 1978 
ALP      GGCCCTATGGCTCACCTGCTTCACGGCGTCCATGAGCAGAACTACATCCCCCACGTCATG 1604 
         ************************************************************ 
 
X1       GCGTATGCCTCCTGCATTGGAGCCAACCTTGACCACTGTGCCTGGGCCAGCTCTGCGAGC 2038 
ALP      GCGTATGCCTCCTGCATTGGAGCCAACCTTGACCACTGTGCCTGGGCCAGCTCTGCGAGC 1664 
         ************************************************************ 
 
X1       AGCCCCTCCCCAGGGGCCCTGCTGCTTCCACTGGCTCTGTTCCCCCTACGCACCCTGTTC 2098 
ALP      AGCCCCTCCCCAGGGGCCCTGCTGCTTCCACTGGCTCTGTTCCCCCTACGCACCCTGTTC 1724 
         ************************************************************ 
 
X1       TGAGGGCCCAGGTCCCACAAGAGCCCACAATGGACAGCCGGCTCCCCTCCCTTTGTGGCC 2158 
ALP      TGAGGGCCCAGGTCCCACAAGAGCCCACAATGGACAGCCGGCTCCCCTCCCTTTGTGGCC 1784 
         ************************************************************ 
 
X1       TGCCACCTGGCCGCCCACACTCAACGGGGAGGCCCAGGCAACCTCGAGCAGGAACAGAAG 2218 
ALP      TGCCACCTGGCCGCCCACACTCAACGGGGAGGCCCAGGCAACCTCGAGCAGGAACAGAAG 1844 
         ************************************************************ 
 
X1       TTTGCTACCTGCCTCACTTCCGCCCGGAACCCTCCGTGGGTCGGATTCCTGGCTCTGCCG 2278 
ALP      TTTGCTACCTGCCTCACTTCCGCCCGGAACCCTCCGTGGGTCGGATTCCTGGCTCTGCCG 1904 
         ************************************************************ 
 
X1       TTGTTTCTCTATTCACTGCCTTTTGGCCAGCAGGGTGGGTTTCTCTCTTGGGCCGGCAGG 2338 
ALP      TTGTTTCTCTATTCACTGCCTTTTGGCCAGCAGGGTGGGTTTCTCTCTTGGGCCGGCAGG 1964 
         ************************************************************ 
 
X1       ACACAGACTGCGCAGATTCCCAAAGCACCTTATTTTTCTACCAAATATACTCTCCAGACC 2398 
ALP      ACACAGACTGCGCAGATTCCCAAAGCACCTTATTTTTCTACCAAATATACTCTCCAGACC 2024 
         ************************************************************ 
 
X1       CTGCAACCATCATGGAACATTCCAGATCTGACCTTCTCTCCCCTACCCCTTCTCTCTGGA 2458 
ALP      CTGCAACCATCATGGAACATTCCAGATCTGACCTTCTCTCCCCTACCCCTTCTCTCTGGA 2084 
         ************************************************************ 
 
X1       ACACTGGGTCCCATAGTCACAGCCAGTCCCTCAACCCAACCCTCCCTGGAGGGAAGACCA 2518 
ALP      ACACTGGGTCCCATAGTCACAGCCAGTCCCTCAACCCAACCCTCCTTGGAGGGAAGACCA 2144 
         ********************************************* ************** 
 
X1       GGTCTGCTCAGGGTGAGACTCCCAGGAAGCCACCTCCGGGGTTGGCTGTCTACCCAGGGT 2578 
ALP      GGTCTGCTCAGGGTGAGACTCCCAGGAAGCCACCTCCGGGGTTGGCTGTCTACCCAGGGT 2204 
         ************************************************************ 
 
X1       GGCCAGGCTGGGAAGAACAACCCAGCCGGACAGGACGCACACACTCCCCACCCAGCTCCA 2638 
ALP      GGCCAGGCTGGGAAGAACAACCCAGCCGGACAGGACGCACACACTCCCCACCCAGCTCCA 2264 
         ************************************************************ 
 
X1       GAGACTCGCCAACCCTTCACTGAAGCGACTCCCCTGTTTGGAATAGCAAAAAAAAAAAAG 2698 
ALP      GAGACTCGCCAACCCTTCACTGAAGCGACTCCCCTGTTTGGAATAGCAAAAAAAAAA-AG 2323 
         ********************************************************* ** 
 
X1       AAAGAAAAAAAAGAAAAAAATTTTAATTTCTCTTTTTGGTGTTGGTTAAAAGGGAACACA 2758 
ALP      AAAGAAAAAAAAGAAAAAAATTTTAATTTCTCTTTTTGGTGTTGGTTAAAAGGGAACACA 2383 
         ************************************************************ 
 
X1       AGACATTTAAATAAAATGTTCCAAATATT--- 2787 
ALP      AGACATTTAAATAAAATGTTCCAAATAAAAAA 2415 
         ***************************      
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Figure C2: PCR using TNAP bone-type primers with a 60 °C annealing temperature. Lanes 1 and 8, 
molecular weight marker, lane 2 – 4, bmMSC OM samples 1-3; lanes 4-6, bmMSC AM samples 1-3.  
 
 
Figure C3: Alignment of sequenced fragment using TNAP bone-type primer set with TNAP mRNA 
NM_013059.1 (ALP). Forward primer sequence (BmMSC_AM_ALPBF) and reverse primer sequence 
(BmMSC_AM_ALPBRev). Clustal O (1.2.1) software was used to generate the alignment. 
 
 
BmMSC_AM_ALPBF      ---------------------------------------------------------TAG 3 
ALP                 CACGGCGCTCCTTAGGGCCACCGCTCGGCGCGCCGGGACAGACCCTCCCCACTCCTGCCT 60 
                                                                                 
 
BmMSC_AM_ALPBF      GSKKMGGAYCGGACGTCATTAACGGCTGACACTGCCCCCCACCTCTTCCCACCCATCTGG 63 
ALP                 GCAGGATCGGAACGTCAATTAACGGCTGACACTGCCCCCCACCTCTTCCCACCCATCTGG 120 
                    *                ******************************************* 
 
BmMSC_AM_ALPBF      GCTCCAGCGAGGAACGGATCTCGGGGTACACCATGATCTTGCCATTTTTAGTACTGGCCA 123 
ALP                 GCTCCAGCGAGGAACGGATCTCGGGGTACACCATGATCTTGCCATTTTTAGTACTGGCCA 180 
                    ************************************************************ 
 
BmMSC_AM_ALPBF      TCGGCACCTGCCTTACCAACTCATTTGTGCCAGAGAAAGAGAAAGACCCCAGTTACTGGC 183 
ALP                 TCGGACCCTGCCTTACCAACTCATTTGTGCCAGAGAAAGAGAAAGACCCCAGTTACTGGC 240 
                    ****  ****************************************************** 
 
BmMSC_AM_ALPBF      GACAGCAAGCCCAAGAGACCTTGAAAAATGCCCTGAAACTCCAAAAACTCAACACCAACG 243 
ALP                 GACAGCAAGCCCAAGAGACCTTGAAAAATGCCCTGAAACTCCAAAAACTCAACACCAACG 300 
                    ************************************************************ 
 
BmMSC_AM_ALPBF      TGGCCAAGAACATCATCATGTTCCTGGGAGATGGTATGGGCGTCTCCACAGTGACAGCTG 303 
ALP                 TGGCCAAGAACATCATCATGTTCCTGGGAGATGGTATGGGCGTCTCCACAGTGACAGCTG 360 
                    ************************************************************ 
 
BmMSC_AM_ALPBF      CCCGCATCCTTAAGGGCCAGCTACACCACAACACGGGCGAGGAGACACGGCTGGAGATGG 363 
ALP                 CCCGCATCCTTAAGGGCCAGCTACACCACAACACGGGCGAGGAGACACGGCTGGAGATGG 420 
                    ************************************************************ 
 
BmMSC_AM_ALPBF      ACAAGTTCCCCTTTGTGGCTCTCTCCAAGACGTACAACACCAACGCTCAGGTCCCCGACA 423 
ALP                 ACAAGTTCCCCTTTGTGGCTCTCTCCAAGACGTACAACACCAACGCTCAGGTCCCCGACA 480 
                    ************************************************************ 
 
BmMSC_AM_ALPBF      GCGCGGGCACTGCCACTGCCTACTTGTGTGGCGTGAAGGCCAACGAGGGCACCGTGGGAG 483 
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ALP                 GCGCGGGCACTGCCACTGCCTACTTGTGTGGCGTGAAGGCCAACGAGGGCACCGTGGGAG 540 
                    ************************************************************ 
 
BmMSC_AM_ALPBF      TGAGCGCGGCCACTGAGCGCACGCGATGCAACACCACTCAGGGGAACGAGGTCACGTCCA 543 
ALP                 TGAGCGCGGCCACTGAGCGCACGCGATGCAACACCACTCAGGGGAACGAGGTCACGTCCA 600 
                    ************************************************************ 
 
BmMSC_AM_ALPBF      TCCTGCGCTGGGCCAAGGATGCTGGGAAGTCCGTGGGCATCGTGACCACCACTCGGGTGA 603 
ALP                 TCCTGCGCTGGGCCAAGGATGCTGGGAAGTCCGTGGGCATCGTGACCACCACTCGGGTGA 660 
                    ************************************************************ 
 
BmMSC_AM_ALPBF      ACCACGCCACTCCCAGTGCAGCCTATGCGCACTCGGCCGATCGGGACTGGTACTCGGACA 663 
ALP                 ACCACGCCACTCCCAGTGCAGCCTATGCGCACTCGGCCGATCGGGACTGGTACTCGGACA 720 
                    ************************************************************ 
 
BmMSC_AM_ALPBF      ATGAGATGCCGCCAGAGGYTCTGAGCCAGGGCTGCAAGGACATCGCCTATCAGCTAATGC 723 
ALP                 ATGAGATGCGCCCAGAGGCTCTGAGCCAGGGCTGCAAGGACATCGCCTATCAGCTAATGC 780 
                    *********  ******* ***************************************** 
 
BmMSC_AM_ALPBF      ACAACATCAAGGACATCGATGTGATCATGGGTGGCGGCCGGAAGTACATGTACCCCAAGA 783 
ALP                 ACAACATCAAGGACATCGATGTGATCATGGGTGGTGGCCGGAAGTACATGTACCCCAAGA 840 
                    ********************************** ************************* 
 
BmMSC_AM_ALPBF      ACAGAACTTGATGTGGAATATGAACTGKATGAGTAAGGCCAKGGGYACCAGACTGGWATG 843 
ALP                 ACAGAACTGA-TGTGGAATATGAACTGGATGAGAAGGCCAGGGG-CACCAGACT-GGATG 897 
                    ********   **************** ***** * * *   **  ******** * *** 
 
BmMSC_AM_ALPBF      GKCYKGACCTCATCTKCWTTTTGGAAGAGCTT---------------------------- 875 
ALP                 GCCTGGACCTCATCAGCATTTGGAAGAGCTTCAAACCTAGACACAAGCACTCCCACTATG 957 
                    * *  *********  * *** * *     *                              
 
BmMSC_AM_ALPBF      ------------------------------------------------------------ 875 
ALP                 TCTGGAACCGCACTGAACTGCTGGCCCTTGACCCCTCCAGGGTGGACTACCTCTTAGGTC 1017 
                                                                                 
 
BmMSC_AM_ALPBF      ------------------------------------------------------------ 875 
ALP                 TCTTTGAGCCCGGGGACATGCAGTATGAGTTGAATCGGAACAACCTGACTGACCCTTCCC 1077 
                                                                                 
 
BmMSC_AM_ALPBF      ------------------------------------------------------------ 875 
ALP                 TCTCGGAGATGGTGGAGGTGGCCCTCCGGATCCTGACAAAGAATCCCAAAGGCTTCTTCT 1137 
                                                                                 
 
BmMSC_AM_ALPBF      ------------------------------------------------------------ 875 
ALP                 TGCTAGTGGAAGGAGGCAGGATTGACCACGGGCACCATGAAGGCAAGGCCAAGCAGGCGC 1197 
                                                                                 
 
BmMSC_AM_ALPBF      ------------------------------------------------------------ 875 
ALP                 TGCATGAGGCCGTGGAGATGGATGAGGCCATCGGAAAGGCGGGCACCATGACTTCCCAGA 1257 
                                                                                 
 
BmMSC_AM_ALPBF      ------------------------------------------------------------ 875 
ALP                 AAGACACGTTGACTGTGGTTACTGCTGATCACTCCCACGTTTTCACGTTTGGTGGCTACA 1317 
                                                                                 
 
BmMSC_AM_ALPBF      ------------------------------------------------------------ 875 
ALP                 CCCCCAGGGGCAACTCCATTTTTGGTCTGGCTCCCATGGTGAGCGACACGGACAAGAAGC 1377 
                                                                                 
 
BmMSC_AM_ALPBF      ------------------------------------------------------------ 875 
ALP                 CCTTCACAGCCATCCTGTATGGCAACGGGCCTGGTTACAAGGTGGTGGACGGTGAACGGG 1437 
                                                                                 
 
BmMSC_AM_ALPBF      ------------------------------------------------------------ 875 
ALP                 AGAACGTCTCCATGGTGGATTATGCTCACAACAACTACCAGGCCCAGTCCGCTGTCCCCC 1497 
                                                                                 
 
BmMSC_AM_ALPBF      ------------------------------------------------------------ 875 
ALP                 TGCGGCACGAGACCCACGGTGGGGAAGATGTGGCGGTCTTTGCCAAGGGCCCTATGGCTC 1557 
                                                                                 
 
BmMSC_AM_ALPBF      ------------------------------------------------------------ 875 
ALP                 ACCTGCTTCACGGCGTCCATGAGCAGAACTACATCCCCCACGTCATGGCGTATGCCTCCT 1617 
                                                                                 
 
BmMSC_AM_ALPBF      ------------------------------------------------------------ 875 
ALP                 GCATTGGAGCCAACCTTGACCACTGTGCCTGGGCCAGCTCTGCGAGCAGCCCCTCCCCAG 1677 
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BmMSC_AM_ALPBF      ------------------------------------------------------------ 875 
ALP                 GGGCCCTGCTGCTTCCACTGGCTCTGTTCCCCCTACGCACCCTGTTCTGAGGGCCCAGGT 1737 
                                                                                 
 
BmMSC_AM_ALPBF      ------------------------------------------------------------ 875 
ALP                 CCCACAAGAGCCCACAATGGACAGCCGGCTCCCCTCCCTTTGTGGCCTGCCACCTGGCCG 1797 
                                                                                 
 
BmMSC_AM_ALPBF      ------------------------------------------------------------ 875 
ALP                 CCCACACTCAACGGGGAGGCCCAGGCAACCTCGAGCAGGAACAGAAGTTTGCTACCTGCC 1857 
                                                                                 
 
BmMSC_AM_ALPBF      ------------------------------------------------------------ 875 
ALP                 TCACTTCCGCCCGGAACCCTCCGTGGGTCGGATTCCTGGCTCTGCCGTTGTTTCTCTATT 1917 
                                                                                 
 
BmMSC_AM_ALPBF      ------------------------------------------------------------ 875 
ALP                 CACTGCCTTTTGGCCAGCAGGGTGGGTTTCTCTCTTGGGCCGGCAGGACACAGACTGCGC 1977 
                                                                                 
 
BmMSC_AM_ALPBF      ------------------------------------------------------------ 875 
ALP                 AGATTCCCAAAGCACCTTATTTTTCTACCAAATATACTCTCCAGACCCTGCAACCATCAT 2037 
                                                                                 
 
BmMSC_AM_ALPBF      ------------------------------------------------------------ 875 
ALP                 GGAACATTCCAGATCTGACCTTCTCTCCCCTACCCCTTCTCTCTGGAACACTGGGTCCCA 2097 
                                                                                 
 
BmMSC_AM_ALPBF      ------------------------------------------------------------ 875 
ALP                 TAGTCACAGCCAGTCCCTCAACCCAACCCTCCTTGGAGGGAAGACCAGGTCTGCTCAGGG 2157 
                                                                                 
 
BmMSC_AM_ALPBF      ------------------------------------------------------------ 875 
ALP                 TGAGACTCCCAGGAAGCCACCTCCGGGGTTGGCTGTCTACCCAGGGTGGCCAGGCTGGGA 2217 
                                                                                 
 
BmMSC_AM_ALPBF      ----------------------- 875 
ALP                 AGAACAACCCAGCCGGACAGGAC 2240 
 
 
BmMSC_AM_ALPRev      ------------------------------------------------------------ 0 
ALP                  CACGGCGCTCCTTAGGGCCACCGCTCGGCGCGCCGGGACAGACCCTCCCCACTCCTGCCT 60 
                                                                                  
 
 
BmMSC_AM_ALPRev      ------------------------------------------------------------ 0 
ALP                  GCAGGATCGGAACGTCAATTAACGGCTGACACTGCCCCCCACCTCTTCCCACCCATCTGG 120 
                                                                                  
 
BmMSC_AM_ALPRev      ------------------------------------------------------------ 0 
ALP                  GCTCCAGCGAGGAACGGATCTCGGGGTACACCATGATCTTGCCATTTTTAGTACTGGCCA 180 
                                                                                  
 
BmMSC_AM_ALPRev      ------------------------------------------------------------ 0 
ALP                  TCGGACCCTGCCTTACCAACTCATTTGTGCCAGAGAAAGAGAAAGACCCCAGTTACTGGC 240 
                                                                                  
 
BmMSC_AM_ALPRev      ------------------------------------------------------------ 0 
ALP                  GACAGCAAGCCCAAGAGACCTTGAAAAATGCCCTGAAACTCCAAAAACTCAACACCAACG 300 
                                                                                  
 
BmMSC_AM_ALPRev      ------------------------------------------------------------ 0 
ALP                  TGGCCAAGAACATCATCATGTTCCTGGGAGATGGTATGGGCGTCTCCACAGTGACAGCTG 360 
                                                                                  
 
BmMSC_AM_ALPRev      ------------------------------------------------------------ 0 
ALP                  CCCGCATCCTTAAGGGCCAGCTACACCACAACACGGGCGAGGAGACACGGCTGGAGATGG 420 
                                                                                  
 
BmMSC_AM_ALPRev      ------------------------------------------------------------ 0 
ALP                  ACAAGTTCCCCTTTGTGGCTCTCTCCAAGACGTACAACACCAACGCTCAGGTCCCCGACA 480 
                                                                                  
 
BmMSC_AM_ALPRev      ------------------------------------------------------------ 0 
ALP                  GCGCGGGCACTGCCACTGCCTACTTGTGTGGCGTGAAGGCCAACGAGGGCACCGTGGGAG 540 
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BmMSC_AM_ALPRev      ------------------------------------------------------------ 0 
ALP                  TGAGCGCGGCCACTGAGCGCACGCGATGCAACACCACTCAGGGGAACGAGGTCACGTCCA 600 
                                                                                  
 
BmMSC_AM_ALPRev      ------------------------------------------------------------ 0 
ALP                  TCCTGCGCTGGGCCAAGGATGCTGGGAAGTCCGTGGGCATCGTGACCACCACTCGGGTGA 660 
                                                                                  
 
BmMSC_AM_ALPRev      ---------------------------------NNCNAATTCGGNAATGATACTTCGGAC 27 
ALP                  ACCACGCCACTCCCAGTGCAGCCTATGCGCACTCGGCCGATCGGGACT-GGTACTCGGAC 719 
                                                             **** * *      ****** 
 
BmMSC_AM_ALPRev      AAAGAGATGACNCCAGAGGNTTTGACCNGGG-TGCNAAGGACATCNCCTATTCAGNTAAA 86 
ALP                  AATGAGATGCGCCCAGAGGCTCTGAGCCAGGGCTGCAAGGACATCGCCTATCAGCTAAT- 778 
                     ** ******   ******* * *** *  **     ********* *****      *   
 
BmMSC_AM_ALPRev      NGCACAACATTCAAGGACATNGATGTGATTCATGGGTNGCGNCNGNAAGTACATGTACCN 146 
ALP                  --GCACAACATCAAGGACATCGATGTGA-TCATGGGTGGTGGCCGGAAGTACATGT-ACC 834 
                           *   ********** ******* ******** * * * * **********  *  
 
BmMSC_AM_ALPRev      CAAAGAACAGAACTGATGTGGAATATGAACTGGATGAGAAGGCCAGGGGCACCAGANTGG 206 
ALP                  CCAAGAACAGAACTGATGTGGAATATGAACTGGATGAGAAGGCCAGGGGCACCAGACTG- 893 
                     * ****************************************************** **  
 
BmMSC_AM_ALPRev      GATGGGCCTGGACCTCATCAGCATTNGGAAGAGCTTCAAACCTAGACACAAGCACTCCCA 266 
ALP                  -GATGGCCTGGACCTCATCAGCATTTGGAAGAGCTTCAAACCTAGACACAAGCACTCCCA 952 
                         ********************* ********************************** 
 
BmMSC_AM_ALPRev      CTATGTCTGGAACCGCANTGAAACTGCTGGCCCTTGACCCCTCCAGGGTGGACTACCTCT 326 
ALP                  CTATGTCTGGAACCGCACTGA-ACTGCTGGCCCTTGACCCCTCCAGGGTGGACTACCTCT 1011 
                     ***************** *** ************************************** 
 
BmMSC_AM_ALPRev      TAGGTCTCTTTGAGCCCGGGGACATGCAGTATGAGTTGAATCGGAACAACCTGACTGACC 386 
ALP                  TAGGTCTCTTTGAGCCCGGGGACATGCAGTATGAGTTGAATCGGAACAACCTGACTGACC 1071 
                     ************************************************************ 
 
BmMSC_AM_ALPRev      CTTCCCTCTCGGAGATGGTGGAGGTGGCCCTCCGGATCCTGACAAAGAATCCCAAAGGCT 446 
ALP                  CTTCCCTCTCGGAGATGGTGGAGGTGGCCCTCCGGATCCTGACAAAGAATCCCAAAGGCT 1131 
                     ************************************************************ 
 
BmMSC_AM_ALPRev      TCTTCTTGCTAGTGGAAGGAGGCAGGATTGACCACGGGCACCATGAAGGCAAGGCCAAGC 506 
ALP                  TCTTCTTGCTAGTGGAAGGAGGCAGGATTGACCACGGGCACCATGAAGGCAAGGCCAAGC 1191 
                     ************************************************************ 
 
BmMSC_AM_ALPRev      AGGCGCTGCATGAGGCCGTGGAGATGGATGAGGCCATCGGAAAGGCGGGCACCATGACTT 566 
ALP                  AGGCGCTGCATGAGGCCGTGGAGATGGATGAGGCCATCGGAAAGGCGGGCACCATGACTT 1251 
                     ************************************************************ 
 
BmMSC_AM_ALPRev      CCCAGAAAGACACGTTGACTGTGGTTACTGCTGATCACTCCCACGTTTTCACGTTTGGTG 626 
ALP                  CCCAGAAAGACACGTTGACTGTGGTTACTGCTGATCACTCCCACGTTTTCACGTTTGGTG 1311 
                     ************************************************************ 
 
BmMSC_AM_ALPRev      GCTACACCCCCAGGGGCAACTCCATTTTTGGTCTGGCTCCCATGGTGAGNGACACGGACA 686 
ALP                  GCTACACCCCCAGGGGCAACTCCATTTTTGGTCTGGCTCCCATGGTGAGCGACACGGACA 1371 
                     ************************************************* ********** 
 
BmMSC_AM_ALPRev      AGAAGCCCTTCACAGCCATCCTGTATGGCAACGGGCCTGGTTACAAGGTGGTGGACGGTG 746 
ALP                  AGAAGCCCTTCACAGCCATCCTGTATGGCAACGGGCCTGGTTACAAGGTGGTGGACGGTG 1431 
                     ************************************************************ 
 
BmMSC_AM_ALPRev      AACGGGAGAACGTCTCCATGGTGGATTATGCTCACAACAACTACCAGGCCCAGTCCGCTG 806 
ALP                  AACGGGAGAACGTCTCCATGGTGGATTATGCTCACAACAACTACCAGGCCCAGTCCGCTG 1491 
                     ************************************************************ 
 
BmMSC_AM_ALPRev      TCCCCCTGCGGCACGAGACCCACGGTGGGGAAGATGTGGCGGTCTTTGCCAAGGGCCCTA 866 
ALP                  TCCCCCTGCGGCACGAGACCCACGGTGGGGAAGATGTGGCGGTCTTTGCCAAGGGCCCTA 1551 
                     ************************************************************ 
 
BmMSC_AM_ALPRev      TGGCTCACCTGCTCACGGCGTCCANAGCAGAGTNNGCCANTNANCNTG------------ 914 
ALP                  TGGCTCACCTGCTTCACGGCGTCCATGAGCAGAACTACATCCCCCACGTCATGGCGTATG 1611 
                     *************    *    *   *   **     **     *  *             
 
BmMSC_AM_ALPRev      ------------------------------------------------------------ 914 
ALP                  CCTCCTGCATTGGAGCCAACCTTGACCACTGTGCCTGGGCCAGCTCTGCGAGCAGCCCCT 1671 
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BmMSC_AM_ALPRev      ------------------------------------------------------------ 914 
ALP                  CCCCAGGGGCCCTGCTGCTTCCACTGGCTCTGTTCCCCCTACGCACCCTGTTCTGAGGGC 1731 
                                                                                  
 
BmMSC_AM_ALPRev      ------------------------------------------------------------ 914 
ALP                  CCAGGTCCCACAAGAGCCCACAATGGACAGCCGGCTCCCCTCCCTTTGTGGCCTGCCACC 1791 
                                                                                  
 
BmMSC_AM_ALPRev      ------------------------------------------------------------ 914 
ALP                  TGGCCGCCCACACTCAACGGGGAGGCCCAGGCAACCTCGAGCAGGAACAGAAGTTTGCTA 1851 
                                                                                  
 
BmMSC_AM_ALPRev      ------------------------------------------------------------ 914 
ALP                  CCTGCCTCACTTCCGCCCGGAACCCTCCGTGGGTCGGATTCCTGGCTCTGCCGTTGTTTC 1911 
                                                                                  
 
BmMSC_AM_ALPRev      ------------------------------------------------------------ 914 
ALP                  TCTATTCACTGCCTTTTGGCCAGCAGGGTGGGTTTCTCTCTTGGGCCGGCAGGACACAGA 1971 
                                                                                  
 
BmMSC_AM_ALPRev      ------------------------------------------------------------ 914 
ALP                  CTGCGCAGATTCCCAAAGCACCTTATTTTTCTACCAAATATACTCTCCAGACCCTGCAAC 2031 
                                                                                  
 
BmMSC_AM_ALPRev      ------------------------------------------------------------ 914 
ALP                  CATCATGGAACATTCCAGATCTGACCTTCTCTCCCCTACCCCTTCTCTCTGGAACACTGG 2091 
                                                                                  
 
BmMSC_AM_ALPRev      ------------------------------------------------------------ 914 
ALP                  GTCCCATAGTCACAGCCAGTCCCTCAACCCAACCCTCCTTGGAGGGAAGACCAGGTCTGC 2151 
                                                                                  
 
BmMSC_AM_ALPRev      ------------------------------------------------------------ 914 
ALP                  TCAGGGTGAGACTCCCAGGAAGCCACCTCCGGGGTTGGCTGTCTACCCAGGGTGGCCAGG 2211 
                                                                                  
 
BmMSC_AM_ALPRev      ----------------------------- 914 
ALP                  CTGGGAAGAACAACCCAGCCGGACAGGAC 2240 
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